WO2005026163A1 - Dioxolane derivatives as cell adhesion inhibitors - Google Patents

Dioxolane derivatives as cell adhesion inhibitors Download PDF

Info

Publication number
WO2005026163A1
WO2005026163A1 PCT/IB2004/003047 IB2004003047W WO2005026163A1 WO 2005026163 A1 WO2005026163 A1 WO 2005026163A1 IB 2004003047 W IB2004003047 W IB 2004003047W WO 2005026163 A1 WO2005026163 A1 WO 2005026163A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
carbonyl
amino
phenyl
dioxolane
Prior art date
Application number
PCT/IB2004/003047
Other languages
French (fr)
Inventor
Venkata P. Palle
Viswajanani J. Sattigeri
Mohammad Salman
Ajay Soni
Abhijit Ray
Sunanda G. Dastidar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP04769418A priority Critical patent/EP1668007A1/en
Publication of WO2005026163A1 publication Critical patent/WO2005026163A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to dioxolane derivatives as cell adhesion inhibitors. These compounds can be useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis.
  • This invention also relates to pharmacological compositions containing the compounds of the present invention, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds.
  • CAMs cell adhesion molecules
  • CAMs can be classified into three groups - integrins, selectins and the immunoglobulin superfamily.
  • integrins are key mediators in the adhesive interactions between hemopoietic cells and their microenvironment. They are comprised of alpha-beta heterodimers that integrate signals from outside to the inside of cells and vice versa. Integrins can be classified on the basis of the beta subunits they contain. For example, the beta-1 subfamily contains beta-1 subunit noncovalently linked to one of the 10 different alpha subunits.
  • the alpha-4 beta-1 integrin also known as VLA-4 (very late activation antigen 4), is a member of the beta-1 integrin family, and comprises alpha-4 and beta-1 subunits.
  • VCAM-1 vascular cell adhesion molecule
  • CS1 region of the protein fibronectin Adhesion mediated by VLA-4 is central to the process of transendothelial migration of leukocytes. Ligation of VLA-4 is followed by gross rearrangement of the cytoskeleton, leading to flattening of cells along the blood vessel wall, followed by expression of specific molecules, which digest the endothelial cell wall and diapedesis. Once in the extraluminal region, the interactions of VLA-4 with extracellular fibronectin play a crucial role in migration to the site of inflammation, T cell proliferation, and the expression of cytokines and inflammatory mediators.
  • VLA-4 ligation provides co-stimulatory signals to the leukocytes, resulting in enhanced immunoreactivity. Therefore, it is expected that VLA-4 antagonists would ameliorate the immune response through twofold actions: inhibition of T cell recruitment at the site of inflammation; and inhibition of costimulatory activation of immune cells.
  • inhibitors of VLA-4 interactions have demonstrated beneficial therapeutic effects in several animal models of inflammatory, and allergic diseases including sheep allergic asthma.
  • the region of CS1 moiety of fibronectin involved in the interaction with VLA-4 has been identified as the tripeptide Leu-Asp-Val, also known as LDV.
  • U.S. Patent No. 6,329,344 Bl discloses several monosaccharide derivatives as cell adhesion inhibitors. It generally relates to substituted pentose and hexose monosaccharide derivatives, which exhibit potent anti-cell adhesion and anti-inflammatory activities.
  • Patent application WO 00/42054 discloses several monosaccharide derivatives as cell adhesion inhibitors.
  • Patent application WO 00/43369 provides compounds which bind to VLA-4, as well as triazine derivatives which inhibit leukocyte adhesion mediated by VLA-4.
  • WO 99/06434 discloses 4-aminophenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
  • WO 01/12186 discloses cell adhesion inhibitors which interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion.
  • WO 98/58902 discloses molecules which are potent inhibitors of ⁇ ⁇ ,-mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing ⁇ ⁇ ,-mediated adhesion mediated conditions.
  • U.S. Patent No. 6,291,511 discloses several biarylalkanoic acids as cell adhesion inhibitors.
  • GB 2354440 discloses several aryl amides as cell adhesion inhibitors.
  • WO 98/53814 discloses heterocyclic amide compounds as cell adhesion inhibitors.
  • WO 01/12183 discloses heterocyclic amides as cell adhesion inhibitors.
  • WO 99/20272 and U.S. Patent No. 6,069,163 discloses several azapeptide acids as cell adhesion inhibitors.
  • U.S. Patent 6,020,347 discloses 4-substituted-4-piperidine carboxamide derivatives useful in the inhibition or prevention of cell adhesion and cell adhesion mediated pathologies.
  • U.S. Patent 6,191,171 discloses para-aminomethyl aryl carboxamide derivatives as cell adhesion inhibitors.
  • U.S. Patent 6,090,841 discloses substituted pyrrole derivatives as cell adhesion inhibitors.
  • Bioorg & Med. Chem., JO (2002), 1567-1580 discloses synthesis of potential thrombm inhibitors and incorporation of tartaric acid templates as P2 pro line mimetics.
  • the compounds of the present invention may be screened for inhibitory activity in VLA-4 mediated cell adhesion assay and the classical murine hypersensitivity assay in mice. These compounds could be used in treatment of chronic, cell adhesion mediated, allergic, autoimmune and inflammatory disorders, such as bronchial asthma, multiple sclerosis, rheumatoid arthritis etc.
  • Some of the prior art describes development of peptide derivatives as cell adhesion antagonists for treatment of these diseases.
  • substituted dioxolane derivatives which can be used as cell adhesion inhibitors.
  • a compound having the structure of Formula I having the structure of Formula I
  • Formula I its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein m is an integer from 0-2;
  • Ri can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclylalkyl;
  • R 2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;
  • Ri and R 2 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F,C1, Br, I), aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;
  • Rs and R$ may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R 5 and R$ may together join to form a cycloalkyl ring.
  • alkyl unless and otherwise specified refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms.
  • Alkyl groups may further be substituted with one or more substituents selected such as alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, aryl, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryloxy, aminosulfonyl, aminocarbonylamino, aminothiocarbonylamino, hydroxyamino, alkoxyamino, nitro, SH, S-alkyl, S-Salkyl, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO 2 -alkyl, SO 2 -aryl and -SO 2 - heteroaryl, further alkyl may be substituted
  • substituents may optionally be further substituted by 1 -3 substituents chosen from alkyl, carboxy, carboxy-alkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and - S(O) n R ⁇ 2 , where R ⁇ 2 can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl and heterocyclyl and n is 0, 1 or 2; or or an alkyl group as defined above that is interrupted by 1-5 atoms of groups independently chosen from oxygen, sulfur and -NR a - ⁇ where R a is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl.
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R ⁇ 2 , where n and R ⁇ 2 are the same as defined earlier; or an alkyl group as defined above that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above.
  • alkenyl refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 20 carbon atoms with cis or trans geometry either in a acyclic or cyclic ring system wherein the cyclic may include mono- or multicyclic ring forms. In the event that alkenyl is attached to the heteroatom, the double bond cannot be alpha to the heteroatom.
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF , amino, substituted amino, cyano, and -S(O) n R ⁇ 2 , where R ⁇ 2 is the same as defined above and n is 0, 1 or 2.
  • alkynyl refers to a monoradical of an unsaturated hydrocarbon, preferably having from 2 to 20 carbon atoms. In the event that alkynyl is attached to the heteroatom, the triple bond cannot be alpha to the heteroatom.
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R ⁇ 2 , where R
  • cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, for example cyclobutyl, cyclopentyl, adamantyl and the like.
  • Cycloalkyl groups may further be substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO- heteroaryl, -SO 2 -alkyl, -SO 2 -aryl and -SO 2 -heteroaryl; further cycloalkyl may be substituted with a group represented by (CH 2 ) 0-3
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) interceptR ⁇ , where R ⁇ 2 is the same as defined above and n is 0, 1 or 2.
  • R ⁇ 2 is the same as defined above and n is 0, 1 or 2.
  • Alkoxy denotes the group O-alkyl wherein alkyl is the same as defined above.
  • alkyl is the same as defined above.
  • alkyl is the same as defined above.
  • alkyl is the same as defined above.
  • alkyl is the same as defined above.
  • alkyl refers to (CH ) P aryl, wherein p is an integer in the range of 1-6 and aryl is as defined below.
  • aryl herein refers to phenyl or naphthyl ring and the like, which may optionally be fused to cycloalkyl or heterocyclyl.
  • R ⁇ 0 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl.
  • Aryloxy denotes the group O-Aryl wherein aryl is the same as defined above.
  • Alkoxy denotes the group O-aralkyl wherein aralkyl is the same as defined above.
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF , amino, substituted amino, cyano, and -S(O) n Ri 2 , where R ⁇ 2 is the same as defined above and n is 0, 1 or 2.
  • heterocryl groups may optionally be fused to an aryl ring wherein aryl is the same as defined earlier.
  • the term 'heterocyclyl refers to a non aromatic cycloalkyl group having 5 to 10 atoms in which 1 to 3 carbon atoms in a ring are replaced by heteroatoms such as O, S or N, and are optionally benzofused or fused heteroaryl of 5-6 ring members and/or are optionally substituted wherein the substituents can be halogen (F, CI, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO 2 - alkyl, -SO 2 -aryl and -SO 2 -heteroaryl, aryl, alkoxy, aralkyl, cyano, nitro, amino or substituted amino, cyano
  • Heteroarylalkyl refers to heteroaryl (wherein heteroaryl is same as defined earlier) linked through alkyl (wherein alkyl is the same as defined above) portion and the said alkyl portion contains carbon atoms from 1-6.
  • Heterocyclylalkyl refers to heterocyclyl (wherein heterocyclyl is same as defined earlier) linked through alkyl (wherein alkyl is the same as defined above) portion and the said alkyl portion contains carbon atoms from 1-6.
  • Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides of these compounds are also provided.
  • compositions containing the compounds can be used for the treatment of cell adhesion mediated pathologies including inflammatory and autoimmune diseases such as . bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis.
  • the term "leaving group” generally refers to groups that exhibit the desirable properties of being labile under the defined synthetic conditions and also, of being easily separated from synthetic products under defined conditions. Examples of such leaving groups include but are not limited to halogen (F, CI, Br, I), triflates, tosylate, mesylates, alkoxy, thioalkoxy, hydroxy radicals and the like.
  • Protecting groups is used herein to refer to known moieties which have the desirable property of preventing specific chemical reaction at a site on the molecule undergoing chemical modification intended to be left unaffected by the particular chemical modification. Also, protecting groups, unless otherwise specified, may be used with groups such as hydroxy, amino, carboxy and examples of such groups are found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2 nd Ed, John Wiley and Sons, New York, N.Y., which is incorporated herein by reference.
  • the species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting group employed is not critical as long as the derivatised moieties/moiety is/are stable to conditions of subsequent reactions and can be removed at the appropriate point without distrupting the remainder of the molecule.
  • Compounds provided herein can contain one or more asymmetric carbon atoms and thus can occur as racemates, mixtures of enantiomers, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included herein.
  • Each stereogenic carbon may be of the R or S configuration.
  • a compound of Formula XI, XII and XVI can be prepared according to Scheme I.
  • R 2 is p-hydroxybenzyl.
  • the hydrolysis of a compound of Formula II to a compound of Formula III can be carried out in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof.
  • the hydrolysis of a compound of Formula II to compound of Formula III can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the condensation of a compound of Formula III with compound of Formula IV to give a compound of Formula V can be carried out in an organic solvent, for example tetrahydrofuran, dichloromethane or dimethylformamide.
  • the condensation of a compound of Formula III with a compound of Formula IN can be carried out in the presence of an organic base, for example ⁇ -methylmorpholine, diisopropylethylamine or triethylamine.
  • the condensation of a compound of Formula III with a compound of Formula IV can be carried out in a condensing agent, for example 1- (3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride, dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • the hydrolysis of a compound of Formula V to give a compound of Formula VI can be carried out in a solvent system, for example tetrahydrofuran, methanol, ethanol, dioxane or water or combinations thereof.
  • the hydrolysis of a compound of Formula V to give a compound of Formula VI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the condensation of a compound of Formula VI with a compound of Formula VII to give a compound of Formula VIII can be carried out in a organic solvent, for example tetrahydrofuran or dimethylformamide.
  • the condensation of a compound of Formula VI with a compound of Formula VII can be carried out in the presence of a condensing agent, for example l-(3-dimethylaminopropyl)-3-ethyl carbodiimide or dicyclohexylcarbodiimide.
  • a condensing agent for example l-(3-dimethylaminopropyl)-3-ethyl carbodiimide or dicyclohexylcarbodiimide.
  • the condensation of a compound of Formula VI with a compound of Formula VII can be carried out in the presence of a base, for example N-methylmorpholine, diisopropylethylamine or triethylamine.
  • the reaction of a compound of Formula VIII (Path a) with a compound Formula IX to give compound of Formula X can be carried out in an organic solvent, for example acetone, dichloromethane, carbon tetrachloride, dimethylformamide or chloroform.
  • the reaction of a compound of Formula VIII with a compound Formula IX can be carried out in the presence of a base, for example, sodium hydride, sodium carbonate or potassium carbonate.
  • the hydrolysis of a compound of Formula X to give a compound of Formula XI can be carried out in a solvent system, for example ethanol, dimethylformamide, dimethylsulphoxide, dioxane, tetrahydrofuran, methanol or water or combination thereof.
  • the hydrolysis of a compound of Formula X (when P is methyl, ethyl or benzyl) to give a compound of Formula XI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • a base for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the hydrolysis of a compound of Formula X (when P is tert-butyl) to give a compound of Formula XI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid, in a solvent, for example tetrahydrofuran in water or dichloromethane.
  • Morpholine-4-carboxylic acid 4-((S)-2- ⁇ [(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino ⁇ -2-carboxy-ethyl)-phenyl ester (Compound No. 15)
  • the hydrolysis of compound of Formula VIII (when P is a protecting group such as methyl, ethyl or benzyl) to give a compound of Formula XII can be carried out in the presence of an organic base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the hydrolysis of a compound of Formula VIII (when P is tert-butyl) to give a compound of Formula XI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid.
  • the reduction of a compound of Formula VIII to give a compound of Formula XIII can be carried out in the presence of hydrogen using a catalyst, for example palladium on carbon or platinum on carbon.
  • a catalyst for example palladium on carbon or platinum on carbon.
  • the condensation of a compound of Formula XIII with a compound of Formula XIN to give a compound of Formula XV can be carried out in an organic solvent, for example dimethylformamide, tetrahydrofuran or dimethylsulphoxide.
  • the condensation of a compound of Formula XIII with a compound of Formula XIV can be carried out in the presence of an organic base, for example N-methylmorpholine ⁇ triethylamine or diisopropylethylamine.
  • the condensation of a compound of Formula XIII (when X is OH) with a compound of Formula XIV can be carried out in the presence of a condensing agent, for example l-(3-dimethylaminopropyl)-3-carbodiimide or dicyclohexyl carbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • a condensing agent for example l-(3-dimethylaminopropyl)-3-carbodiimide or dicyclohexyl carbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • the condensation of a compound of Formula XIII (when X is CI or Br) with a compound of Formula XIV can be carried out in the presence of an organic base, for example N-methyl
  • the hydrolysis of a compound of Formula XV to give a compound of Formula XVI can be carried out in a solvent or solvent system, for example ethanol, tetrahydrofuran, dimethylformamide, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • a solvent or solvent system for example ethanol, tetrahydrofuran, dimethylformamide, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • the hydrolysis of a compound of Formula XV (when P is a protecting group such as methyl, ethyl or benzyl) to give a compound of Formula XVI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • a compound of Formula XXI can be prepared according to Scheme II.
  • the condensation of a compound of Formula III with compound of Formula XVII to give a compound of Formula XVIII can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide or dimethylsulphoxide.
  • the condensation of a compound of Formula III with a compound of Formula XVII can be carried out in the presence of an organic base, for example N-methylmorpholine, diisopropylethylamine or triethylamine.
  • the condensation of a compound of Formula III with a compound of Formula XVII can be carried out in the presence of a condensing agent, for example l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide hydrochloride or dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • a condensing agent for example l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide hydrochloride or dicyclohexylcarbodiimide
  • chloroformates for example ethyl chloroformate or isobutyl chloroformate.
  • the hydrolysis of a compound of Formula XVIII (when P is ethyl) to give a compound of Formula XIX can be carried out in a solvent system, for example ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • a solvent system for example ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • the hydrolysis of a compound of Formula XVIII (when P is ethyl) to give a compound of Formula XIX can be carried out in a presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the condensation of a compound of Formula XIX with a compound of Formula IV to give a compound of Formula XX can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide or dimethylsulphoxide.
  • the condensation of a compound of Formula XIX with a compound of Formula IV can be carried out in the presence of an organic base, for example N-methylmorpholine, diisopropylethylamine or triethylamine.
  • the condensation of a compound of Formula XIX with a compound of Formula IV to give a compound of Formula XX can be carried out with condensing agent for example l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride or dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • the condensation of a compound of Formula XIX with a compound of Formula IV can also be carried out by mixed anhydride reaction using chloroformates for example, ethyl chloroformate or isobutyl chloroformate.
  • the hydrolysis of a compound of Formula XX (when P is t-butyl) to give a compound of Formula XXI can be carried out in a solvent, for example tetrahydrofuran in water or dichloromethane.
  • the hydrolysis of a compound of Formula XX (when P is t-butyl) to give a compound of Formula XXI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid.
  • the hydrolysis of a compound of Formula XX (when P is ethyl, methyl or benzyl) to give a compound of Formula XXI can be carried out in an organic solvent for example, ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • an organic solvent for example, ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof.
  • the hydrolysis of a compound of Formula XVIII to give a compound of Formula XXII can be carried out in a solvent system, for example tetrahydrofuran in water or dichloromethane.
  • the hydrolysis of a compound of Formula XVIII to give a compound of Formula XXII can be carried out in the presence of an acid, trifluoroacetic acid or hydrochloric acid.
  • the compound of Formula XXII is condensed with a compound of Formula IV to give a compound of Formula XXI in an organic solvent, for example methanol, ethanol, dimethylformamide or tetrahydrofuran.
  • Compounds(s) prepared following Scheme II, path b are:
  • a compound of Formula XXIV can be prepared according to Scheme II thus a compound of Formula XVIII (Path c) is reacted with a compound of Formula IX to give a compound of Formula XXIII, which undergoes hydrolysis to give a compound of Formula XX1N.
  • the reaction of a compound of Formula XVIII with a compound of Formula IX to give a compound of Formula XXIII can be carried out in a organic solvent, for example acetone, dichloromethane, tetrahydrofuran, dimethylformamide or acetonitrile.
  • the reaction of a compound of Formula XVIII with a compound of Formula IX can be carried out in the presence of a base, for example sodium hydride, sodium carbonate or potassium carbonate.
  • a base for example sodium hydride, sodium carbonate or potassium carbonate.
  • the hydrolysis of a compound of Formula XXIII (when P is ethyl, methyl or benzyl) to give a compound of Formula XXIV is carried out in a solvent system, for example ethanol, dimethylformamide, dimethylsulphoxide, dioxane, tetrahydrofuran, methanol or water or combinations thereof.
  • a solvent system for example ethanol, dimethylformamide, dimethylsulphoxide, dioxane, tetrahydrofuran, methanol or water or combinations thereof.
  • XXIII (when P is ethyl, methyl or benzyl) to give a compound of Formula XXIV can be carried out in the presence of base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • base for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • P is t-butyl
  • XXVI can be carried out in an organic solvent, for example tetrahydrofuran, dimethoxyethane, diethoxyethane, methanol, dioxane or water or combination thereof.
  • the reduction of a compound of Formula XXV to give a compound of Formula XXVI through an intermediacy of a mixed anhydride can be carried out in the present of a base, for example N-methylmorpholine, pyridine, triethylamine or diisopropylethylamine with chloroformates, for example ethyl chloroformate or isobutyl chloroformate.
  • the reduction of a compound of Formula XXV to give a compound of Formula XXVI can be carried out with a reducing agent, for example sodium borohydride or sodium cyanoborohydride.
  • a reducing agent for example sodium borohydride or sodium cyanoborohydride.
  • the hydrolysis a compound of Formula XXVI (when Pi is ethyl) to give a compound of Formula XXVII can be carried out in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof.
  • the hydrolysis of a compound of Formula XXVI (when Pi is ethyl) to give a compound of Formula XXVII can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the hydrolysis of a compound of Formula XXVI (when Pi is t-butyl) to give a compound of Formula XXVII can be carried out in an organic solvent, for example, tetrahydrofuran in water or dichloromethane.
  • the hydrolysis of a compound of Formula XXVI (when Pi is t-butyl) to give a compound of Formula XXVII can be carried out in the presence of an acid, for example, trifluoroacetic acid or hydrochloric acid.
  • Compound(s) prepared following the procedure described in Scheme III (Path a) include:
  • a compound of Formula XXVI (Path b) is reacted with a compound Rm- hal [wherein Rm is alkyl and hal is halogen (CI, Br, I)] to give a compound of Formula XXVIII and XXIX, which are further hydrolyzed to give a compound of Formula XXXIII and XXXrV.
  • the reaction of a compound of Formula XXVI with a compound Rm-hal to give a compound of Formula XXVIII and XXIX can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide, di ethyl ether or dioxane.
  • the reaction of a compound of Formula XXVI with a compound Rm-hal to give a compound of Formula XXVIII and XXIX can be carried out in the presence of a base, for example sodium hydride or potassium tert-butoxide.
  • a base for example sodium hydride or potassium tert-butoxide.
  • a compound of Formula XXVIII and XXIX (Pi is t- butyl) can be hydrolyzed to give a compound of Formula XXXIII and XXXIV in the presence of an acid for example trifluoroacetic acid or hydrochloric acid in a solvent system, for example tetrahydrofuran in water or dichloromethane.
  • a compound of Formula XXVIII and XIX (when Pi is ethyl) can be hydrolyzed to give a compound of
  • a compound of Formula XXVI (Path c) is reacted with a compound L-hal [wherein OL is mesyl or tosyl and hal is halogen (CI, Br, I)] to give a compound of Formula XXX, which is reacted with a compound IV (wherein R 7 and R 8 are the same as defined earlier) to give a compound of Formula XXXI, which undergoes hydrolysis to give a compound of Formula XXXII.
  • a compound of Formula XXVI is reacted with a compound L-hal to give a compound of Formula XXX in an organic solvent, for example dichloromethane, dichloroethane, chloroform or carbon tetrachloride.
  • reaction of a compound of Formula XXVI with a compound L-hal to give a compound of Formula XXX can be carried out in the presence of a base, for example triethylamine, pyridine, sodium carbonate, sodium bicarbonate or diisopropylethylamine.
  • a base for example triethylamine, pyridine, sodium carbonate, sodium bicarbonate or diisopropylethylamine.
  • the reaction of a compound of Formula XXX with a compound of Formula IV to give a compound of Formula XXI can be earned out in an organic solvent, for example tetrahydrofuran, dimethylformamide, dioxane or di ethyl ether.
  • the reaction of a compound of Formula XXX with a compound of Formula IV to give a compound of Formula XXXI can be carried out in the presence of an organic base, for example diisopropylethylamine, pyridine, N-methylmorpholine or triethylamine.
  • an organic base for example diisopropylethylamine, pyridine, N-methylmorpholine or triethylamine.
  • the hydrolysis of a compound of Formula XXXI (when Pi is t-butyl) to give a compound of Formula XXXII can be carried out in a solvent, for example dichloromethane or tetrahydrofuran in water with an acid, for example trifluoroacetic acid or hydrochloric acid.
  • Formula XXXVIII A compound of Formula XXXVIII can be prepared according to Scheme IV.
  • a compound of Formula XXXV (wherein R 5 and R ⁇ are the same as defined earlier R t is H or CH 3 ) undergoes hydrolysis to give a compound of Formula XXXVI, which is reacted with a compound of Formula VII to give a compound of Formula XXXVII, which is hydrolyzed to give a compound of Formula XXXVIII.
  • a compound of Formula XXXV undergoes hydrolysis to give a compound of
  • Formula XXXVI in a solvent system for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof in the presence of base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • base for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • the reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out in an organic solvent for example, dimethylformamide, tetrahydrofuran, dioxane or di ethyl ether.
  • reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out in the presence of an organic base for example, in the presence of an organic base for example, N-methylmorpholine, triethylamine, pyridine or diisopropylethylamine.
  • the reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out with a condensing agent for example, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide or dicyclohexylcarbodiimide.
  • hydrolysis of a compound of Formula XXXVII to a compound of Formula XXXVIII can be carried out in a solvent system for example, tetrahydrofuran, tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof.
  • a solvent system for example, tetrahydrofuran, tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof.
  • Formula XXXVII to a compound of Formula XXXVIII can be carried out in the presence of a base for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • a base for example lithium hydroxide, sodium hydroxide or potassium hydroxide.
  • a compound of Formula XL can be prepared according to Scheme V.
  • a compound of Formula VI is condensed with a compound of Formula XXXIX to give a compound of Formula XL.
  • XXXIX to give a compound of Formula XL can be carried out in an organic solvent for example, tetrahydrofuran, dimethylformamide, dioxane or diethyl ether.
  • the condensation of a compound of Formula VI with a compound of Formula XXXIX to give a compound of Formula XL can be carried out in the presence of a base for example, N- methylmorpholine, triethylamine, pyridine or diisopropylethylamine.
  • a base for example, N- methylmorpholine, triethylamine, pyridine or diisopropylethylamine.
  • Formula XL can be carried out with condensing agents for example, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide or dicyclohexylcarbodiimide.
  • condensing agents for example, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide or dicyclohexylcarbodiimide.
  • Formula XL can also be carried out by a mixed anhydride reaction using chloroformates for example, ethyl chloroformate or isobutyl chloroformate.
  • chloroformates for example, ethyl chloroformate or isobutyl chloroformate.
  • the compounds(s) prepared following the procedure described in Scheme V include:
  • the reaction mixture was concentrated and the crude oil was taken in water and extracted with ethyl acetate (2x50 ml). The aqueous layer was then acidified (cone. HC1) and extracted with ethyl acetate (2x200 ml). The combined organic extracts were then washed with water and brine (100 ml) and dried over sodium sulphate. Evaporation of the solvent under vacuo furnished the title compound (8.7g crude) as a sticky solid.
  • Step 1 Synthesis of (4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester.
  • N-methyl-morpholine (NMM) (265 mg, 2.63 mmol) was added to the compound of Formula III (0.5 g, 2.63 mmol) in dry tetrahydrofuran (10 ml) at -15°C followed by the addition of ethyl chloroformate (285 mg, 2.63 mmol).
  • the reaction mixture was stirred at the same temperature for 30 min. and then 2-aminobiphenyl (444 mg, 2.63 mmol) and p- toluenesulfonic acid (49 mg, 0.263 mmol) were added.
  • the reaction mixture was stirred at -10°C for 30 min. followed by stirring at 0°C for 2 hour and then at room temperature overnight.
  • the reaction was quenched with water and extracted the compound with ethyl acetate (2x25 ml).
  • the combined organic extract was washed with brine and dried over sodium sulphate and concentrated to obtain the crude residue.
  • the residue was then purified over a silica gel column using 30% ethyl acetate hexane as eluent to obtain the title compound (0.6 gm, 67%) as a light yellow solid.
  • Step 2 Synthesis of (4R, 5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carboxylic acid.
  • Step 3 Synthesis of Methyl (S)-2- ⁇ [(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyI]-amino ⁇ -3-(4-nitro phenyl)-propionate.
  • reaction mixture was taken into water (50 ml) and organic compound was extracted with ethyl acetate (2x50 ml). The combined organic layer was washed with water and brine and dried over sodium sulphate (anhydrous). Evaporation of the solvent followed by purification of the residue over a silica gel column using 2.5% methanol dichloromethane as eluent furnished the title compound (1.78 g, 73%) as a solid.
  • Step 4 Synthesis of Methyl (S)-3-(4-amino-phenyl)-2- ⁇ [(4R, 5R)-5-(biphenyI-2- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino ⁇ -propionate.
  • Step 5 Synthesis of Methyl (S)-2- ⁇ [((4R, 5R)-5-biphenyl-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino ⁇ -3- ⁇ 4-[(pyridine-4-carbonyl)-amino]-phenyl ⁇ - propionate.
  • the aniline obtained from step 4 above (150 mg, 0.31 mmol) in dry dimethyl formamide (2.5 ml) was coupled to isonicotinic acid (37 mg, 0.31 mmol) following the conditions as used for step 3 above, using hydroxybenzotriazole (45 mg, 0.33 mmol), N- methylmorpholine (35 mg, 0.35 mmol) and l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC. ⁇ C1)(60 mg, 0.32 mmol) to furnish the title compound (110 mg, 61%) as a solid after column purification over silica gel.
  • hydroxybenzotriazole 45 mg, 0.33 mmol
  • N- methylmorpholine 35 mg, 0.35 mmol
  • l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC. ⁇ C1)(60 mg, 0.32 mmol)
  • Step 6 Synthesis of (S)-2- ⁇ [(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino ⁇ -3- ⁇ 4-[(pyridine-4-carbonyl)-amino]-phenyl ⁇ -propionic acid.
  • step 5 above The compound obtained from step 5 above (104 mg, 0.1 mmol) was subjected to basic hydrolysis using lithium hydroxide monohydrate (7.6 mg, 0.18 mmol) following the procedure as described in step 2 above furnished after acidic workup the title compound
  • Step 1 Synthesis of Benzyl (S)-2- ⁇ [(4R, 5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxoIane-4-carbonyl]-amino ⁇ -3-(4-hydroxy-phenyl)-propionate.
  • Step 2 Synthesis of Benzyl (S)-2- ⁇ [(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino ⁇ -3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionate Potassium carbonate (98 mg, 0.71 mmol) and 2,6-dichlorobenzyl bromide (93 mg, 0.39 mmol) was added to the phenol obtained from step 1 above (200 mg, 0.35 mmol) in dry acetone (5 ml) and the mixture was refluxed for 5.6 hour.
  • Step 3 Synthesis of (S)-2- ⁇ [(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino ⁇ -3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid
  • Lithium hydroxide monohydrate (25 mg, 0.59 mmol) was added to the ester obtained from step 2 above (210 mg, 9.29 mmol) and following the general procedure as outlined in
  • Example 2 the title compound was obtained (140 mg, 76%) as a yellow sticky solid.
  • Morpholine-4-carboxylic acid 4-((S)-2- ⁇ [(4R,5R)-5-(biphenyl-2-yl-carbamoy ⁇ )- [1 ,3]dioxolane-4-carbonyl]-amino ⁇ -2-carboxy-ethyl)-phenyl ester (Compound No. 15)
  • Step a Synthesis of (4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester.
  • N-methyl morpholine (1.06 g) and stirred the reaction mixture for 10 minutes at the same temperature.
  • ethyl chloroformate (0.57 g) and stirred the reaction mixture for 20 minutes followed by the addition of p-toluene sulphonic acid (95 mg) and bis-thiophene-2-ylmethyl amine (1.29 g).
  • the reaction mixture was stirred for 30 minutes at -20°C for 30 minutes followed by stirring at 0°C for 3 hours and subsequently overnight at room temperature.
  • the reaction mixture was diluted with ethyl acetate and water.
  • the organic layer was washed with water & brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure.
  • the residue thus obtained was purified by column chromatography using 20% ethyl acetate in hexane as eluent to furnish the title compound (22.5 g).
  • Step b Synthesis of (4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3]dioxolane- 4-carboxylic acid
  • lithium hydroxide monohydrate 124 mg
  • the reaction mixture was concentrated under reduced pressure.
  • the residue thus obtained was taken in water and acidified with concentrated hydrochloric acid.
  • the organic layer was extracted with ethyl acetate, washed with water and brine. The organic layer was concentrated under reduced pressure to furnish the title compound (440 mg).
  • Step c Synthesis of (S)-2- ⁇ [(4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3] dioxolane-4-carbonyl]-amino ⁇ -3-[4-(2,6-dichIoro-benzyloxy)-phenyl]propionic acid methyl ester.
  • the reaction mixture was warmed to room temperature, diluted with water and ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous sodium sulphate. The organic layer was concentrated under reduced pressure to furnish the title compound (145 mg).
  • Step d Synthesis of (S)-2- ⁇ [(4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)- [l,3]dioxolane-4-carbonyI]-amino ⁇ -3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88)
  • Step a Synthesis of (4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester.
  • the solution of the compound (4R,5R)-[l,3]dioxolane-4,5-dicarboxylic acid monoethyl ester (1 g) (Formula III) in thionyl chloride (10 ml) was refluxed at 80°C for 1 hour. The excess of thionyl chloride was removed under reduced pressure and the residue thus obtained was taken into xylene (10ml).
  • Step b Synthesis of (4R,5R)-5-(2,6-diethyl-phenyIcarbamoyI)-[l,3]-dioxolane-4- carboxylic acid.
  • Step c Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2- ⁇ [(4R,5R)-5-(2,6- diethyI-phenylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]-amino ⁇ -propionic acid ethyl ester.
  • reaction mixture was stirred at 0°C for 30 minutes followed by the addition of l-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (162 mg) and stirred the reaction mixture it room temperature for overnight.
  • the reaction mixture was quenched with water and extracted with ethyl acetate.
  • the organic layer was separated, dried over anhydrous sodium sulphate and concentrated.
  • the residue thus obtained was purified by column chromatography using 50% ethyl acetate in hexane as eluent to furnish the title compound (210 mg).
  • Step d Synthesis of (S)-3-[4-(2,6-DichIoro-benzyloxy)-phenyl]-2- ⁇ [(4R,5R)-5-(2,6- diethyl-phenylcarbamoyl)-[l,3]dioxoIane-4-carbonyl]-amino ⁇ -propionic acid (Compound No. 90)
  • Stepl Synthesis of (4R,5R)- ⁇ lS-tert-butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)- phenyl]-ethyl-carbamoyl ⁇ -[l,3]dioxolane-4-carboxylic acid ethyl ester
  • O-(2,6-dichloro-benzyl)-L-tyrosine-t-butyl ester (430 mg, 1.08 mmol) was added to the compound of Formula III (20.6 mg, 1.08 mmol) in dry dimethylformamide (5 ml) under stirring.
  • the reaction mixture was cooled to 0°C and then N-methylmorpholine (109 mg, 1.08 mmol) and hydroxybenzotriazole (146 mg, 1.08 mmol) were added and the mixture was stirred for 20 minutes.
  • To the mixture was then added l-(3-dimethylaminopropyl)-3- ethyl carbodiimide hydrochloride (EDC.HCl) (206 mg, 1.08 mmol) under stirring.
  • Step 2 Synthesis of S-(4R,5R)-5- ⁇ lS-tert-butoxy-carbamoyl-2-[4-(2,6-di-chloro- benzyIoxy)-phenyl]-ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid
  • Lithium hydroxide monohydrate (26 mg, 0.62 mmol) was added to the ethyl ester obtained from Step 1 above (350 mg, 0.62 mmol) in tetrahydrofuran: water: methanol (3:1:1 ml), was added and the reaction mixture was stirred at room temperature for 2 hours. The solvents were evaporated; the residue was taken into water and extracted the organic layer with ethyl acetate. The aqueous layer was then acidified with saturated aqueous sodium bisulphate solution and then extracted with ethyl acetate (3x20 ml). The combined organic extract was washed with brine and dried over sodium sulphate and concentrated to obtain the title compound as a white solid (330 mg).
  • Step 3 Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2- ⁇ [(4R,5R)-5-(4- methyl-piperazine-l-carbonyl)-[l,3]dioxolane-4-carbonyl]-amino ⁇ -propionic acid tert-butyl ester N-methylpiperazine (57 mg, 0.57 mmol), N-methylmorpholine (58 mg, 0.58 mmol) and hydroxybenzotriazole (78 mg, 0.58 mmol) was added to the acid obtained from Step 2 above (310 mg, 0.57 mmol) in dry dimethyl formamide (5 ml) at 0°C.
  • Step 4 Synthesis of (S)-3- ⁇ 4-(2,6-Dichloro-benzyloxy)-phenyl-2- ⁇ [(4R,5R)-5-(4- methyl-piperazine-l-carbamoyl)-[l,3]dioxolane-4-cabonyl]-amino ⁇ -propionic acid trifluoroacetic acid salt
  • Step a Synthesis of (4R,5R)-5-[(S)-l-benzyloxycarbonyl-2-(4-hydroxy-phenyl)- ethylcarbamoyl]-[l,3]dioxolane-4-carboxy!ic acid ethyl ester
  • Step b Synthesis of (4R,5R)-5- ⁇ (S)-l-benzyloxy carbonyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethylcarbamoyl-[l,3]dioxolane-4-carboxylic acid ethyl ester
  • Step c Synthesis of (4R,5R)-5- ⁇ (S)-l-carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]- ethylcarbamoyl ⁇ -[l,3]dioxolane-4-carboxylic acid (Compound No. 35)
  • Step a Synthesis of (4R,5R)-5- ⁇ (S)-l-tert-butoxycarbenyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethylcarbamoyl ⁇ -[l,3]dioxolane-4-carboxylic acid ethyl ester
  • Step b Synthesis of (4R,5R)-5- ⁇ (S)-l-carboxy-2-[4-(2,6-dichloro-benzyloxy)- phenyl)ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46)
  • Step a Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxy methyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert butyl ester
  • N-methylmorpholine hydrochloride salt 51 mg
  • isobutyl chloroformate 70 mg
  • N-methylmorpholine was removed by filtration, washed with 1,2-dimethoxyethane (10 ml) and the filtrate was cooled to -10°C.
  • a solution of sodium borohydride in water (2 ml) followed by the addition of water and extracted with ethyl acetate.
  • the organic layer was concentrated under reduced pressure and the residue thus obtained was purified by column chromatography using 50% ethyl acetate in hexane to furnish the title compound (180 mg).
  • Step b Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- hydroxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid
  • Step a Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxy methyI-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert butyl ester and (S)-3- [4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[l,3]dioxoIane-4- carbonyl)-methyI-amino]-propionic acid tert-butyl ester
  • Step b Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- methoxymethyl-[l,3]dioxolane-4-carbonyl)-methyI-amino]-propionic acid (Compound No. 126)
  • dichloromethane 1 ml
  • trifluoro acetic acid 1 ml
  • Step a (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl- [1, 3] dioxolane-4-carbonyl)-amino] -propionic acid (Compound No.
  • Example 12 Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezyloxy)-phenyl]-2- r((4R,5S)-5-pyrrolidin- 1 -ylmethyl-[ 1 ,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146)
  • Step a Synthesis of (S)-3-[4-(2,6-dichloro-benzyIoxy)-phenyl]-2-[((4R,5S)-5-methane sulphonyloxymethyI-[l,3]-dioxolane-4-carbonyl amino]-propionic acid tert-butyl ester
  • step a Example 9
  • methanesulphonyl chloride 43.6 mg, 0.06 ml
  • triethylamine 0.051 ml
  • Step b Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- pyrrolidin-l-yloxymethyl)-[l,3]-dioxolane-4-carbonyl]-amino ⁇ -propionic acid tert- butyl ester.
  • Step c Synthesis of triflate salt of l-((4S,5R)- ⁇ (S)-l-Carboxy-2-[4-(2,6-dichloro- benzyloxy)-phenyI]-ethylcarbomoyl ⁇ -[l,3]dioxolane-4-ylmethyl)-pyrrolidinum
  • Example 13 (SV3-r4-(2.6-Dichloro-benzyloxy -phenyll-2-r((S)-2,2-dimethyl- ⁇ .31 dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 122)
  • Step a Synthesis of lithium salt (S)-2,2-dmethyl-[l,3]dioxoIane-4-carboxylic acid To a solution of (S)-2,2-dimethyl-[l,3]dioxolane-4-carboxylic acid methyl ester
  • Step b Synthesis of (S)-3-[4-(2,6-Dichloro-benzyIoxy)-phenyl]-2-[((S)-2,2-dimethyl- [l,3]dioxo!ane-4-carbonyI)-amino]-propionic acid ethyl ester
  • Step c Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid ethyl ester (Compound No.
  • Example 14 (4R,5R)-[l,3]Dioxolane-4,5-dicarboxylic acid 4-(((S)-l-carbamoyl-2-[4- (2,6-dichloro-benzyloxy)-phenyl1-ethyl)-amino)-5-[(2-chloro-phenyl)-amide (Compound No. 118)
  • VCAM-1 (lOOng/well) was coated in Maxisorp microtitre modules at 4°C overnight. Non-specific blocking was carried out with 3% BSA for two hours and the wells washed with TBS (50mM) Tris, 0.15M NaCI pH 7.4, O.lmM CaCl , O.lmM MgCl 2 ). U937 cells were suspended in fresh medium and incubated at 37°C for two hours before the assay. Cells were then washed in TBS solution and 180 ⁇ l of cell suspension (lxl 0 6 cells/ml in TBS buffer) was added per well in VCAM-1 coated wells.
  • Compounds of this invention tested for activity have shown activities following this assay in the range of from about 100 nM to about 100 ⁇ M, for example, from about 100 nM to 10 ⁇ M, or from about 100 nM to about 3 ⁇ M, or from about 100 nM to about 1 ⁇ M.
  • the compounds disclosed herein for utility for the treatment of asthma and the symptoms of asthma, as well as for the treatment of multiple sclerosis, rheumatoid arthritis, allergic rhinitis, inflammatory bowel disease, and other cell adhesion - associated diseases and conditions and relief from the symptoms thereof.

Abstract

The present invention relates to dioxolane derivatives as cell adhesion inhibitors. These compounds can be useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. This invention also relates to pharmacological compositions containing the compounds of the present invention, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds.

Description

DIOXOLANE DERIVATIVES AS CELL ADHESION INHIBITORS
Field of the Invention The present invention relates to dioxolane derivatives as cell adhesion inhibitors. These compounds can be useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. This invention also relates to pharmacological compositions containing the compounds of the present invention, and the methods of treating bronchial asthma, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or autoimmune disorders, using the compounds.
Background of the Invention Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localize within the extra-cellular matrix. These interactions are mediated by specialized molecules called cell adhesion molecules (CAMs). CAMs have been demonstrated to participate in various cell-cell, cell-extracellular matrix, and platelet- platelet interactions. They influence the adhesion of leukocytes to the vascular endothelium, their transendothelial migration, retention at extravascular sites and activation of T cells and eosinophils. These processes are central to the pathogenesis of inflammatory and autoimmune diseases. Therefore, CAMs are considered as potential targets to treat such disorders. CAMs can be classified into three groups - integrins, selectins and the immunoglobulin superfamily. Of these, integrins are key mediators in the adhesive interactions between hemopoietic cells and their microenvironment. They are comprised of alpha-beta heterodimers that integrate signals from outside to the inside of cells and vice versa. Integrins can be classified on the basis of the beta subunits they contain. For example, the beta-1 subfamily contains beta-1 subunit noncovalently linked to one of the 10 different alpha subunits. The alpha-4 beta-1 integrin, also known as VLA-4 (very late activation antigen 4), is a member of the beta-1 integrin family, and comprises alpha-4 and beta-1 subunits. It interacts with two specific ligands, the vascular cell adhesion molecule (VCAM-1) and the CS1 region of the protein fibronectin. Adhesion mediated by VLA-4 is central to the process of transendothelial migration of leukocytes. Ligation of VLA-4 is followed by gross rearrangement of the cytoskeleton, leading to flattening of cells along the blood vessel wall, followed by expression of specific molecules, which digest the endothelial cell wall and diapedesis. Once in the extraluminal region, the interactions of VLA-4 with extracellular fibronectin play a crucial role in migration to the site of inflammation, T cell proliferation, and the expression of cytokines and inflammatory mediators. In addition, VLA-4 ligation provides co-stimulatory signals to the leukocytes, resulting in enhanced immunoreactivity. Therefore, it is expected that VLA-4 antagonists would ameliorate the immune response through twofold actions: inhibition of T cell recruitment at the site of inflammation; and inhibition of costimulatory activation of immune cells. In support of this concept, inhibitors of VLA-4 interactions have demonstrated beneficial therapeutic effects in several animal models of inflammatory, and allergic diseases including sheep allergic asthma. The region of CS1 moiety of fibronectin involved in the interaction with VLA-4 has been identified as the tripeptide Leu-Asp-Val, also known as LDV. Taking a lead from this, several peptides containing the LDV sequence were synthesised which have shown to inhibit the in vivo interaction of VLA-4 to its ligands. Despite these advances, there remains a need for small and specific inhibitors of VLA-4 dependent cell adhesion molecules. Engineering of new generation of more stable and potent molecules with improved oral efficacy would provide useful agents for treatment, prevention or suppression of various inflammatory pathologies mediated by VLA-4 binding. U.S. Patent No. 6,329,344 Bl discloses several monosaccharide derivatives as cell adhesion inhibitors. It generally relates to substituted pentose and hexose monosaccharide derivatives, which exhibit potent anti-cell adhesion and anti-inflammatory activities. PCT application WO 00/42054 discloses several monosaccharide derivatives as cell adhesion inhibitors. Patent application WO 00/43369 provides compounds which bind to VLA-4, as well as triazine derivatives which inhibit leukocyte adhesion mediated by VLA-4. WO 99/06434 discloses 4-aminophenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. WO 01/12186 discloses cell adhesion inhibitors which interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. WO 98/58902 discloses molecules which are potent inhibitors of α β,-mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing α β,-mediated adhesion mediated conditions. Ann. Rep. Med. Chem. 37, (2002) summaries the highlights of work in the area of VLA-4 biology and small molecule antagonists. U.S. Patent No. 6,291,511 discloses several biarylalkanoic acids as cell adhesion inhibitors. GB 2354440 discloses several aryl amides as cell adhesion inhibitors. WO 98/53814 discloses heterocyclic amide compounds as cell adhesion inhibitors. WO 01/12183 discloses heterocyclic amides as cell adhesion inhibitors. WO 99/20272 and U.S. Patent No. 6,069,163 discloses several azapeptide acids as cell adhesion inhibitors. U.S. Patent 6,020,347 discloses 4-substituted-4-piperidine carboxamide derivatives useful in the inhibition or prevention of cell adhesion and cell adhesion mediated pathologies. U.S. Patent 6,191,171 discloses para-aminomethyl aryl carboxamide derivatives as cell adhesion inhibitors. U.S. Patent 6,090,841 discloses substituted pyrrole derivatives as cell adhesion inhibitors. Bioorg & Med. Chem., JO (2002), 1567-1580 discloses synthesis of potential thrombm inhibitors and incorporation of tartaric acid templates as P2 pro line mimetics.
Summary of the Invention Herein are disclosed classes of compounds containing a dioxolane moiety which may be used as therapy for the inhibition, prevention and suppression of VLA-4 mediated cell adhesion and pathologies associated with such adhesion. The compounds of the present invention may be screened for inhibitory activity in VLA-4 mediated cell adhesion assay and the classical murine hypersensitivity assay in mice. These compounds could be used in treatment of chronic, cell adhesion mediated, allergic, autoimmune and inflammatory disorders, such as bronchial asthma, multiple sclerosis, rheumatoid arthritis etc. Some of the prior art describes development of peptide derivatives as cell adhesion antagonists for treatment of these diseases. However, because treatment of chronic diseases requires prolonged (mid term to long term) administration of drugs, development of small molecule, specific, orally available inhibitors of cell adhesion would be very beneficial. Herein are provided substituted dioxolane derivatives, which can be used as cell adhesion inhibitors. In accordance with one aspect of the invention, there is provided a compound having the structure of Formula I
Figure imgf000005_0001
Formula I its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein m is an integer from 0-2;
Ri can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclylalkyl;
R2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;
Ri and R2 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F,C1, Br, I), aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;
R3 can be NH2j NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or ORm (wherein Rm can be hydrogen, alkyl, aralkyl, aryl, or metal ions ( Na+, K+, Li+, Ca+ or Mg+ )); R4 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, -(CH2)ι-4-O-R' (wherein R' can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclylalkyl, or heteroarylalkyl), -C(=O)-R3 (wherein R is the same as defined above) -C(=O)Rz (wherein Rz is -NR7R wherein R and Rs can be independently selected from hydrogen (provided that both R7 and R8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO2R9 (wherein R9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R7 and Rg may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,C1, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or (CH2)ι- NRxRy [wherein Rx and Ry can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YRU (wherein Y is C(=O), C(=S) or SO and Ru is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), -C(-T)NRU (wherein T is oxygen, sulphur, -CH(NO ), -N(NO2) or -N(CN) and Ru is the same as defined above) or - C(=O)ORu (wherein Ru is the same as defined above)].
Rs and R$ may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R5 and R$ may together join to form a cycloalkyl ring. The following definitions apply to terms as used herein. The term "alkyl" unless and otherwise specified refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. Alkyl groups may further be substituted with one or more substituents selected such as alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, aryl, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryloxy, aminosulfonyl, aminocarbonylamino, aminothiocarbonylamino, hydroxyamino, alkoxyamino, nitro, SH, S-alkyl, S-Salkyl, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, SO2-aryl and -SO2- heteroaryl, further alkyl may be substituted with a group represented by (CH2)0- 3C(=O)NR R8 wherein R7 and R8 are same as defined earlier. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1 -3 substituents chosen from alkyl, carboxy, carboxy-alkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and - S(O)nRι2, where Rι2 can be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl and heterocyclyl and n is 0, 1 or 2; or or an alkyl group as defined above that is interrupted by 1-5 atoms of groups independently chosen from oxygen, sulfur and -NRa-} where Ra is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nRι2, where n and Rι2 are the same as defined earlier; or an alkyl group as defined above that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above. The term "alkenyl" refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 20 carbon atoms with cis or trans geometry either in a acyclic or cyclic ring system wherein the cyclic may include mono- or multicyclic ring forms. In the event that alkenyl is attached to the heteroatom, the double bond cannot be alpha to the heteroatom. Alkenyl groups may further be substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO- heteroaryl, -SO -alkyl, SO2-aryl and -SO2-heteroaryl, further alkenyl may be substituted with a group represented by (CH2)0-3C(=O)NR7R8 wherein R7 and R8 are the same as defined earlier. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF , amino, substituted amino, cyano, and -S(O)nRι2, where Rι2 is the same as defined above and n is 0, 1 or 2. The term "alkynyl" refers to a monoradical of an unsaturated hydrocarbon, preferably having from 2 to 20 carbon atoms. In the event that alkynyl is attached to the heteroatom, the triple bond cannot be alpha to the heteroatom. Alkynyl groups may further be substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO- heteroaryl, -SO2-alkyl, SO2-aryl and -SO2-heteroaryl; further alkynyl may be substituted with a group represented by (CH2)0-3C(=O)NR R8 wherein R7 and R8 are the same as defined earlier. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nRι2, where R|2 is the same as defined above and n is 0, 1 or 2. The term "cycloalkyl" refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, for example cyclobutyl, cyclopentyl, adamantyl and the like. Cycloalkyl groups may further be substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO- heteroaryl, -SO2-alkyl, -SO2-aryl and -SO2-heteroaryl; further cycloalkyl may be substituted with a group represented by (CH2)0-3C(=O)NR R8 wherein R7 and R8 are the same as defined earlier. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)„Rι , where Rι2 is the same as defined above and n is 0, 1 or 2. "Alkoxy" denotes the group O-alkyl wherein alkyl is the same as defined above. "Aralkyl" refers to (CH )P aryl, wherein p is an integer in the range of 1-6 and aryl is as defined below. The term "aryl" herein refers to phenyl or naphthyl ring and the like, which may optionally be fused to cycloalkyl or heterocyclyl. The aryl group may optionally be substituted with 1 to 3 substituents such as aryloxy, cyano, amino, aminothiocarbonyl, alkoxycarbonyl, azido, oxo, thiocarbonyl, thiol, cycloalkoxy, aminosulfonyl, aminocarbonylamino, hydroxy, hydrogen, halogen (F, CI, Br, I), alkyl, alkenyl, alkynyl, cycloalkyl, (CH2)0-3C(=O)NR7R8 wherein R7 and R8 are the same as defined earlier, - NHC(=O)R (wherein R9 is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl or heterocyclylalkyl), alkoxy, alkenyloxy, alkynyloxy, carboxy, nitro, aryl, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2- alkyl, -SO2-aryl and -SO2-heteroaryl, heteroaryl, heterocyclyl, amino, NR7R8 wherein R7 and R8 are the same as defined above;
Figure imgf000008_0001
or -NH-O-(CH2)0-4- (C=O)o-ιR9 wherein R9 is the same as defined above; SO„Rι2 wherein n is an integer in the range of 0-2 and R]2 is the same as defined above; C(=O)R wherein R can be hydrogen, alkyl, aryl, aralkyl, hydroxy, alkoxy, amino or substituted amino. The term "carboxy" as defined herein refers to -C(=O)O-Rι0 wherein Rι0 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl. "Aryloxy" denotes the group O-Aryl wherein aryl is the same as defined above. "Aralkoxy" denotes the group O-aralkyl wherein aralkyl is the same as defined above. "Substituted amino" unless and otherwise specified refers to a group -N(Rr)2 wherein each Rr can be hydrogen (provided that both Rr groups are not hydrogen), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, SO2Rι2 wherein Rι is the same as defined above; C(=O)Rι2 wherein Rι2 is the same as defined above; C(=O)ORl wherein Rl can be alkyl, aralkyl, heteroarylalkyl, aryl, heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF , amino, substituted amino, cyano, and -S(O)nRi2, where Rι2 is the same as defined above and n is 0, 1 or 2. The term "heteroaryl" as used herein refers to an aromatic ring structure containing 5 or 6 carbon atoms, or a bicyclic aromatic group having 8 to 10 carbon atoms, with one or more heteroatom(s) such as N, O and S optionally substituted with 1 to 3 substituent(s) which can be halogen (F, CI, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkoxy, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-aryl and -SO2-heteroaryl, aralkyl, cyano, nitro, amino or substituted amino, cyano, oxo, carboxy; C(=O)R wherein R is the same as defined earlier; C(=O)NR R8 wherein R7 and R8 are the same as defined earlier; or SOnRι2 wherein n and R]2 are the same as defined earlier. Further, heterocryl groups may optionally be fused to an aryl ring wherein aryl is the same as defined earlier. The term 'heterocyclyl" as used herein refers to a non aromatic cycloalkyl group having 5 to 10 atoms in which 1 to 3 carbon atoms in a ring are replaced by heteroatoms such as O, S or N, and are optionally benzofused or fused heteroaryl of 5-6 ring members and/or are optionally substituted wherein the substituents can be halogen (F, CI, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2- alkyl, -SO2-aryl and -SO2-heteroaryl, aryl, alkoxy, aralkyl, cyano, nitro, amino or substituted amino, cyano, oxo; =O)R wherein R is the same as defined earlier; C(=O)NR7R8 wherein R7 and R8 are the same as defined earlier; or SO„Rι2 wherein n and Rι2 are the same as defined earlier. The term "Heteroarylalkyl" refers to heteroaryl (wherein heteroaryl is same as defined earlier) linked through alkyl (wherein alkyl is the same as defined above) portion and the said alkyl portion contains carbon atoms from 1-6. The term "Heterocyclylalkyl" refers to heterocyclyl (wherein heterocyclyl is same as defined earlier) linked through alkyl (wherein alkyl is the same as defined above) portion and the said alkyl portion contains carbon atoms from 1-6. Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides of these compounds are also provided. Pharmaceutical compositions containing the compounds, which may also contain pharmaceutically acceptable carriers or diluents, can be used for the treatment of cell adhesion mediated pathologies including inflammatory and autoimmune diseases such as . bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The term "leaving group" generally refers to groups that exhibit the desirable properties of being labile under the defined synthetic conditions and also, of being easily separated from synthetic products under defined conditions. Examples of such leaving groups include but are not limited to halogen (F, CI, Br, I), triflates, tosylate, mesylates, alkoxy, thioalkoxy, hydroxy radicals and the like. The term "Protecting groups" is used herein to refer to known moieties which have the desirable property of preventing specific chemical reaction at a site on the molecule undergoing chemical modification intended to be left unaffected by the particular chemical modification. Also, protecting groups, unless otherwise specified, may be used with groups such as hydroxy, amino, carboxy and examples of such groups are found in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd Ed, John Wiley and Sons, New York, N.Y., which is incorporated herein by reference. The species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting group employed is not critical as long as the derivatised moieties/moiety is/are stable to conditions of subsequent reactions and can be removed at the appropriate point without distrupting the remainder of the molecule. Compounds provided herein can contain one or more asymmetric carbon atoms and thus can occur as racemates, mixtures of enantiomers, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included herein. Each stereogenic carbon may be of the R or S configuration. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are envisioned as part of the invention. Also, geometric isomers of olefins, C=N double bonds and the like, can be present in the compounds of this invention, and all such stable isomers are contemplated. Other aspects will be set forth in accompanying description which follows and in the part will be apparent form the description or may be learnt by the practice of the invention.
Detailed Description of the Invention The compounds disclosed herein may be prepared by techniques well known in the art and familiar to a synthetic organic chemist of ordinary skill. In addition, the compounds provided herein may be prepared by the following reaction sequences as depicted in Schemes I, II, III and IV. Scheme I
Figure imgf000011_0002
Figure imgf000011_0001
Formula VI
Figure imgf000011_0003
A compound of Formula XI, XII and XVI can be prepared according to Scheme I. Thus, a compound of Formula II is hydrolysed to give a compound of Formula III, which on condensation with a compound of Formula IV gives a compound of Formula V (wherein R7 and R8 are the same as defined earlier), which on further hydrolysis gives a compound of Formula VI, which on condensation with a compound of Formula VII (wherein P is a protecting group such as methyl, ethyl, t-butyl or benzyl) gives a compound of Formula VIII (wherein R is the same as defined earlier), which on condensation with a compound of Formula LX (Path a) (wherein Y is CI, Br, I, O-Ms or O- Ts) gives a compound of Formula X (wherein R9 is the same as defined earlier), which is finally hydrolyzed to give a compound of Formula XI (Formula I, Ri = H, R2 = aralkyl, R3 = -ORm where Rm is H, 1^= -C(=O)Rz where Rz is -NR7Rs and R5 and R may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R5 and Re may together join to form a cycloalkyl ring). For path a), R2 is p-hydroxybenzyl. The hydrolysis of a compound of Formula II to a compound of Formula III can be carried out in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof. The hydrolysis of a compound of Formula II to compound of Formula III can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. The condensation of a compound of Formula III with compound of Formula IV to give a compound of Formula V can be carried out in an organic solvent, for example tetrahydrofuran, dichloromethane or dimethylformamide. The condensation of a compound of Formula III with a compound of Formula IN can be carried out in the presence of an organic base, for example Ν-methylmorpholine, diisopropylethylamine or triethylamine. The condensation of a compound of Formula III with a compound of Formula IV can be carried out in a condensing agent, for example 1- (3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride, dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate. The hydrolysis of a compound of Formula V to give a compound of Formula VI can be carried out in a solvent system, for example tetrahydrofuran, methanol, ethanol, dioxane or water or combinations thereof. The hydrolysis of a compound of Formula V to give a compound of Formula VI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. The condensation of a compound of Formula VI with a compound of Formula VII to give a compound of Formula VIII can be carried out in a organic solvent, for example tetrahydrofuran or dimethylformamide. The condensation of a compound of Formula VI with a compound of Formula VII can be carried out in the presence of a condensing agent, for example l-(3-dimethylaminopropyl)-3-ethyl carbodiimide or dicyclohexylcarbodiimide. The condensation of a compound of Formula VI with a compound of Formula VII can be carried out in the presence of a base, for example N-methylmorpholine, diisopropylethylamine or triethylamine. The reaction of a compound of Formula VIII (Path a) with a compound Formula IX to give compound of Formula X can be carried out in an organic solvent, for example acetone, dichloromethane, carbon tetrachloride, dimethylformamide or chloroform. The reaction of a compound of Formula VIII with a compound Formula IX can be carried out in the presence of a base, for example, sodium hydride, sodium carbonate or potassium carbonate. The hydrolysis of a compound of Formula X to give a compound of Formula XI can be carried out in a solvent system, for example ethanol, dimethylformamide, dimethylsulphoxide, dioxane, tetrahydrofuran, methanol or water or combination thereof. The hydrolysis of a compound of Formula X (when P is methyl, ethyl or benzyl) to give a compound of Formula XI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. Alternatively, the hydrolysis of a compound of Formula X (when P is tert-butyl) to give a compound of Formula XI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid, in a solvent, for example tetrahydrofuran in water or dichloromethane.
Compound(s) prepared following the procedure described in Schemel (Path a) are:
(S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)- [l,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound no. 6)
(S)-2- {[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-[4- (2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.10)
Lithium salt of (S)-2- {[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No.l 1) Lithium salt of (S)-2- {[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3'-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No. 12) Lithium salt of (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxalane-4-carbonyl]- amino}-3-[4-(2-piperidin-l-yl-ethoxy)-phenyl]-propionate (Compound No. 13)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14)
Morpholine-4-carboxylic acid 4-((S)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15)
4-Methyl-piperazine-l-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [1 ,3]dioxolane-4-carbonyl]-amino} -2-carboxy-ethyl)-phenyl ester (Compound No. 16)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25) (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26)
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-(4- prop-2-ynyloxy-phenyl)-propionic-acid (Compound No. 27)
(S)-2-{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-difluoro-benzyloxy]-phenyl]-propionic-acid (Compound No. 30)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-{[(4R,5R)-5-phenyl-carbamoyl- [1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (compound no 32)
-(S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholine-4-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No.55) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,5-dichloro-phenyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No.71) A compound of Formula XII can be prepared according to Scheme I. Thus, hydrolyzing a compound of Formula VIII (Path b) can give a compound of Formula XII (Formula I, Ri =H, R3 = -ORm where Rm is H, R,= -C(=O)RZ where R2 = -NR7Rs and R5 and Rό are the same as defined earlier). The hydrolysis of compound of Formula VIII (when P is a protecting group such as methyl, ethyl or benzyl) to give a compound of Formula XII can be carried out in the presence of an organic base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. Alternatively, the hydrolysis of a compound of Formula VIII (when P is tert-butyl) to give a compound of Formula XI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid.
Compounds prepared following the procedures described in Scheme I (Path b) are:
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxy-phenyl)-propionic acid (Compound No. 1)
(S)-3-(4-Hydroxy-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[l,3]dioxolane- 4-carbonyl]-amino}-propionic acid (Compound No. 4)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxyl-phenyl)-propionic acid (Compound No. 24)
(S)-3-(4-(2,6-Dichlorobenzyloxy)-phenyl]-2-[{(4R,5R)-5-[thiophen-2-yl-methyl)- carbamoyl]-[ 1 ,3]dioxolane-4-carbonyl} -amino] -propionic acid (Compound No. 31)
(S)-2-{[(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridin-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No 33) (S)-2-{[(4S,5S)-5-(Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichlorobenzloxy-phenyl]-propionic acid (Compound No.34)
Lithium salt of (S)-2-[{(4R,5R)-5-Cyclopropyl-carbamoyl-[l,3]dioxolane-4-carbonyl}- amino]-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionate (Compound No. 36)
(S)-2-[ {(4R,5R)-5-Cyclohexane-carbamoyl-[ 1 ,3]dioxolane-4-carbonyl} -amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No 37)
(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{([4R,5R)-5-(thiazol-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 38)
(S)-2-{[(4R,5R)-5-(Cyclopropyl-carbamoyl)-[l,3]dioxolane-4-carbonyl)-amino]-3-{4- [(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No 39) (S)-2-[{(4R,5R)-5-Cyclohexyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-{4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 40)
(S)-2-{[4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbamoyl]-amino}- 3- {4-[(pyridine-4-carbonyl-amino]-phenyl} -propionic acid (Compound No. 41)
(4R,5R)-5-[(S)-l-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[l,3]dioxolane-4- carboxylic acid ethyl ester (Compound No. 42)
(S)-2- {[(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} - 3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic-acid (Compound No. 45)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-isopropylcarbamoyl- [l,3]dioxolane-4-carbonyl} -amino]- propionic acid (Compound No.47) (S)-2-{[(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.53)
(S)-3-[4-(2,6,-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,3-dihydro-indole-l- carbonyl)-[l, 3 ]dioxolane-4-carbonyl] -amino} -propionic acid (Compound No. 62)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-methyl-[l,3,4]thiadiazol-2- yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No.63)
(S)-2{[(4R,5R)-5-(Biρhenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxyphenyl)-propionic acid (Compound No. 64)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[4R,5R)-5-(2,6-dichlorophenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 72)
(S)-2-{[4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-difluoro- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92)
(S)-2-{[(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl)-amino}-3- (4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 93) (S)-2-{[(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- (4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 94)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98)
(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,4-dimethyl-isoxazol-5- ylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]amino-propionic acid (Compound No. 107)
{2-[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolone-4-carbonyl]-l,2,3,4- tetrahydro-isoqunoline}-3-carboxylic acid (Compound No. 109)
2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(lH- indol-3-yl)-propionic acid (Compound No. 110) (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino)-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. I l l)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113) (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[l,3]dioxolane-4- carbonyl]amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 1-15) (S)-2- {[(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[l ,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133)
3-Benzo[ 1 ,3]dioxol-5-yl-3- {[(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4- carbonyl] -amino} -propionic acid (Compound No. 134)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(2- methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135) (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid (Compound No. 136)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- (2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137)
(S)-3-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}- propionic acid (Compound No. 138)
3-[((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-(3,4-dimethoxy- benzyl)-amino] -propionic acid (Compound No. 140)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-(3,5-dichloro-pyridin-4- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 142) (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-[((4R,5R)-5-(2-fluoro- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 143)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[2-(lH-indol-3-yl)- ethylcarbamoyl]-[l,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 144)
(S)-2-[((4R,5R)-5-Cyclohexylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl] -propionic acid (Compound No. 145) (S)-2-[((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[(thiophen-2-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 148)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(thiazol-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 150)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 154) A compound of Formula XVI can be prepared according to Scheme I. Thus a compound of Formula VIII (Path c) is reduced to give compound of Formula XIII (wherein R and R8 are the same as defined earlier), which on condensation with a compound of Formula XIV (wherein X is OH, CI or Br) gives a compound of Formula XV (wherein R9 is the same as defined earlier), which is finally hydrolysed to give a compound of Formula XVI (Formula I, Rj =H, R2=aralkyl, R4= -C(=O)Rz where Rz is - NR7Rs and R5 and R are the same as defined earlier). For path c), R2 is p-nitro benzyl. The reduction of a compound of Formula VIII to give a compound of Formula XIII can be carried out in the presence of hydrogen using a catalyst, for example palladium on carbon or platinum on carbon. The condensation of a compound of Formula XIII with a compound of Formula XIN to give a compound of Formula XV can be carried out in an organic solvent, for example dimethylformamide, tetrahydrofuran or dimethylsulphoxide. The condensation of a compound of Formula XIII with a compound of Formula XIV can be carried out in the presence of an organic base, for example N-methylmorpholineτ triethylamine or diisopropylethylamine. The condensation of a compound of Formula XIII (when X is OH) with a compound of Formula XIV can be carried out in the presence of a condensing agent, for example l-(3-dimethylaminopropyl)-3-carbodiimide or dicyclohexyl carbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate. Alternatively, the condensation of a compound of Formula XIII (when X is CI or Br) with a compound of Formula XIV can be carried out in the presence of an organic base, for example N-methylmorpholine, triethylamine or diisopropylethylamine. The hydrolysis of a compound of Formula XV to give a compound of Formula XVI can be carried out in a solvent or solvent system, for example ethanol, tetrahydrofuran, dimethylformamide, dimethylsulphoxide, dioxane, methanol or water or combinations thereof. The hydrolysis of a compound of Formula XV (when P is a protecting group such as methyl, ethyl or benzyl) to give a compound of Formula XVI can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. Alternatively, the hydrolysis of a compound of Formula XV (when P is tert-butyl) to give a compound of Formula XVI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid. Compound(s) prepared following the procedure described in Scheme 1 (path c) are:
(S)-2- {[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 2) (S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 3)
(S)-2- {[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 5)
(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7)
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4- [(pyridine-4-carbonyl)-amino]-ρhenyl} -propionic acid (Compound No. 17)
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4- [(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 18)
(S)-2-{[(4R,5R)-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(piperidine-4-carbonyl)-amino]-phenyl}-propionic-acid, salt with trifluoroacetic acid (Compound No.19)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridine-3-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 20)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridine-2-carbonyl)-amino]-phenyl} -propionic-acid (Compound No. 21 )
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [6-bromo-pyridine-2-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 22) (S)-3-(4-Benzoylamino-phenyl)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[l ,3]dioxolane- 4-carbonyl] -amino} -propionic acid (Compound No. 23)
(S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(4R,5R)-5-(2-methoxy- benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 28)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2- methoxy-benzyl-amino)-phenyl]-propionic acid (Compound No 29)
(S)-3-(4-benzoylaminophenyl)-2-[ {(4R,5R)-5-(isopropyl-carbamoyl)-[ 1 ,3]dioxolane-4- carbonyl} -amino] -propionic acid (Compound No. 43)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-methoxy- benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 151) Scheme II
Figure imgf000020_0001
A compound of Formula XXI can be prepared according to Scheme II. Thus, a compound of Formula III is condensed with a compound of Formula XVII (wherein P is the same as defined earlier) to give a compound of Formula XVIII (wherein R2 is the same as defined earlier), which on hydrolysis (Path a) gives a compound of Formula XIX, which on condensation with a compound of Formula IV gives a compound of Formula XX (wherein R7 and R8 are same as defined earlier), which is finally hydrolysed to give a compound of Formula XXI (Formula I, Ri = H, R3 = -ORm where Rm is H, R4= -C(=O)Rz wherein Rz = -NR R8 and R5 and R$ may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R5 and R may together join to form a cycloalkyl ring). The condensation of a compound of Formula III with compound of Formula XVII to give a compound of Formula XVIII can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide or dimethylsulphoxide. The condensation of a compound of Formula III with a compound of Formula XVII can be carried out in the presence of an organic base, for example N-methylmorpholine, diisopropylethylamine or triethylamine. The condensation of a compound of Formula III with a compound of Formula XVII can be carried out in the presence of a condensing agent, for example l-(3- dimethylaminopropyl)-3 -ethyl carbodiimide hydrochloride or dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate. The hydrolysis of a compound of Formula XVIII (when P is ethyl) to give a compound of Formula XIX can be carried out in a solvent system, for example ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof. The hydrolysis of a compound of Formula XVIII (when P is ethyl) to give a compound of Formula XIX can be carried out in a presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. The condensation of a compound of Formula XIX with a compound of Formula IV to give a compound of Formula XX can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide or dimethylsulphoxide. The condensation of a compound of Formula XIX with a compound of Formula IV can be carried out in the presence of an organic base, for example N-methylmorpholine, diisopropylethylamine or triethylamine. The condensation of a compound of Formula XIX with a compound of Formula IV to give a compound of Formula XX can be carried out with condensing agent for example l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride or dicyclohexylcarbodiimide or by a mixed anhydride reaction using chloroformates, for example ethyl chloroformate or isobutyl chloroformate. Alternatively the condensation of a compound of Formula XIX with a compound of Formula IV can also be carried out by mixed anhydride reaction using chloroformates for example, ethyl chloroformate or isobutyl chloroformate. The hydrolysis of a compound of Formula XX (when P is t-butyl) to give a compound of Formula XXI can be carried out in a solvent, for example tetrahydrofuran in water or dichloromethane. The hydrolysis of a compound of Formula XX (when P is t-butyl) to give a compound of Formula XXI can be carried out in the presence of an acid, for example trifluoroacetic acid or hydrochloric acid. The hydrolysis of a compound of Formula XX (when P is ethyl, methyl or benzyl) to give a compound of Formula XXI can be carried out in an organic solvent for example, ethanol, dimethylformamide, tetrahydrofuran, dimethylsulphoxide, dioxane, methanol or water or combinations thereof. The hydrolysis of a compound of Formula XX (when P is ethyl, methyl or benzyl) can be carried out in a presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide Compound(s) prepared following the procedure described in Scheme II (Path a) are: (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl-2-{[(4R,5R)-5-(4-methyl-piperazine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid salt with trifluoroacetic acid (Compound No 44)
(S)-2-[ {(4R,5R)-5-tert-Butyl-carbamoyl-[ 1 ,3]dioxolane-4-carbonyl} -amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48)
(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-[{(4R,5R)-5-(3-methyl-butylcarbamoyl)- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 49) (S)-3-[4-(2,6,Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(R)-l-phenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 50)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(S)-l-phenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 51)
(S)-l-{(4R,5R)-5-{(S)-l-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl- carbamoyl}-[l,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid benzyl ester(Compound No. 52) (S)-2-[(4R,5R)-{5-Benzyloxy-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54)
(S)-2-[((4R,5R)-{5-allyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56) l-{(4R,5R)-5-[(S)-l-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid (Compound No.57)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(tetrahydro-furan-2-yl- methyl)-carbamoyl]-[ 1 ,3]dioxolane-4-carbonyl} -amino] -propionic acid (Compound No. 58)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[2-(lH-indol-3-yl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 59)
(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(2-thiophen-2-yl-ethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 60)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[(pyridin-4-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.61)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-(methyl-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.65) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{4R,5R)-5-[methyl-(l-methyl-ρiρeridine-4- yl)-carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 66)
(S)-3-[4-(2,6-Dichloro-benzyloxy-ρhenyl]-2-{[(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 67)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-phenyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 68)
(S)-2-{[(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69)
(S)-2- {[(4R,5R)-5-(3-Chloro-ρhenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-o-tolyl-carbamoyl- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound no.73) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-dimethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl)-2-[{(4R,5R)-5-methyl-carbamoyl- [l,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75)
(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methoxy-carbamoyl- [l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 76)
(4R,5R)-5-{(S)-l-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl]- ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid (Compound No.77)
(S)-2,3-[4(2,6-Dichloro-benzyloxy)-ρhenyl]-2-[{(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 78)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyrrolidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(R)-3-hydroxy-pyrrolidine-l- carbonyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 80) l-((4R,5R)-5-{(S)-l-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]- ethylcarbamoyl}-[l,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(l-hydroxymethyl- propylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 82)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-[((4R,5R)-5-ethylcarbamoyl-[l,3]dioxolane- 4-carbonyl)-amino] -propionic acid (Compound No. 83) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-prop-2-ynylcarbamoyl- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 84)
Trifluoro acetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2- moφholin-4-yl-ethylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 85)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 86)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(piperidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 87)
(S)-2-{[(4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 91)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-((R)-2-hydrox-l-phenyl- ethylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 97) (S)-2-{[(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 99)
(S)-2- {[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-trifluoromethyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 102)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropoxy- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 103) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-piperidine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 104)
(S)-2-{[(4R,5R)-5-Cyclopentylcarbamoyl-[l,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl] -propionic acid (Compound No. 105)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-hexylcarbamoyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 106)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyridin-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 108) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 112)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy- cyclohexylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 114)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-heptylcarbamoyl- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 116)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 117)
(S)-2-{[(4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[l,3]dioxolane-4- carbonyl]-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119)
(S)-2-[((4R,5R)-5-cycloheptylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulphanyl-
[ 1 ,3,4]thiadiazol-2-ylcarbamoyl)-[l ,3]dioxolane-4-carbonyl]-amino} -propionic acid
(Compound No. 121) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethylthiazol-2- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 123)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-oxo-piperidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 125)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(indan-5-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 127)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{((4R,5R)-5-phenethylcarbamoyl- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 128)
(S)-2-( {(4R,5R)-5-[(Benzo[ 1 ,3]dioxol-5-ylmethyl)-carbamoyl]-[ 1 ,3]dioxolane-4- carbonyl}-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129)
(S)-2-{[(4R,5R)-5-Butylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro- benzyloxy)-phenyl] -propionic acid (Compound No. 130)
(S)-2-{[(4R,5R)-5-(4-Acetyl-piperazine-l-carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}- 3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 131)
(S)-2- {[(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 132) (S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-[((4R,5R)-5-octylcarbamoyl-[l,3]dioxolane- 4-carbonyl)-amino]-propionic acid (Compound No. 139)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2- {[(4R,5R)-5-(4-methyl-piperazine- 1 - carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 152)
(S)-2-{[(4R,5R)-5-Cyclopropylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl] -propionic acid (Compound No. 153) A compound of Formula XXI can be prepared according to Scheme II, thus a compound of Formula XVIII (Path b) undergoes hydrolysis to give a compound of Formula XXII. The hydrolysis of a compound of Formula XVIII to give a compound of Formula XXII can be carried out in a solvent system, for example tetrahydrofuran in water or dichloromethane. The hydrolysis of a compound of Formula XVIII to give a compound of Formula XXII can be carried out in the presence of an acid, trifluoroacetic acid or hydrochloric acid. The compound of Formula XXII is condensed with a compound of Formula IV to give a compound of Formula XXI in an organic solvent, for example methanol, ethanol, dimethylformamide or tetrahydrofuran. Compounds(s) prepared following Scheme II, path b are:
(4R,5R)-5-{(S)-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethylcarbamoyl]- [l,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46)
(S)-2-[((4R,5R)-5-Carbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro- benzyloxy)-phenyl] -propionic acid (Compound No. 96)
A compound of Formula XXIV can be prepared according to Scheme II thus a compound of Formula XVIII (Path c) is reacted with a compound of Formula IX to give a compound of Formula XXIII, which undergoes hydrolysis to give a compound of Formula XX1N. The reaction of a compound of Formula XVIII with a compound of Formula IX to give a compound of Formula XXIII can be carried out in a organic solvent, for example acetone, dichloromethane, tetrahydrofuran, dimethylformamide or acetonitrile. The reaction of a compound of Formula XVIII with a compound of Formula IX can be carried out in the presence of a base, for example sodium hydride, sodium carbonate or potassium carbonate. The hydrolysis of a compound of Formula XXIII (when P is ethyl, methyl or benzyl) to give a compound of Formula XXIV is carried out in a solvent system, for example ethanol, dimethylformamide, dimethylsulphoxide, dioxane, tetrahydrofuran, methanol or water or combinations thereof. The hydrolysis of a compound of Formula
XXIII (when P is ethyl, methyl or benzyl) to give a compound of Formula XXIV can be carried out in the presence of base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide. Alternatively, when P is t-butyl, the hydrolysis of a compound of
Formula XXIII to give a compound of Formula XXIV in the presence of a base for example, lithium hydroxide, sodium hydroxide or potassium hydroxide followed by hydrolysis in the presence of an acid for example trifluoroacetic acid or hydrochloric acid in an organic solvent, for example tetrahydrofuran in water or dichloromethane. Compound(s) prepared following Scheme II, Path c are: (4R,5R)-5-{(S)-l-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl}- [l,3]dioxolane-4-carboxylic acid (Compound No. 35)
Figure imgf000027_0001
Compounds of Formulae XXVII, XXXIII, XXXIV and XXXII can be prepared according to Scheme III. Thus, a compound of Formula XXV [wherein P] is alkyl (for example, ethyl or t-butyl) or aralkyl (for example, benzyl) and R2, R5 and Rό are the same as defined earlier] is reduced to give a compound of Formula XXVI, which is hydrolyzed (Path a) to give a compound of Formula XXVII. The reduction of a compound of Formula XXV to give a compound of Formula
XXVI can be carried out in an organic solvent, for example tetrahydrofuran, dimethoxyethane, diethoxyethane, methanol, dioxane or water or combination thereof. The reduction of a compound of Formula XXV to give a compound of Formula XXVI through an intermediacy of a mixed anhydride can be carried out in the present of a base, for example N-methylmorpholine, pyridine, triethylamine or diisopropylethylamine with chloroformates, for example ethyl chloroformate or isobutyl chloroformate. The reduction of a compound of Formula XXV to give a compound of Formula XXVI can be carried out with a reducing agent, for example sodium borohydride or sodium cyanoborohydride. The hydrolysis a compound of Formula XXVI (when Pi is ethyl) to give a compound of Formula XXVII can be carried out in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof. The hydrolysis of a compound of Formula XXVI (when Pi is ethyl) to give a compound of Formula XXVII can be carried out in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. The hydrolysis of a compound of Formula XXVI (when Pi is t-butyl) to give a compound of Formula XXVII can be carried out in an organic solvent, for example, tetrahydrofuran in water or dichloromethane. The hydrolysis of a compound of Formula XXVI (when Pi is t-butyl) to give a compound of Formula XXVII can be carried out in the presence of an acid, for example, trifluoroacetic acid or hydrochloric acid. Compound(s) prepared following the procedure described in Scheme III (Path a) include:
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxymethyl-[l,3]dioxolane- 4-carbonyl)-amino]-propionic acid (Compound No. 95) A compound of Formula XXXIII and XXXIV can be prepared according to Scheme III. Thus a compound of Formula XXVI (Path b) is reacted with a compound Rm- hal [wherein Rm is alkyl and hal is halogen (CI, Br, I)] to give a compound of Formula XXVIII and XXIX, which are further hydrolyzed to give a compound of Formula XXXIII and XXXrV. The reaction of a compound of Formula XXVI with a compound Rm-hal to give a compound of Formula XXVIII and XXIX can be carried out in an organic solvent, for example tetrahydrofuran, dimethylformamide, di ethyl ether or dioxane. The reaction of a compound of Formula XXVI with a compound Rm-hal to give a compound of Formula XXVIII and XXIX can be carried out in the presence of a base, for example sodium hydride or potassium tert-butoxide. A compound of Formula XXVIII and XXIX (Pi is t- butyl) can be hydrolyzed to give a compound of Formula XXXIII and XXXIV in the presence of an acid for example trifluoroacetic acid or hydrochloric acid in a solvent system, for example tetrahydrofuran in water or dichloromethane. A compound of Formula XXVIII and XXIX (when Pi is ethyl) can be hydrolyzed to give a compound of
Formula XXXIII and XXXIV in the presence of a base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof. Compounds prepared following the procedure described in Scheme III (Path b) are:
(S)-2-[((4R,5R)-5-Benzyloxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-methoxymethyl-[l,3]dioxolane- 4-carbonyl)-methyl-amino] -propionic acid (Compound No. 126)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[l,3]dioxolane- 4-carbonyl)-amino]-propionic acid (Compound No. 141) A compound of Formula XXXII can be prepared according to Scheme III. Thus a compound of Formula XXVI (Path c) is reacted with a compound L-hal [wherein OL is mesyl or tosyl and hal is halogen (CI, Br, I)] to give a compound of Formula XXX, which is reacted with a compound IV (wherein R7 and R8 are the same as defined earlier) to give a compound of Formula XXXI, which undergoes hydrolysis to give a compound of Formula XXXII. A compound of Formula XXVI is reacted with a compound L-hal to give a compound of Formula XXX in an organic solvent, for example dichloromethane, dichloroethane, chloroform or carbon tetrachloride. The reaction of a compound of Formula XXVI with a compound L-hal to give a compound of Formula XXX can be carried out in the presence of a base, for example triethylamine, pyridine, sodium carbonate, sodium bicarbonate or diisopropylethylamine. The reaction of a compound of Formula XXX with a compound of Formula IV to give a compound of Formula XXXI can be earned out in an organic solvent, for example tetrahydrofuran, dimethylformamide, dioxane or di ethyl ether. The reaction of a compound of Formula XXX with a compound of Formula IV to give a compound of Formula XXXI can be carried out in the presence of an organic base, for example diisopropylethylamine, pyridine, N-methylmorpholine or triethylamine. The hydrolysis of a compound of Formula XXXI (when Pi is t-butyl) to give a compound of Formula XXXII can be carried out in a solvent, for example dichloromethane or tetrahydrofuran in water with an acid, for example trifluoroacetic acid or hydrochloric acid. The hydrolysis of a compound of Formula XXXI (when Pi is ethyl) to give a compound of Formula XXXII can be carried out in the presence of a base for example, lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent system for example, tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof. Compounds(s) prepared following the procedure described in Scheme III (Path c) include:
Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezyloxy)-phenyl]-2-[((4R,5S)-5-ρyrrolidin- l-ylmethyl-[l,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146).
Scheme IV
Hydrolysis
Figure imgf000030_0002
Figure imgf000030_0001
Formula XXXV Formula XXXVI Formula XXXVII hydrolysis
Figure imgf000030_0003
Formula XXXVIII A compound of Formula XXXVIII can be prepared according to Scheme IV. Thus a compound of Formula XXXV (wherein R5 and Rό are the same as defined earlier Rt is H or CH3) undergoes hydrolysis to give a compound of Formula XXXVI, which is reacted with a compound of Formula VII to give a compound of Formula XXXVII, which is hydrolyzed to give a compound of Formula XXXVIII. A compound of Formula XXXV undergoes hydrolysis to give a compound of
Formula XXXVI in a solvent system, for example tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof in the presence of base, for example lithium hydroxide, sodium hydroxide or potassium hydroxide. The reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out in an organic solvent for example, dimethylformamide, tetrahydrofuran, dioxane or di ethyl ether. The reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out in the presence of an organic base for example, in the presence of an organic base for example, N-methylmorpholine, triethylamine, pyridine or diisopropylethylamine. The reaction of a compound of Formula XXXVI with a compound of Formula VII to give a compound of Formula XXXVII can be carried out with a condensing agent for example, l-(3-dimethylaminopropyl)-3-ethylcarbodiimide or dicyclohexylcarbodiimide. The hydrolysis of a compound of Formula XXXVII to a compound of Formula XXXVIII can be carried out in a solvent system for example, tetrahydrofuran, tetrahydrofuran, methanol, dioxane, ethanol or water or combinations thereof. The hydrolysis of a compound of
Formula XXXVII to a compound of Formula XXXVIII can be carried out in the presence of a base for example lithium hydroxide, sodium hydroxide or potassium hydroxide. Compound(s) prepared following the procedure described in Scheme IV are:
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-amino] -propionic acid (Compound No. 122) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((R)-2,2-dimethyl-[ 1 ,3]dioxolane-4- carbonyl)-amino] -propionic acid (Compound No. 124)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-2,2,5-trimethyl-[l,3]dioxolane-4- carbonyl)-amino] -propionic acid (Compound No. 149)
Scheme V
Figure imgf000031_0001
Formula XL
A compound of Formula XL can be prepared according to Scheme V. Thus, a compound of Formula VI is condensed with a compound of Formula XXXIX to give a compound of Formula XL. The condensation of a compound of Formula VI with a compound of Formula
XXXIX to give a compound of Formula XL can be carried out in an organic solvent for example, tetrahydrofuran, dimethylformamide, dioxane or diethyl ether. The condensation of a compound of Formula VI with a compound of Formula XXXIX to give a compound of Formula XL can be carried out in the presence of a base for example, N- methylmorpholine, triethylamine, pyridine or diisopropylethylamine. The condensation of a compound of Formula VI with a compound of Formula XXXIX to give a compound of
Formula XL can be carried out with condensing agents for example, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide or dicyclohexylcarbodiimide. The reaction of a compound of Formula VI with a compound of Formula XXXIX to give a compound of
Formula XL can also be carried out by a mixed anhydride reaction using chloroformates for example, ethyl chloroformate or isobutyl chloroformate. The compounds(s) prepared following the procedure described in Scheme V include:
(4R,5R)-[l,3]Dioxolane-4,5-dicarboxylic acid-4-({(S)-l-carbamoyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethyl}-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118)
Table I
Figure imgf000032_0001
Formula I (wherein Rι=H, R2= /-©-« , R3= -ORm where Rm=H, R»= -C(=O)R2, R5=R6=H, m=0)
Figure imgf000032_0002
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0004
* li hi l f ** represents trifluoro acetate salt of *** diastereomer of Compound No. 2 **** represents isomer of Compound No. 50 ***** diastereomer of Compound No. 9
Table II
Figure imgf000037_0001
Formula (wherein R,=H,
Figure imgf000037_0002
R6 = H, m=0)
Figure imgf000037_0003
Table III
Figure imgf000038_0001
Formula I (wherein R5=R6=H and m=0)
Figure imgf000038_0002
Table IV
Figure imgf000039_0001
Formula I
****** represents a diastereomer of Compound No. 124. EXPERIMENTAL
General procedure: Synthesis of (4R, 5R)-[ 1 ,31dioxolane-4, 5-dicarboxylic acid diethyl ester (Formula II) The title compound was prepared following the procedure outlined in Biorg. Med. Chem. 10, 1567-1580 (2002) starting from diethyl L-tartrate.
Synthesis of (4R.5R)-[1.31dioxolane-4, 5-dicarboxylic acid monoethyl ester (Formula III) An ethanolic solution of potassium hydroxide (2.68 gm in 100 ml of ethanol) was added dropwise to a solution of diethyl (4R, 5R)-[l,3]dioxolane-4,5-dicarboxylate (20 gm) in ethanol (150 ml), and the reaction mixture was stirred at room temperature for 1 hour.
The reaction mixture was concentrated and the crude oil was taken in water and extracted with ethyl acetate (2x50 ml). The aqueous layer was then acidified (cone. HC1) and extracted with ethyl acetate (2x200 ml). The combined organic extracts were then washed with water and brine (100 ml) and dried over sodium sulphate. Evaporation of the solvent under vacuo furnished the title compound (8.7g crude) as a sticky solid.
1H NMR (CDC13, 300 MHz):δ 5.32 (1H, s) & 5.25 (1H, s) [OCH2O], 4.81 (2Η, s, OCHχ2), 4.30 (2Η, q, J=7.1Hz, OCH2) and 1.39 (3Η, t, J=7.1Hz, CH3).
SCHEME 1 PATH C PROCEDURE Example 1 : Synthesis of (SV2-ir(4R. 5RV5-(Biρhenyl-2-yl-carbamoyl)-rL3]dioxolane-4- carbonvπ-amino) -3- (4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 17)
Step 1: Synthesis of (4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester.
N-methyl-morpholine (NMM) (265 mg, 2.63 mmol) was added to the compound of Formula III (0.5 g, 2.63 mmol) in dry tetrahydrofuran (10 ml) at -15°C followed by the addition of ethyl chloroformate (285 mg, 2.63 mmol). The reaction mixture was stirred at the same temperature for 30 min. and then 2-aminobiphenyl (444 mg, 2.63 mmol) and p- toluenesulfonic acid (49 mg, 0.263 mmol) were added. The reaction mixture was stirred at -10°C for 30 min. followed by stirring at 0°C for 2 hour and then at room temperature overnight. The reaction was quenched with water and extracted the compound with ethyl acetate (2x25 ml). The combined organic extract was washed with brine and dried over sodium sulphate and concentrated to obtain the crude residue. The residue was then purified over a silica gel column using 30% ethyl acetate hexane as eluent to obtain the title compound (0.6 gm, 67%) as a light yellow solid. 1H NMR (CDC13, 300 MHz): δ 8.45 (IH, s, NH), 8.36 (1Η, d, J=9Ηz) & 7.20-7.50 (8H, m) [aromatic], 5.02 (IH, s) & 4.87 (IH, s) [OCH2O], 4.86 (1Η, d, J=3Ηz) & 4.68 (IH, d, J=3Hz) [OCHχ2], 4.28 (2Η, q, J=6Hz, OCH2) and 1.32 (3Η, t, J=6Hz, CH3). LCMS (m/e): 342.5 (M+l, 100%).
Step 2: Synthesis of (4R, 5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carboxylic acid.
Hydrolysis of the ethyl ester obtained from step 1 above (3.2 gm, 9.3 mmol) in tetrahydrofuran: water: methanol (3:1:1, 10 ml) using lithium hydroxide monohydrate (394 mg, 9.3 mmol) afforded after general aqueous workup and acidification, the title compound (2.7 gm, 93%) as a white solid.
1H NMR (DMSO-d6, 300 MHz):δ 9.30 (IH, s, NH), 7.75 (1Η, d, J=7.8Ηz) & 7.25-7.50 (8H, m) [aromatic], 5.00 (2H, d, J=3Hz, OCH2O) and 4.69 (1Η, d, J=1.5Ηz) & 4.59 (IH,
Figure imgf000041_0001
Step 3: Synthesis of Methyl (S)-2-{[(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyI]-amino}-3-(4-nitro phenyl)-propionate.
4-Nitro-L-phenylalanine methyl ester hydrochloride (1.24g, 4.7 mmole), N- methylmorpholine (1.19 gm, 11.8 mmol) and hydrobenzotriazole (646 mg, 4.8 mmol) were added to the acid obtained from step 2 above (1.5 g, 4.7 mmol) in dry dimethyl formamide (10 ml) at 0°C. The reaction mixture was stirred at 0°C temperature for 30 min. followed by addition of l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC.ΗC1) (915 mg, 4.8 mmol). The reaction mixture was warmed gradually and stirred at room temperature overnight. The reaction mixture was taken into water (50 ml) and organic compound was extracted with ethyl acetate (2x50 ml). The combined organic layer was washed with water and brine and dried over sodium sulphate (anhydrous). Evaporation of the solvent followed by purification of the residue over a silica gel column using 2.5% methanol dichloromethane as eluent furnished the title compound (1.78 g, 73%) as a solid.
'H NMR (CDC13, 300 MHz): δ 8.41 (IH, s, NH), 8.30 (1Η, d, J=6Ηz), 8.17 (2H, d, J=9Hz), 7.15-7.50 (1 IH, m) [aromatic], 4.95 (IH, s), 4.77 (IH, s) [OCH2O], 4.93 (1Η, m, NCH), 4.65 (1Η, d, J=6Ηz) & 4.56 (IH, d, J=6Hz) [OCHχ2], 3.77 (3Η, s, OCH3) and 3.33 (1Η, dd, J=15 and 6Ηz) & 3.19 (IH, dd, J=15 and 6Hz) [CH2Ar]. LCMS (m/e): 520.4 (M+l, 100%).
Step 4: Synthesis of Methyl (S)-3-(4-amino-phenyl)-2-{[(4R, 5R)-5-(biphenyI-2- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionate.
Palladium on carbon (10% dry, 300 mg) was added to the nitro compound obtained from step 3 above (1.7 gm) in tetrahydrofuran (50 ml), and the reaction mixture was shaken under a hydrogen atmosphere at 50 psi for 3 hour. The reaction mixture was filtered through a celite pad and the filtrate was concentrated to obtain the title compound (1.4 gm, 88%>) as a solid.
1H NMR (CDC13, 300 MHz): δ 8.44 (IH, s), 8.32 (IH, d, J=8.1Hz), 6.25-7.50 (8H, m), 6.95 (IH, d, J=8.4Hz), 6.89 (2H, d, J=8.1Hz) & 6.60 (2H, d, J=8.1Hz) [aromatic & NH], 4.91 (1Η, s) & 4.78 (1Η, s) [OCH2O], 4.81 (1Η, m, NCH), 4.68 (1Η, d, J=3.9 Ηz) & 4.64 (1Η, d, J=3.6Ηz) [OCHx2], 3.72 (3Η, s, OCH3) and 2.95-3.10 (2Η, m, CH2Ar). LCMS (m/e): 490.5 (M+l, 100%).
Step 5: Synthesis of Methyl (S)-2-{[((4R, 5R)-5-biphenyl-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}- propionate.
The aniline obtained from step 4 above (150 mg, 0.31 mmol) in dry dimethyl formamide (2.5 ml) was coupled to isonicotinic acid (37 mg, 0.31 mmol) following the conditions as used for step 3 above, using hydroxybenzotriazole (45 mg, 0.33 mmol), N- methylmorpholine (35 mg, 0.35 mmol) and l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC.ΗC1)(60 mg, 0.32 mmol) to furnish the title compound (110 mg, 61%) as a solid after column purification over silica gel. 1H NMR (CDCI3, 300 MHz): δ 8.81 (2H, d, J=4.5 Hz), 8.41 (IH, s, NH), 8.26 (1Η, d, J=6Ηz), 7.86 (IH, s, NH), 7.70 (2Η, d, J=4.5Hz), 7.59 (2H, d, J=7.5Hz), 7.17-7.50 (8H, m), 7.15 (2H, d, J=8.1Hz) & 7.02 (IH, d, J=9Hz) [aromatic], 4.94 (IH, s) & 4.85 (IH, s) [OCH2O], 4.89 (1Η, m, NCH), 4.66 (1Η, bs) & 4.63 (1Η, bs) [OCHχ2], 3.75 (3Η, s, OCHs) and 3.19 (1Η, m) & 3.09 (1Η, m) [2Η, m, CH2Ar].
Step 6: Synthesis of (S)-2-{[(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid.
The compound obtained from step 5 above (104 mg, 0.1 mmol) was subjected to basic hydrolysis using lithium hydroxide monohydrate (7.6 mg, 0.18 mmol) following the procedure as described in step 2 above furnished after acidic workup the title compound
(60 mg, 58%) as a solid.
1H NMR (DMSO-d6, 300 MΗz):δ 10.46 (IH, s, NH), 9.35 (1Η, s, NH), 8.78 (2Η, d, J=6Hz), 8.30 (IH, d, NH), 7.85 (2H, d, J=9Hz), 7.70 (IH, d, J=6Hz), 7.68 (2H, d, J=9Hz),
7.30-7.45 (8H, m) & 7.23 (2H, d, J=9Hz), 5.00 (IH, s) & 4.94 (IH, s) [OCH2O], 4.45-4.55
(3Η, m, OCHx2 and NCH) and 3.09 (2Η, m, CH2Ar).
LCMS (m/e): 581.3 (M+l, 100%)
Analogs of (S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]- amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 17) described below were prepared by replacing the appropriate amine or acid in place of 2- aminobiphenyl or isonicotinic acid, respectively, as applicable in each case.
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- {4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 2) Η NMR (DMSO-d6, 300 MHz): δ 12.7 (IH, bs, CO2H), 10.45 (1Η, s, NH), 9.66 (1Η, s,
NH), 8.78 (2Η, d, J=6Hz), 8.41 (IH, d, J=9Hz), 7.86 (2H, d, J=3Hz), 7.79 (IH, d, J=3Hz),
7.68 (2H, d, J=9Hz), 7.52 (IH, d, J=6Hz), 7.36 (IH, t, J=9Hz) & 7.24 (3H, d, J=9Hz) [aromatic], 5.26 (IH, s) & 5.14 (IH, s) [OCH2O], 4.72 (1Η, d, J=3Ηz) & 4.67 (IH, d,
J=3Hz) [OCHx2], 4.51 (1Η, m, NCH) and 2.95-3.20 (2Η, m, CH2Ar).
LCMS (m/e): 539.0 (M+l, 100%).
(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 3) 1H NMR (DMSO-d6, 300 MHz): δ 12.7 (IH, bs, CO2H), 10.25 (1Η, s, NH), 9.72 (1Η, s, NH), 8.45 (1Η, d, J=6Ηz), 8.00 (2H, d, J=9Hz) & 7.85 (IH, d, J=9Hz), 7.75 (2H, d, J=9Hz), 7.62 (4H, m), 7.42 (IH, t, J=9Hz) & 7.27 (3H, m) [aromatic], 5.32 (IH, s) & 5.21 (IH, s) [OCH2O], 4.79 (1Η, d, J=3Ηz) & 4.73 (IH, d, J=6Hz) [OCHχ2], 4.57 (1Η, m, NCH) and 3.00-3.30 (2Η, m, CH2Ar). LCMS (m/e): 538.4 (M+l, 70%).
(S)-2-{[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- {4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 5)
1H NMR (DMSO-d6, 300 MHz): δ 10.46 (IH, s, NH), 8.78 (2Η, d, J=3Hz), 8.55 (IH, s), 8.31 (IH, d, NH), 7.85 (2Η, d, J=3Hz), 7.67 (2H, d, J=9Hz), 7.24 (3H, bs), 7.10 (IH, d, J=3Hz), 6.97 (IH, d, J=6Hz) & 6.90 (IH, t, J=6Hz) [aromatic], 5.16 (IH, s) & 5.09 (IH, s) [OCH2O], 4.51 (2Η, s, OCHχ2), 4.47 (1Η, m, NCH), 4.27 (2Η, s, NCH2Ar), 3.79 (3Η, s, OCH3) and 2.69-3.20 (2Η, m, CH2Ar). LCMS (m/e): 549.2 (M+l, 100%).
(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7)
1HNMR (DMSO-d6, 300 MHz): δ 8.59 (IH, t), 7.94 (IH, t, J=3.3Hz, NH), 7.69 (1Η, s), 7.66 (1Η, s), 7.50-7.60 (5Η, m), 7.09-7.22 (4H, m), 6.90-6.98 (2H, m) [aromatic], 5.16 (IH, s) & 5.09 (IH, s) [OCH2O], 4.54 (2Η, d, J=3.9Hz), 4.46 (IH, m, NCH), 4.28 (2Η, ABq, J=3.6Hz, NCH2Ar), 3.79 (3Η, s, OCH3) and 2.95-3.12 (2Η, m, CH2Ar) LCMS (m/e): 548.3 (M+l, 100%).
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbnyl]-amino} -3- {4- [(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 18)
1H NMR (DMSO-d6, 300 MHz): δ 10.57 (IH, s, CO2H), 9.34 (1Η, s, NH), 8.31 (1Η, d, NH), 8.00 (2Η, s), 7.67 (4H, m), 7.23-7.42 (10H, m) [aromatic], 5.00 (IH, s) & 4.94 (IH, s) [OCH2O], 4.46-4.50 (3Η, m, OCHx2 and NCH) and 2.90-3.20 (2Η, m CH2Ar). LCMS (m/e): 649.1 (M+l, 100%) and 651.0 (M+3, 55%) (S)-2- {[(4R,5R)-(Biρhenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-[4- [(piperidine-4-carbonyl)-amino]-phenyl}-propionic-acid, salt with trifluoroacetic acid (Compound No.19)
1H NMR (DMSO-d6, 300 MHz): δ 9.98 (IH, s, NH), 9.38 (1Η, s, NH), 8.50 (1Η, bs, NH),
8.29 (2Η, m, NH2), 7.67 (1Η, d, J=6Ηz), 7.30-7.50 (10H, m) & 7.15 (2H, d, J=9Hz)
[aromatic], 5.00 (IH, s), 4.94 (IH, s) [OCH2O], 4.50 (1Η, d, J=3Ηz) & 4.42 (2H, m)
[OCHX 2 and NCH], 3.35 (3Η, m), 3.07 (IH, m), 2.94 (2H, m) & 2.64 (IH, m) [NCH2 X 2, CH2Ar and COCH] and 2.12 (2Η, m) & 2.06 (2H, m) [CH2 X 2 (ring)].
LCMS (m/e): 587.2 (M+l, 100%).
(S)-2- {[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-[4- [(pyridine-3-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 20)
Η NMR (DMSO-d6, 300 MHz): δ 10.40 (IH, s, CO2H), 9.37 (1Η, s, NH), 9.09 (1Η, s),
8.75 (1Η, d, J=3Ηz), 8.29 (2H, m), 7.58 (2H, d, J=6Hz), 7.43 (IH, d, J=6Hz), 7.30-7.40 (6H, m) & 7.20 (2H, d, J=9Hz) [aromatic], 5.00 (IH, s) & 4.94 (IH, s) [OCH2O], 4.52 (1Η, d, J=3Ηz), 4.45 (IH, d, J=3Hz) [OCHχ2], 4.44 (1Η, m, NCH) and 3.20 (2Η, m, CH2Ar).
LCMS (m/e): 581.2 (M+l, 100%)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridine-2-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 21)
Η NMR (DMSO-d6, 300 MHz): δ 10.58 (IH, s, NH), 9.35 (1Η, s, NH), 8.74 (1Η, d, J=6Ηz), 8.30 (IH, d, NH), 8.15 (1Η, d, J=6Ηz), 8.07 (IH, t, J=7.8Hz), 7.81 (2H, d, J=9Hz), 7.69 (2H, m), 7.30-7.45 (8H, m) & 7.21 (2H, d, J=9Hz) [aromatic], 5.00 (IH, s) & 4.94 (IH, s) [OCH2O], 4.51 (1Η, d, J=3Ηz) & 4.46 (2H, m) [OCHχ2 and NCH] and 2.95- 3.17 (2Η, m, CH2Ar).
LCMS (m/e): 581.4 (M+l, 100%)
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [6-bromo-pyridine-2-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 22)
1H NMR (DMSO-d6, 300 MHz): δ 10.35 (IH, s, NH), 9.35 (1Η, s, NH), 8.29 (1Η, d, NH), 8.13 (1Η, d, J=6Ηz), 8.00 (IH, t, J=9Hz), 7.91 (IH, d, J=6Hz), 7.76 (2H, d, J=6Hz), 7.70 (IH, d, J=9Hz), 7.30-7.45 (7H, m) & 7.22 (2H, d, J=6Hz) [aromatic], 5.00 (IH, s) & 4.94
(IH, s) [OCH2O], 4.51 (1Η, d, J=3Ηz) & 4.47 (2H, m) [OCHx2 and NCH] and 2.95-3.15
(2Η, m, CH2Ar).
LCMS (m/e): 659.1 (M+l, 85%) and 661.5 (M+3, 100%).
(S)-3-(4-Benzoylamino-phenyl)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane- 4-carbonyl] -amino} -propionic acid (Compound No. 23)
Η NMR (DMSO-d6, 300 MHz): δ 10.20 (IH, s, NH), 9.35 (1Η, s, NH), 8.28 (1Η, d, NΗ), 7.94 (2Η, d, J=6Hz), 7.68 (2H, d, J=9Hz), 7.56 (2H, m), 7.30-7.55 (12H, m) & 7.19 (2H, d, J=9Hz) [aromatic], 5.01 (IH, s) & 4.94 (IH, s) [OCH2O], 4.52 (1Η, d, J=3Ηz) 8c 4.47 (2H, m) [OCHχ2 and NCH] and 2.95-3.15 (2Η, m, CH2Ar). LCMS (m/e): 580.5 (M+l, 100%).
(S)-3- {4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl} -2- {[(4R,5R)-5-(2-methoxy- benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No. 28)
1H NMR (DMSO-d6, 300 MHz): δ 10.56 (IH, s, CO2H), 8.52 (1Η, t), 8.29 (1Η, s, NH), 7.63 (2Η, d, J=9Hz), 7.23 (4H, d, J=9Hz), 7.08 (IH, d, J=9Hz), 6.96 (IH, d, J=9Hz), 6.88 (2H, t, J=9Hz) [aromatic], 5.15 (IH, s) & 5.07 (IH, s) [OCH2O], 4.49 (3Η, bs, OCHx2 and NCH), 4.25 (2Η, s, NCH2Ar), 3.78 (3Η, s, OCH3) and 2.88 (2Η, m, CH2Ar). LCMS (m/e): 617.1 (M+l, 100%).
(S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2- methoxy-benzyl amino)-phenyl]-propionic acid (Compound No 29)
Η NMR (DMSO-d6, 300 MΗz):δ 10.08 (IH, s, NH), 9.38 (IH, s, NH), 8.3 (1Η, m, NH), 7.0-7.70 (17Η, aromatic), 5.01 (IH, s) & 4.94 (IH, s) [OCH2O], 4.52 (1Η, d, J=3Ηz) & 4.45 (IH, d) [OCHx2], 4.45 (1Η, m, NCH), 3.89 (3Η, s, OCH3) and 3.06 (2Η, m, CH2Ar) LCMS (m/e): 610.2 (M+l, 80%)
(S)-3-(4-benzoylaminophenyl)-2-[ {(4R,5R)-5-(isopropyl-carbamoyl)-[ 1 ,3]dioxolane-4- carbonyl}-amino]-propionic acid (Compound No. 43)
1H NMR (DMSO-d6, 300 MHz):δ 10.17 (IH, s, NH), 8.19 (1Η, d, NH), 7.93 (3Η, m), 7.67 (2H, m), 7.53 (3H, m) & 7.20 (2H, d, J=9Hz) [aromatic], 5.09 (IH, s), 5.06 (IH, s) [OCH2O], 4.48 (2Η, bs) & 4.37 (IH, d, J=3Hz) [OCHχ2 and NCH], 3.89 (1Η, m, NCHCΗ3), 3.03 (2H, m, CH2Ar) and 1.08 (d, J=3Ηz) & 1.07 (d, J=6Hz) [CH3x2]. LCMS (m/e): 470.1 (M+l, 100%)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 151)
Η NMR (DMSO, 300MΗz):δ 10.67 (IH, bs), 8.3 (IH, bs), 8.15 (IH, bs), 7.57 (5H, m), 7.20 (4H, m), 6.96 (2H, m), 5.16 (IH, s), 5.10 (IH, s), 4.53 (3H, m), 4.28 (2H, bs), 3.8 (3H, s), 3.33 (2H, m).
LCMS (m/e): 616.42 (M+l)+ [100%], 618.38 (M+3)+ [70%]
SCHEME I, PATH A PROCEDURE
Example 2: (S)-2-(r(4R,5R)-5-(Biphenyl-2-ylcarbamoylVπ.31dioxolane-4-carbonyll- amino|-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25)
Step 1: Synthesis of Benzyl (S)-2-{[(4R, 5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxoIane-4-carbonyl]-amino}-3-(4-hydroxy-phenyl)-propionate. The compound (4R, 5R)-5-(biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carboxylic acid (as prepared in Example 1, Step 2) (1.5 gm, 4.7 mmol) was coupled to L-tyrosine benzyl ester p-toluene sulfonate salt (2.12 gm, 4.7 mmol) following the general procedure as described in Example 1, Step 3) using hydroxybenzotriazole (646 mg, 4.8 mmol), N- methylmorpholine (1.21gm, 12 mmol) and l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC.HCl) (915 mg, 4.8 mmol) furnished the title compound (2.2 gm 83%>) after purification of the crude residue over a silica gel column using 50% ethyl acetate: hexane solvent mixture as eluent.
1H NMR (CDC13, 300 MHz): δ 8.44 (IH, s, NH), 8.29 (1Η, d, J=8.1Ηz), 7.20-7.50 (13H, m), 7.01 (IH, d, NH), 6.87 (2Η, d, J=8.1Hz) & 6.67 (2H, d, J=8.1Hz) [aromatic], 5.15 (2H, ABq, J=12Hz, OCH2Ph), 4.86 (1Η, s) & 4.73 (1Η, s) [OCH2O], 4.89 (1Η, m, NCH), 4.66 (1Η, d, J=3.6Ηz), 4.58 (IH, d, J=3.6Hz) [OCHx2] and 2.95-3.12 (2Η, m, CH2Ar). LCMS (m/e): 567.5 (M+l, 100%).
Step 2: Synthesis of Benzyl (S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionate Potassium carbonate (98 mg, 0.71 mmol) and 2,6-dichlorobenzyl bromide (93 mg, 0.39 mmol) was added to the phenol obtained from step 1 above (200 mg, 0.35 mmol) in dry acetone (5 ml) and the mixture was refluxed for 5.6 hour. Solvent was evaporated off and the crude residue was taken into water and extracted with ethyl acetate (3x15 ml). The combined organic extracts were washed with brine and dried over anhydrous sodium sulphate. Evaporation of the solvent followed by purification of the residue over a silica gel column using 40% ethyl acetate: hexane solvent mixture as eluent furnished the title compound (210 mg, 83%) as a white solid. 1HNMR (CDC13;300 MHz,): δ 8.41 (14, s, NH), 8.36 (1Η, d, J=9Ηz), 7.20-7.50 (15H, m), 6.89-7.00 (5H, m) [aromatic], 5.22 (2H, s, OCH2Ar), 5.14 (2Η, ABq, J=12Hz, OCH2Ph), 4.91 (1Η, m, NCH), 4.88 (1Η, s) & 4.75 (1Η, s) [OCH2O], 4.69 (1Η, d, J=3Ηz) & 4.61 (IH, d, J=3Hz) [OCHχ2] and 3.10 (2Η, t, J=6Hz, CH2Ar).
LCMS (m/e): 725.5 (M+l, 100%), 727.6 (M+3, 65%), 726.4 (M+2, 38%) & 728.6 (M+4, 35%).
Step 3: Synthesis of (S)-2-{[(4R, 5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid
Lithium hydroxide monohydrate (25 mg, 0.59 mmol) was added to the ester obtained from step 2 above (210 mg, 9.29 mmol) and following the general procedure as outlined in
Example 2, Step 2, the title compound was obtained (140 mg, 76%) as a yellow sticky solid.
1H NMR (DMSO-d6, 300 MHz): δ 9.34 (IH, s, NH), 8.25 (1Η, d, NH), 7.71 (1Η, d,
J=7.5Ηz), 7.30-7.60 (1 IH, m), 7.17 (2H, d, J=8.4Hz) & 6.97 (2H, d, J=8.7Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.0 (1Η, s) & 4.94 (1Η, s) [OCH2O], 4.42-4.52 (3Η, m, NCH and
OCHx2) and 2.93-3.00 (2Η, m, CH2Ar).
LCMS (m/e): 635.4 (M+l, 100%), 637.4 (M+3, 83%).
Analogs of (S)-2-{[(4R,5R)-5-(Biρhenyl-2-yl-carbamoyl)-[l,3]dioxalane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 25), which are described below, can be prepared by replacing the appropriate amine or acid.
(S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)- [l,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 6) 1H NMR (DMSO-d6, 300 MHz):δ 12.7 (IH, bs, CO2H), 8.51 (1Η, d, NH), 8.27 (1Η, d,
NH), 7.49 (1Η, m), 7.05-7.20 (6Η, m) & 6.80-6.98 (4H, m) [aromatic], 5.13 (IH, s), 5.05
(IH, s) & 5.02 (2H, s) [OCH2O and OCH2Ar], 4.50 (2Η, d, J=3.9Hz, OCHx2), 4.47 (1Η, m, NCH), 4.24 (2Η, Abq, J=5.7Hz, NCH2Ar), 3.76 (3Η, s, OCH3) and 2.90-3.32 (2Η, m,
CH2Ar).
LCMS (m/e): 571.1 (M+l, 100%).
2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6- difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8)
1H NMR (DMSO-d6, 300 MΗz):δ 2.97-3.07 (2H, m, ArCH2), 4.46-4.68 (1Η, m, NΗCHCO), 4.63-4.68 (2Η, OCHCOχ2), 5.06 (2Η, s, ArCH2O), 5.11-5.13 (1Η, m) and 5.23-5.24 (1Η, m) [OCΗ2O], 6.89-6.95 (3H, m), 7.09-7.19 (4H, m), 7.26-7.38 (2H, m), 7.49-7.54 (2H, m) [aromatic]. LCMS (m/e): 561.3 (M+l)
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9)
1H NMR (DMSO-d6, 300 MHz): δ 9.73 (IH, s, NH), 7.84 (1Η, d, J=8.1Ηz), 7.72 (IH, bs, NH), 7.40-7.55 (4Η, m), 7.36 (IH, t, J=7.2 Hz), 7.23 (IH, t, J=7.8Hz), 7.07 (2H, d, J=8.4Hz) & 6.87 (2H, d, J=8.4Hz), 5.22 (IH, s) & 5.15 (3H, m) [OCH2O and OCH2Ar], 4.77 (1Η, d, J=4.2Ηz) & 4.64 (IH, d, J=4.2 Hz), 3.79 (IH, m, NCH) and 2.95-3.10 (2Η, m, CH2Ar). LCMS (m/e): 593.2 (M+l, 90%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No.10)
Η NMR (DMSO-d6, 300 MHz): δ 12.7 (IH, bs, CO2H), 8.56 (1Η, s, NH), 8.31 (1Η, d, NH), 7.56 (2Η, dd, J=8.4 and 1.2Hz), 7.48 (IH, dd, J=6.9 and 2.1Hz), 7.05-7.25 (4H, m) & 6.85-7.00 (4H, m) [aromatic], 5.17 (3H, d, J=3Hz) & 5.09 (IH, s) [OCH2Ar and OCH2O], 4.54 (1Η, d, J=3.9Ηz) 8c 4.50 (IH, d, J=3.9Hz) [OCHχ2], 4.48 (1Η, m, NCH), 4.27 (2Η, ABq, J=5.74Hz, NCH2Ar), 3.79 (3Η, s, OCH3) and 2.95-3.10 (2Η, m, CH2Ar). LCMS (m/e): 603.3 (M+l, 100%).
Lithium salt of (S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No.l 1)
Η NMR (DMSO-d6, 300 MHz): δ 7.80 (IH, d, J=7.9Hz), 7.63 (IH, d, J=6Hz), 7.50 (IH, d, J=7.78Hz), 7.32 (IH, t, J=7.66Hz), 7.19 (IH, t), 7.00 (2H, d, J=6.69Hz), 6.71 (2H, d,
J=8.3Hz) [aromatic], 5.19 (IH, d, J=4.35Hz) & 5.12 (IH, s) [OCH2O], 4.71 (1Η, s) & 4.59
(1Η, d, J=3.85Ηz), [OCHχ2], 3.91 (3Η, ABq, J=5.1Hz) (NCH and OCH2), 2.99 (2Η, m, CH2Ar), 2.35 (6Η, m, NCH2), 1.81 (2Η, t, J=6.4Hz) and 1.47 (4H, bs) & 1.46 (2H, bs)
Figure imgf000050_0001
LCMS (m/e): 560.3 (M+l, 100%).
Lithium salt of (S)-2-{[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No. 12)
Η NMR (TFA-d, 300 MHz): δ 7.52 (IH, t, J=9Hz), 7.40 (3H, t, J=6Hz), 7.17 (2H, t, J=9Hz) & 7.03 (2H, t, J=6Hz), 5.40 (2H, s, OCH2O), 5.22 (1Η, m, NCH), 5.01 (2Η, s, OCHχ2), 4.78 (2Η, s, NCH2 Ar), 4.43 (2Η, s, OCH2), 4.11 (3Η, s, OCH3), 4.03 (2Η, bs, NCH2), 3.65 (3Η, m) & 3.33 (IH, m) [NCH2x2], 3.16 (2Η, bs, CH2Ar), 2.54 (2Η, m, OCH2CH2) and 2.06-2.35 (6Η, m, CH2 χ3 (ring)). LCMS (m/e): 570.3 (M+l, 100%).
Lithium salt of (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxalane-4-carbonyl]- amino}-3-[4-(2-piperidin-l-yl-ethoxy)-phenyl]-propionate (Compound No. 13)
1H NMR (DMSO-d6, 300 MHz): δ 9.38 (IH, s, NH), 7.68 (1Η, d, J=6Ηz), 7.51 (IH, d, J=6Hz), 7.30-7.50 (7H, m), 6.97 (2H, d, J=6Hz) & 6.71 (2H, d, J=9Hz) [aromatic], 4.96 (IH, s) & 4.90 (IH, s) [OCH2O], 4.54 (1Η, d, J=3Ηz) & 4.37 (IH, d, J=3Hz) [OCHx2], 3.97 (2Η, t, J=6Hz, OCH2CH2), 3.85 (IH, ABq, J=3Hz, NCH), 2.96 (2Η, m, NCH2) & 2.61 (2Η, t, J=6z, NCH2), 2.40 (4Η, t, J=3Hz, NCH2), 1.48 (4Η, t, J=6Hz) and 1.36 (2H, t,
Figure imgf000050_0002
LCMS (m/e): 588.2 (M+l, 100%) (free acid). (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14)
Η NMR (DMSO-d6, 300 MHz): δ 9.33 (IH, s, NH), 8.23 (1Η, d, NH), 7.69 (1Η, m), 6.94-7.50 (13Η, m) & 6.92 (2H, t, J=6Hz) [aromatic], 5.06 (2H, s, OCH2Ar), 4.99 (1Η, s) & 4.93 (1Η, s) [OCH2O], 4.46 (3Η, m, NCH and OCHχ2) and 2.94-3.35 (2Η, m, CH2Ar). LCMS (m/e): 603.3 (M+l, 100%).
Morpholine-4-carboxylic acid 4-((S)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyι)- [1 ,3]dioxolane-4-carbonyl]-amino} -2-carboxy-ethyl)-phenyl ester (Compound No. 15)
Η NMR (DMSO-d6, 300 MHz): δ 9.33 (IH, s, NH), 8.20 (1Η, s, NH), 7.70 (1Η, d, J=6Ηz), 7.30-7.50 (8H, m), 7.20 (2H, d, J=9Hz) & 7.01 (2H, d, J=6Hz) [aromatic], 4.98 (IH, s) & 4.92 (IH, s) [OCH2O], 4.51 (1Η, d, J=3Ηz) & 4.46 (IH, d, J=3Hz) [OCHx2], 4.41 (1Η, m, NCH), 3.63 (8Η, d, J=3Hz, OCH2x2 and NCH2χ2) and 2.95-3.20 (2Η, m, CH2Ar). LCMS (m/e): 590.1 (M+l, 50%) and 607.1 (M+l 8, 100%).
4-Methyl-piperazine-l-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 16)
Η NMR (DMSO-de, 300 MΗz):δ 9.34 (IH, s, NH), 8.12 (1Η, d, NH), 7.70 (1Η, d, J=7.8Ηz), 7.25-7.50 (8H, m), 7.19 (2H, d, J=8.4Hz) 8c 6.98 (2H, d, J=8.1Hz) [aromatic], 4.98 (IH, s) 8c 4.92 (IH, s) [OCH2O], 4.51 (1Η, d, J=2.7Ηz) & 4.45 (IH, d, J=3.3Hz) [OCHx2], 4.33 (1Η, m, NCH), 3.64 (2Η, m) & 3.57 (2H, m) [NCH2χ2], 3.10 (1Η, m) 8c 3.00 (1Η, m) [CH2Ar], 2.35 (4Η, bs, NCH2χ2) and 2.22 (3Η, s, N-CH3). LCMS (m/e): 603.3 (M+l, 100%).
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26)
1H NMR (DMSO-d6, 300 MHz): δ 9.34 (IH, s, NH), 8.23 (1Η, d, NH), 7.70 (1Η, d, J=7.8Ηz), 7.30-7.60 (12H, m), 7.15 (2H, d, J=8.4Hz) & 6.92 (2H, d, J=8.4Hz) [aromatic], 5.11 (2H, s OCH2Ar), 4.99 (1Η, s) & 4.93 (1Η, s [OCH2O], 4.40-4.49 (3Η, m, OCH*2 and NCH) and 2.90-3.09 (2Η, m, CH2Ar).
LCMS (m/e): 601.6 (M+l, 100%), 602.5 (M+2, 35%). (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- prop-2-ynyloxy-phenyl)-propionic-acid (Compound No. 27)
Η NMR (DMSO-d6, 300 MHz): δ 8.45 (IH, s, NH), 8.28 (1Η, d), 6.88-7.47 (13Η, m) [aromatic & NH], 4.54-4.90 (7Η, m, OCH2O, OCHX 2, NCH, OCH2C), 3.02-3.25 (2Η, m, CH2Ar) and 2.49 (1Η, d, J=3Ηz, CH(alkyne)). LCMS (m/e): 515.5 (M+l, 100%).
(S)-2-{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonoyl]-amino}- 3-[4-(2,6-difluoro-benzyloxy]-phenyl]-propionic-acid (Compound No. 30)
Η NMR (DMSO-d6, 300 MΗz):δ 8.19 (s), 7.51 (m), 7.31 (s), 7.15 (m) & 6.92 (d, J=9Hz, aromatic], 5.21 (IH, s) & 5.13 (IH, s) [OCH2O], 5.05 (2Η, s, OCH2Ar), 4.66 (IH, d) & 4.62 (IH, d) [OCHx2], 4.47 (1Η, m, NCH) and 3.01 (2Η, m, CH2Ar). LCMS (m/e): 595.1 (M+l, 100%) and 597.0 (M+3, 95%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-phenyl-carbamoyl- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (compound No. 32)
Η NMR (DMSO-d6, 300 MHz):δ 10.14 (IH, s, NH), 8.20 (1Η, d, NH), 6.90-7.70 (12Η, m, aromatic), 5.22 (IH, s) & 5.14 (IH, s) [OCH2O], 5.17 (2Η, s, OCH2Ar), 4.66 (1Η, d, J=3Ηz) & 4.61 (IH, d, J=3Hz) [OCHχ2], 4.43 (1Η, m, NCH) and 3.34 (2Η, m, CH2Ar). LCMS (m/e): 558.7 (M+l, 100%) and 561.3 (M+3, 70%).
(S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholine-4-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No.55)
1Η NMR (DMSO-de, 300 MHz): δ 7.55 (2H, d, J=7.5 Hz), 7.46 (IH, m), 7.18 (2H, d, J=7.8Hz) & 6.97 (2H, d, J=7.5 Hz) [aromatic] 5.21 (2H, s, OCH2Ar), 5.12 (1Η, s) & 5.03 (1Η, s) [OCH2], 4.45-4.70 (5Η, m, OCHx 2, NCH and OCΗ2 (ring))], 3.35-3.60 (6H, m) [OCH2 and NCH2 x 2 (ring)] and 3.11 (lΗ,m) & 3.00 (lH,m) [CH2Ar]. LCMS (m/e): 553.5 (M+l, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,5-dichloro-phenyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No. 71) 'HNMR(DMSO-d6, 300 MHz) δ 10.43 (IH, s, NH), 8.35 (1Η, d, NH), 7.80 (2Η, d, J=3Hz), 7.55 (2H, d, J=9Hz), 7.45 (IH, m), 7.31 (IH, s), 7.19 (2H, d, J=9Hz) & 6.95 (2H, d, J=9Hz) [aromatic], 5.22 (IH, s) & 5.14 (IH, s) [OCH2O], 5.17 (2Η, s, OCH2Ar), 4.68 (IH, d, J=3Hz) & 4.62 (IH, d, J=3Hz) [OCHX 2], 4.49 (lΗ,m NCH) and 3.02 (2Η, m, CH2Ar)
SCHEME I, PATH B PROCEDURE
Example 3: (S)-2-(r(4R.5R)-5-(Bis-thioρhen-2-ylmethyl-carbamoylVπ.31dioxolane-4- carbonvH-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl1-propionic acid (Compound No. 88}
Step a: Synthesis of (4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester. To a solution of the compound of Formula III (1 g) in tetrahydrofuran (20ml) at -20° C, was added N-methyl morpholine (1.06 g) and stirred the reaction mixture for 10 minutes at the same temperature. To it was added ethyl chloroformate (0.57 g) and stirred the reaction mixture for 20 minutes followed by the addition of p-toluene sulphonic acid (95 mg) and bis-thiophene-2-ylmethyl amine (1.29 g). The reaction mixture was stirred for 30 minutes at -20°C for 30 minutes followed by stirring at 0°C for 3 hours and subsequently overnight at room temperature. The reaction mixture was diluted with ethyl acetate and water. The organic layer was washed with water & brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 20% ethyl acetate in hexane as eluent to furnish the title compound (22.5 g).
Step b: Synthesis of (4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3]dioxolane- 4-carboxylic acid To the solution of the compound obtained from step a above (750 mg) in tetrahydrofuran:methanol:water (3:1:1) was added lithium hydroxide monohydrate (124 mg) and stirred the reaction mixture for 3 hours. The reaction mixture was concentrated under reduced pressure. The residue thus obtained was taken in water and acidified with concentrated hydrochloric acid. The organic layer was extracted with ethyl acetate, washed with water and brine. The organic layer was concentrated under reduced pressure to furnish the title compound (440 mg). Step c: Synthesis of (S)-2-{[(4R,5R)-5-(bis-thiophen-2-ylmethyl-carbamoyl)-[l,3] dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichIoro-benzyloxy)-phenyl]propionic acid methyl ester. To a solution of the compound obtained from step a above (322 mg) in dimethylformamide (5 ml) at 0°C, was added N-methylmorpholine (0.21 g), hydroxybenzotriazole (0.105 mg) and 2-amino-3-[4-(2,6-dichloro-benzyloxy)-phenyl]- propionic acid methyl ester (Bioorg. & Med Chem Letters 12(2002) 1591-1594) (250 mg). The reaction mixture was stirred for 30 minutes at same temperature and l-(3- dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (149 mg) was added. The reaction mixture was warmed to room temperature, diluted with water and ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous sodium sulphate. The organic layer was concentrated under reduced pressure to furnish the title compound (145 mg).
Step d: Synthesis of (S)-2-{[(4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)- [l,3]dioxolane-4-carbonyI]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88)
To a solution of the compound obtained from step c above (163 mg) in tetrahydrofuran:methanol: water (3:1:1), was added lithium hydroxide monohydrate (10 mg). The reaction mixture was stirred for 2 hours and concentrated under reduced pressure. The residue thus obtained was taken in water, washed with ethyl acetate. The aqueous layer was acidified with sodium bisulphate and extracted with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound (120 mg).
1H NMR (DMSO, 300MHz):δ 8.3 (IH, m), 7.57-7.42 (5H, m), 7.15 (2H, d, 9Hz), 7.05- 6.91 (6H, m), 5.14 (4H, m), 4.95 (IH, d, 6Hz), 4.88 (IH, bs), 4.78 (IH, d, 6Hz), 4.62 (2H, s), 4.5 (2H, m), 3.06-2.98 (2H, m). LCMS (m/e): 675.11 (M+, 100%), 677.13 (M+Z, 70%), 678.09 (M+3, 30%).
The analogues of (S)-2- {[(4R,5R)-5-(bicyclo[2.2.1 ]hept-2-ylcarbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88) described below, can be prepared by condensing appropriate amine and an acid, respectively, as applicable in each case.
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxy-phenyl)-propionic acid (Compound No. 1)
1H NMR (DMSO-d6, 300 MHz): δ 12.5 (IH, bs, CO2H), 9.67 (1Η, s, NH), 9.22 (1Η, bs, OH), 8.31 (1Η, d, NH), 7.78 (1Η, d, J=7.9Ηz), 7.53 (IH, d, J=7.9Hz), 7.35 (IH, t, J=7.5 Hz), 7.26 (IH, t, J=7.6Hz), 7.00 (2H, t, J=7.9Hz) & 6.65 (2H, d, J=7.7Hz) [aromatic], 5.25 (IH, s) & 5.13 (IH, s) [OCH2O], 4.70 (1Η, d, J=3.4Ηz), 4.66 (IH, d, J=3.3 Hz) [OCHx2], 4.41 (1Η, m, NCH) and 2.85-3.00 (2Η, m, CH2Ar).
(S)-3-(4-Ηydroxy-phenyl)-2- {[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[ 1 ,3]dioxolane- 4-carbonyl] -amino} -propionic acid (Compound No. 4)
1H NMR (DMSO-d6, 300 MHz): δ 8.44 (IH, t, NH), 8.05 (1Η, d, NH), 7.22 (1Η, t, J=7.41Ηz), 7.13 (IH, d, J=7.3Hz), 6.99 (2H, d, J=8.24Hz), 6.92 (2H, m), 6.65 (2H, d, J=8.1Hz), 5.16 (IH, s) & 5.10 (IH, s) [OCH2O], 4.55 (1Η, d, J=3.9Ηz), 4.51 (IH, d, J=3.83Hz) [OCHx2], 4.46 (1Η, m, NCH), 4.31 (2Η, ABq, J=5.7Hz, NCH2Ar), 3.82 (3Η, s, OCH3) and 2.90-3.00 (2Η, m, CH2Ar). LCMS (m/e): 445.4 (M+l, 100%).
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxyl-phenyl)-propionic acid (Compound No. 24)
Η NMR (CDC13, 300 MHz): δ 8.48 (IH, s, NΗ), 8.21 (1Η, d, J=8.4Ηz), 7.10-7.43 (9H, m), 6.95 (2H, d, J=8.1Hz) & 6.69 (2H, d, J=8.1Hz) [aromatic], 4.86 (s) & 4.71 (IH, s) [OCH2O], 4.81 (IH, m, CH), 4.65 (1Η, d, J=3.6 Ηz) & 4.57 (1Η, d, J=3.9Ηz, CHx2] and 2.9-3.10 (2Η, m, CH2Ar). LCMS (m/e): 477.5 (M+l, 100%).
(S)-3-(4-(2,6-Dichlorobenzyloxy)-phenyl]-2-[{(4R,5R)-5-[thiophen-2-yl-methyl)- carbamoyl]-[l,3]dioxolane-4-carbamoyl}-amino]-propionic acid (Compound No. 31)
Η NMR (DMSO-d6, 300 MΗz):δ 8.81 (IH, t, NH), 8.21 (1Η, m, NH), 7.40-7.55 (3Η, m), 7.33 (IH, d, J=3.9Hz), 7.17 (2H, d, J=8.4Hz) & 6.93 (4H, m) [aromatic], 5.19 (2H, s, OCH2Ar), 5.12 (1Η, s), 5.10 (1Η, s) [OCH2O], 4.54 (1Η, d, J=3.6Ηz) & 4.47 (4H, bd) [OCHx2, NCH, NCH2Ar] and 3.05 (2Η, m, CH2Ar). LCMS (m/e): 579.1 (M+l, 100%) and 581.0 (M+3, 80%).
(S)-2-{[(4S, 5S)-5-(2-Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-{4- [(pyridin-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 33)
1H NMR (DMSO-d6, 300 MΗz):δ 9.63 (IH, s, NH), 8.78 (2Η, d, J=3Hz), 8.40 (IH, d, J=6Hz), 7.85 (2H, d, J=6Hz), 7.78 (IH, d, J=9Hz), 7.68 (2H, d, J=9Hz), 7.52 (IH, d, J=9Hz), 7.36 (IH, t) & 7.23 (3H, d, J=6Hz) [aromatic and NH], 5.25 (1Η, s) & 5.03 (1Η, s) [OCH2O], 4.71 (1Η, d, J=3Ηz) & 4.64 (IH, d, J=3Hz) & 4.52 (IH, m, NCH) and 2.95- 3.20 (2Η, m, CH2Ar) LCMS (m/e): 539.2 (M+l, 100%)
(S)-2-(4S,5S)-5-(Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6- dichlorobenzloxy-phenyl]-propionic acid (Compound No. 34)
Η NMR (DMSO-d6, 300 MΗz):δ 9.6 (IH, s, NH), 8.36 (1Η, d, NH), 7.80 (1Η, d, J=6.9Ηz), 7.16-7.60 (8H, m) & 6.97 (2H, d, J=8.7Hz) [aromatic], 5.24 (IH, s) & 5.02 (IH, s) [OCH2O], 5.19 (2Η, s, OCH2Ar), 4.70 (1Η, d, J=3.6Ηz) & 4.59 (IH, d, J=3.6Hz) [OCHx2], 4.51 (1Η, m, CHCO) and 2.95-3.20 (2Η, m CH2Ar). LCMS (m/e): 593 (M+l, 80%) and 595.0 (M+3, 100%).
Lithium salt of (S)-2-[{(4R,5R)-5-Cyclopropyl-carbamoyl-[l,3]dioxolane-4-carbonyl}- amino]-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionate (Compound No. 36)
]Η NMR (DMSO-d6, 300 MΗz):δ 8.25 (IH, d, NH), 7.50 (4Η, m), 7.06 (2H, d, J=8.1Hz) & 6.86 (2H, d, J=8.1Hz) [aromatic and NH], 5.16 (1Η, s) & 5.06 (1Η, d, J=3Ηz) [OCH2O], 4.48 (1Η, d, J=3.9Ηz) & 4.39 (IH, d, J=3.6Hz) [OCHx2], 3.98 (1Η, m, NCH), 3.03 (2Η, m, CH2Ar), 2.70 (1Η, t, J=3.6Ηz, NCH (ring)) and 0.62 (2Η, bs) & 0.51 (2H, bs)
Figure imgf000056_0001
LCMS (m/e): 523.4 (M+l(free acid), 100%).
(S)-2-[{(4R,5R)-5-Cyclohexane-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 37) 1H NMR (DMSO-d6, 300 MHz):δ 8.23 (IH, d, NH), 7.90 (1Η, m, NH), 7.40-7.60 (3Η, m), 7.16 (2H, m) & 6.95 (2H, d, J=6Hz), [aromatic], 5.19 (2H, s, OCH2Ar), 5.08 (1Η, s) & 5.06 (1Η, s) [OCH2O], 4.26-4.50 (4Η, m, OCHx2, NCH and NCH and NCH (ring)), 3.00 (2Η, m, CH2Ar) and 1.50-1.10 (10Η, m, CH2χ5 (ring)). LCMS (m/e): 565.3 (M+l, 100%) and 567.3 (M+3, 35%).
(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{([4R,5R)-5-(thiazol-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 38)
Η NMR (DMSO-d6, 300 MΗz):δ 12.7 (IH, bs, CO2H), 12.3 (1Η, bs, NΗ), 8.34 (1Η, bs, NH), 6.90-7.60 (9Η, m, aromatic), 6.21 (IH, s) & 5.12 (IH, s) [OCH2O], 5.17 (2Η, s, OCH2Ar), 4.73 (1Η, bs) & 4.69 (1Η, d, J=3Ηz) [OCHx2], 4.46 (1Η, bs, NCH) and 3.02 (2Η, m, CH2Ar).
(S)-2-{[(4R,5R)-5-(Cyclopropyl-carbamoyl)-[l,3]dioxolane-4-carbonylamino]-3-{4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 39)
1H NMR (DMSO-d6, 300 MHz): δ 10.44 (IH, s, CO2H), 8.77 (2Η, d, J=6Hz), 8.23 (IH, d, J=3Hz), 7.85 (2H, d, J=6Hz), 7.73 (IH, bs), 7.63 (2H, d, J=9Hz) & 7.17 (2H, d, J=9Ηz) [aromatic and 2 NH], 5.05 (2Η, s, OCH2O), 4.49 (1Η, d, J=3Ηz), 4.37 (IH, d, J=3Hz),
4.22 (IH, m, NCHCO), 2.90-3.10 (2Η, m, CH2Ar), 2.69 (1Η, m, NCH (ring), 0.61 (2Η, m) & 0.50 (2H, m) [CH2 x 2(ring)]. LCMS (m/e): 469.2 (M+l, 100%).
(S)-2-[ {(4R,5R)-5-Cyclohexyl-carbamoyl-[ 1 ,3]dioxolane-4-carbonyl} -amino]-3- {4- [(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 40)
Η NMR (DMSO-d6, 300 MΗz):δ 10.42 (IH, s, CO2H), 8.76 (2Η, d, J=3Hz), 8.16 (IH, d, J=6Hz), 7.95 (IH, d, J=9Hz), 7.85 (2H, d, J=3Hz), 7.67 (2H, d, J=9Hz) & 7.21 (2H, d, J=9Hz) [aromatic and NH], 5.09 (1Η, s) & 5.06 (1Η, s) [OCH2O], 4.46 (1Η, d, J=6Ηz) & 4.38 (IH, d, J=3Hz), 1.11-1.70 (10H, m, CH2 (ring)x5 LCMS (m/e): 511.4 (M+l, 100%)
(S)-2- {[4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbamoyl]-amino} - 3- {4-[(pyridine-4-carbonyl-amino]-phenyl} -propionic acid (Compound No. 41) Η NMR (DMSO-de, 300 MHz):δ 10.46 (IH, d, NH), 8.79 (1Η, s), 7.00-8.40 (12Η)
[aromatic and NH], 5.21 (1Η, s), 5.13 (1Η, s) [OCH2O], 4.67 (1Η, bs) & 4.63 (1Η, d,
J=3Ηz), [OCHx2], 4.50 (1Η, bs, NCH) and 3.02 (2Η, m, CH2Ar).
LCMS (m/e): 573.4 (M+1,100%)
(S)-(4R,5R)-5-[l-Carboxy-3-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[l,3]dioxolane-4- carboxylic acid ethyl ester (Compound No. 42)
Η NMR (DMSO-d6, 300 MΗz):δ 9.1 (IH, bs, CO2H), 8.16 (1Η, d, NH), 6.99 (2Η, d, J=7.5Hz) & 6.64 (2H, d, J=7.5Hz), 5.12 (IH, s) & 5.08 (IH, s) [OCH2O], 4.56 (2Η, s, OCHx2), 4.15 (1Η, m, NCH), 4.03 (2Η, q, J=3.9Hz, OCH2), 2.95 (2Η, m, CH2Ar) and 1.22 (3Η, t, J=6.9Ηz, CH3 .
(S)-2- {[(4R, 5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} - 3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic-acid (Compound No. 45)
Η NMR (DMSO-d6, 300MΗz):δ 10.45 (IH, s, NH), 10.13 (1Η, s, NH), 8.78 (2Η, d, ' J=6Hz), 8.39 (IH, d, NH), 7.86 (2Η, d, J=6Hz), 7.67 (2H, d, J=6Hz), 7.54 (2H, d, J=6Hz), 7.37 (IH, m) & 7.24 (2H, d, J=9Hz) [aromatic], 5.24 (IH, s) & 5.19 (IH, s), [OCH2O], 4.69 (1Η, d, J=3Ηz) & 4.63 (IH, d, J=3Hz) [OCHx2], 4.50 (1Η, m, NCH) and 3.05 (2Η, m, CH2Ar). LCMS (m/e): 573.4 (M+l, 100%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-isopropylcarbamoyl- [l,3]dioxolane-4-carbonyl}-amino]- propionic acid (Compound No. 47)
Η NMR (DMSO-d6, 300 MHz): δ 8.21 (IH, d, NH), 7.99 (IH, d, NH), 7.56 (2Η, d, J= 7.5 Hz), 7.46 (IH, m), 7.17 (2H, d, J=8.1 Hz) & 6.96 (2H, d, J=8.4 Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.09 (1Η, s) & 5.06 (1Η, s) [OCH2O], 4.48 (1Η, d, J=3.9 Ηz) & 4.35 (1Η, d, J=3.9Ηz) [OCHx2], 4.46 (1Η, m, NCH) 3.89 (1Η, m, NCHCΗ3), 3.08 (2H, m CH2Ar) and 1.08 (3Η, d, J=6.3 Hz) & 1.07 (3H, d, J=6.3 Hz) [CH3 x 2]. LCMS (m/e) 525.4 (M+l, 100%).
(S)-2-{[(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 53) 1H NMR (DMSO-d6, 300 MHz) δ 8.40 (IH, d, NH), 8.00 (IH, d, J=6Hz), 7.78 (IH, d, J=9Hz), 7.53 (2H, d, J=9Hz), 7.45 (2H, m), 7.32 (IH, t, J=6Hz), 7.19 (2H, d, J=9Hz) & 6.95 (2H, d, J=9Hz) [aromatic], 5.25 (IH, s) & 5.12 (IH, s) [OCH2O], 5.14 (2Η, ABq, J=6Hz, OCH2Ar), 4.81 (1Η, d, J= 3Ηz) & 4.76 (IH, d, J=3Hz) [OCHx2], 4.48 (1Η, m, NCH) and 3.04 (2Η, m, CH2Ar). LCMS (m/e) 616.4 (M+l, 100%).
(S)-3-[4-(2,6,-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,3-dihydro-indole-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 62)
Η NMR (DMSO-d6, 300 MHz): δ 8.26 (IH, m, NH), 7.40-8.25 (4Η, m) & 6.90-7.20 (7H,m) [aromatic], 5.18 (2H, s, OCH∑Ar), 5.12 (1Η, s) & 5.06 (1Η, s) [OCH2O], 3.90-4.55 (5Η, m, OCHx 2, NCΗ and NCH2) and 2.95-3.20 (4Η, m, CH2Ar x2). LCMS (m/e): 585.7 (M+l, 80 %).
3-3[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-methyl-[l,3,4] thiadiazol-2-yl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 63)
1H NMR (DMSO-d6, 300 MHz): δ 8.35 (IH, d, NH), 7.54 (2Η, d, J=9Hz), 7.46 (IH, m), 7.17 (2H, d, J=9Hz) & 6.95 (2H, d, J=9Hz) [aromatic], 5.10-5.22 (4H, m, OCH2Ar and OCΗ2O), 4.99 (IH, s) & 4.72 (IH, m) [OCHx2], 4.50 (1Η, m, NCH), 3.03 (2Η, m, CH2Aι) and 2.63 (3H, s, ArCH3). LCMS (m/e): 581.6 (M +1, 100%).
(S)-2{[(4R,5R)-5-(Biρhenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- phenyl-propionic acid (Compound No. 64)
1H NMR (DMS-d6, 300 MΗz):δ 9.32 (IH, s, NH), 8.29 (1Η, d, NH), 7.70 (1Η, d, J=7.8Ηz) & 7.20-7.45 (12H, m) [aromatic], 4.98 (IH, s) & 4.93 (IH, s) [OCH2O], 4.48 (1Η, m, NCH), 4.48 (1Η, d, J=3.3Ηz) & 4.44 (IH, d, J=3.6Hz) [OCHx2] and 3.08 (2Η, m, CH2Ar). LCMS (m/e): 461.4 (M+l, 100%).
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[l,3]dioxolane-4-carbonyl]- amino} -3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98) 1H NMR (DMSO, 300MHz):δ 7.56-7.36 (10H, m), 7.26-7.14 (3H, m), 6.98-6.92 (2H, m),
6.11 (s) & 6.00 (s) [IH], 5.17 (2H, s), 4.96-4.84 (2H, m), 4.25 (IH, m), 3.10-3.01 (2H, m).
LCMS (m/e): 671.02 (M+2, 100%).
(S)-3-[4-(2,6-dichloro-benzyloxy)-ρhenyl]-2-{[(4R,5R)-5-(3,4-dimethyl-isoxazol-5- ylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 107)
1H NMR (CDC13, 300MHz):δ 10.74 (IH, s), 8.37 (IH, d, 6Hz), 7.54-7.43 (3H, m), 7.18 (2H, d, 9Hz), 6.95 (2H, d, 9Hz), 5.21-5.18 (3H, m), 5.12 (lH,s), 4.66 (IH, s), 4.51-4.43 (IH, m), 3.11-2.94 (2H, m), 2.15 (3H, s), 1.78 (3H, s). LCMS (m/e): 578 (M+).
{2-[5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-l,2,3,4-tetrahydro- isoquinolin-3-yl}-3-carboxylic acid (Compound No. 109)
1H NMR (DMSO, 300MHz):δ 9.63 (IH, m), 7.82-7.80 (IH, m), 7.54 (IH, d, 8Hz), 7.37 (IH, m), 7.27-7.20 (5H, bs), 5.41-5.31 (2H, m), 5.21-5.02 (3H,m), 4.77 (IH, m), 4.48 (IH, m), 3.32 (2H, bs), 3.16 (2H, bs). LCMS (m/e): 431.22 (M+l, 80%), 453.19 (M+Na, 100%).
2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(lH- indol-3-yl)-propionic acid (Compound No. 110)
1H NMR (DMSO, 300MHz):δ 10.85 (IH, s), 8.29-8.20 (IH, m), 7.76 (m) and 7.54-7.51 (m) [2H], 7.32-7.34 (2H,m), 6.98-7.17(3H,m), 5.24-5.04 (2H, m), 4.67-4.74 (2H, m), 4.52- 4.54 (IH, bs), 3.24-3.16 (2H, m). LCMS (m/e): 458 (M+l, 50%).
2-{([4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6- dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. I l l)
1H NMR (DMSO, 300MHz):δ 10.67 (IH, s), 8.38 (IH, m), 7.79 (IH, d, 6Hz), 7.60-7.46 (2H, m), 7.35 (IH, m), 7.19-7.26 (5H, m), 5.26 (IH, s), 5.13 (IH, d, 9Hz), 5.06(lH,s), 4.68-4.73 (IH, m), 4.50-4.55 (2H, m), 3.09-3.00 (2H, m). LCMS (m/e): 608.17 (M+2, 20%). (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113)
1H NMR (DMSO, 300MHz, D2O Exchange):δ 7.94 (IH, d, 7.5Hz), 7.68 (IH, m), 7.55- 7.16 (6H, m), 6.95-6.97 (3H, d, 8Hz), 5.23 (IH, m), 5.19 (2H, s), 4.70-4.62 (2H, m), 4.51 (IH, m), 3.11 (2H, m), 1.50-1.36 (3H, m). LCMS (m/e): 607 (M+l, 100%).
(4R,5R)-2,2-Dimethyl-[ 1 ,3]dioxolane-4,5-dicarboxylic acid 4-[(2-chloro-phenyl)-amide]- 5-({(S)-l-[4-(2,6-dichloro-benzyloxy)-benzyl]-2-methyl-allyl}-amide) (Compound No. 115)
1H NMR (CDC13, 300MHz):δ 9.06 (IH, s, NH), 8.42 (IH, bs, NH), 7.40-7.05 (9H, m, Aromatic), 6.97 (2H, d, 8.1Hz), 5.23 (2H, s), 4.93 (IH, m), 4.73 (2H, bs), 3.20 (2H, m), 1.55 (3H, s), 1.43 (3H, s).
LCMS (m/e): 621.10 (M+l) [100%], 623 [M+3] [98%] 643.13 [M+Na]+ [10%]
(S)-2- {[(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133)
1H NMR (DMSO-d6, 300MHz):δ 9.17 (IH, s), 8.375 (IH, d, 9Hz), 7.985 (IH, d, J=9Hz), 7.43-7.54 (3H, m), 7.17-7.19 (2H, m), 7.03-7.05 (IH, m), 6.87-6.96 (3H, m) [10H aromatic and 2NH], 5.09 (IH, s) and 5.20 (IH, s) [OCH2O], 4.87 (1Η, bs, OCΗ(CΗ2)2), 4.65-4.67 (2H, m, OCHCOx2), 4.49 (1Η, m, NΗCHCO), 2.99-3.07 (2Η, m, ArCH), 1.59- 1.86 (8Η, m, 4CΗ2). LCMS (m/e): 661.32 (M+l, 100%), 663.3 (M+3, 70%)
3-Benzo[l,3]dioxol-5-yl-3-{[(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[l,3]dioxolane-4- carbonyl] -amino} -propionic acid (Compound No. 134)
Η NMR (DMSO-d6, 300MHz):δ 9.67 (IH, d, J=9Hz), 8.71-8.72 (IH, m), 7.78 (IH, m), 7.51-7.54 (IH, m), 7.26-7.36 (IH, m), 7.24 (IH, m), 6.94-6.97 (IH, m), 6.78-6.83 (2H, m) [7H aromatic+2NH], 5.98 (2H, s, OCH2O-Ar), 5.09-5.29 (3H, m, OCH2O, NΗCHAr), 4.54-4.75 (2Η, m, OCHCOx2), 2.71-2.81 (2Η, m, CHCH2COOH). LCMS (m/e): 463.23 (M+l, 25%), 485.2 (M+Na, 100%). (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(2'- methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135)
1H NMR (DMSO-dδ, 300MHz):δ 9.66 (IH, s), 8.47 (IH, d, J=9Hz), 7.765 (IH, d, J=9Hz), 7.51-7.54 (IH, d, J=9Hz), 7.21-7.39 (7H, m), 7.00-7.10 (2H, m) [12H aromatic+2NH], 5.26 (IH, s) and 5.13 (IH, s) [OCH2O], 4.68-4.72 (2Η, m, 2xOCHCO), 4.54 (1Η, m, NΗCHCO), 3.74 (3Η, s, OCH3), 3.06-3.18 (2H, m, ArCH2). LCMS (m/e): 525.53 (M+l, 80%), 547.27 (M+Na, 100%).
2- {[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l ,3]dioxolane-4-carbonyl]-amino} -3-(4- fluoro-phenyl)-propionic acid (Compound No. 136)
Η NMR (DMSO-d6, 300MΗz):δ 9.65 (IH, s, NH), 8.42 (IH, d, 8.1Hz), 7.77 (IH, d, 6.6Hz), 7.53 (IH, dd, 1.2Hz & 6.6Hz), 7.36 (IH, m), 7.26 (3H, m), 7.08 (2H, t, 9Hz), 5.25 (IH, s) & 5.12 (IH, s) [OCH2O], 4.70-4.62 (2Η, m, 2xOCHC(=O))> 4.48 (1Η, m, NΗCHCO), 3.17-3.01 (2Η, m, Ar-CH2). LCMS (m e): 437.22 (M+l+, 50%), 459.22 (M+Na+, 100%).
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- (2',6'-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137)
Η NMR (DMSO, 300MHz):δ 9.65 (IH, bs), 8.49 (IH, d, 9Hz), 7.77 (IH, d, 9Hz), 7.52 (IH, d, 6Hz), 7.35-7.20 (5H, m), 7.11 (2H, d, 6Hz), 6.72 (2H, d, 9Hz), [2H, NH+l lH Aromatic], 5.26 (IH, s) & 5.13 (IH, s), (OCH2O), 4.70 (2Η, s, (2χOCH-C(=O)), 4.54 (1Η, m, NΗCHCO), 3.64 (6Η, s, 2xO-CH3), 3.19-3.02 (2Η, m, Ar-CH2). LCMS (m/e): 555.29 (M+l+, 100%), 577.29 (M-Na+, 82%).
3- {[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 138)
1H NMR (DMSO, 300MΗz):δ 9.61 (IH, bs), 7.80 (IH, t, 6Hz), 7.54 (IH, d, 6Hz), 7.37 (IH, m), 7.25 (IH, m), 5.32-4.96 (4H, m), 3.16 (3H, bs), 2.89 (IH, s). LCMS (m/e): 343.23 (M+l)+ [65%], 365.16 (M+Na)+ [100%].
3-[[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-(3,4-dimethoxy- benzyl)-amino] -propionic acid (Compound No. 140) 1H NMR (DMSO, 300MHz):δ 9.60 (IH, d, 3.3Hz), 8.29 (IH, m), 7.78 (IH, bs), 7.52 (IH, bs), 7.26 (IH, bs), 6.91-6.79 (3H, m), 5.31-4.52 (6H, m) (Ar-CH2N+OCH2O+OCHCOx2),
3.73 (6Η, s, 2xOCH3), 3.67-3.43 (2Η, m, NCH2), 3.35 (2Η, bs, CH2COOH).
LCMS (m/e): 151.20 [100%], 493.50 (M+l, 5%] 515.31 [M+Na+, 8%] (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,5-dichloropyridin-4- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 142)
Η NMR (DMSO, 300MHz):δ 10.5 (IH, bs), 8.70 (2H, s), 8.39 (IH, d, 9Hz), 7.56-7.45 (3H, m), 7.19 (2H, d, 9Hz), 6.95 (2H, d, 9Hz) [9 Aromatic + 2NH], 5.18-5.25 (4Η, m, OCH2O) and (ArCΗ2O), 4.73 (IH, d, J=6Hz) and 4.655 (IH, d, J=3Hz) [OCHCOx2], 4.43-4.48 (1Η, m, NΗCHCO), 2.98-3.11 (2Η, ArCH2CH). LCMS (m/e): 628.24 (M+l, 50%), 630.2 (M+3, 70%).
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-fluoro- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 143)
1H NMR (DMSO-d6, 300MHz):δ 10.68 (IH, s, COOH), 9.90 (1Η, s, NH), 8.34 (1Η, d, 6Ηz, NH), 7.75 (1Η, bs), 7.46-7.60 (5Η, m) and 7.21-7.28 (5H, m) [11H Aromatic], 5.22 (IH, s) and 5.14 (IH, s) [OCH2O], 4.65-4.72 (2Η, m, 2xOCHCO), 4.48 (1Η, bs, NΗCHCO), 3.03-3.14 (2Η, m, ArCH2). LCMS (m/e): 590.30 (M+l, 100%), 592.3 (M+3, 70%)
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[2-(lH-indol-3-yl)- ethylcarbamoyl]-[ 1 ,3]dioxolane-3-carbonyl} -amino)-propionic acid (Compound No. 144)
1H NMR (DMSO, 300MHz):δ 10.78 (IH, bs), 10.67 (IH, bs), 8.26 (2H, m), 7.61-6.97 (10H, m), 5.08 (2H, s), 4.54-4.44 (3H, m), 3.13-2.70 (6H, m). LCMS (m/e): 639.4 (M+l)+ [100%], 641.41 (M+3)+ [68%].
(S)-2-[((4R,5R)-5-Cyclohexylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl] -propionic acid (Compound No. 145) Η NMR (DMSO, 300MHz):δ 10.65 (IH, bs), 8.29 (IH, bs), 7.56 (5H, m), 7.19 (2H, d, 9Hz), 5.07 (2H, d, 9Hz), 4.49-4.38 (4H, m), 3.10-3.06 (2H, m), 1.6-1.07 (4H, m), 1.2 (6H, m). LCMS (m/e): 578, 100% (M+l)+. (S)-2-([(4R,5R)-5-(Cyclohexylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147)
Η NMR (DMSO, 300MHz):δ 10.67 (IH, bs), 9.32 (IH, bs), 8.25 (IH, m), 7.71-7.69 (IH, m), 7.61-7.31 (14H, m), 7.20 (2H, d, 9Hz), 5.01 (lH,s), 4.94 (lH,s) 4.54-4.47(3H,m), 3.08-3.06(2H,m). LCMS (m/e): 698, 100%.
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-( {(4R,5R)-5-[(thiophen-2-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 148)
Η NMR (DMSO, 300MHz):δ 10.68 (IH, bs), 8.84 (IH, bs), 8.30 (IH, d, 9Hz), 7.6-7.46 (5H, m), 7.38 (IH, m), 7.21 (2H, d, 9Hz), 6.94 (2H, d, 9Hz), 5.10 (2H, d, 12Hz), 4.54-4.45 (5H, m), 3.12-2.99 (2H, m). LCMS (m/e): 592, 100-1.
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(thiazol-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 150)
1H NMR (DMSO-d6, 300MHz):δ 10.67 (IH, s, NH), 8.30-8.36 (1Η, m), 7.46-7.61 (6Η, m), 7.19-7.27 (3H, m) [9H aromatic and 1NH), 5.22 (1Η, s) and 5.14 (1Η, s) [OCH2O],
4.765 (1Η, d, 3Ηz), 4.715 (IH, d, 3Hz) [OCHCOx2], 4.48-4.50 (1Η, m, NΗCHCO), 3.03-
3.09 (2Η, m, ArCH2). LCMS (m/e): 579.28 (M+l, 100%), 581.29 (M+3, 70%).
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 154)
Η NMR (DMSO, 300MΗz):δ 10.67 (IH, bs), 9.15 (IH, bs), 7.60-7.49 (5H, m), 7.20 (2H, d, 9Hz), 5.06 (2H, d, 9Hz), 4.45 (2H, m), 4.31 (IH, m), 3.60 (2H, m), 3.05 (2H, m), 2.67 (2H, m), 1.76 (2H, bs), 1.54 (2H, bs), 1.32 (2H, bs). LCMS (m/e): 601-100%.
Example 4: (SV3-r4-(2,6-Dichloro-benzyloxyVphenyll-2- (f(4R.5RV5-(2.6-diethyl- phenylcarbamoyl)-ri,3]dioxolane-4-carbonyl]-amino|-propionic acid (Compound No. 90}
Step a: Synthesis of (4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[l,3]dioxolane-4- carboxylic acid ethyl ester. The solution of the compound (4R,5R)-[l,3]dioxolane-4,5-dicarboxylic acid monoethyl ester (1 g) (Formula III) in thionyl chloride (10 ml) was refluxed at 80°C for 1 hour. The excess of thionyl chloride was removed under reduced pressure and the residue thus obtained was taken into xylene (10ml). To it was added 2,6-diethyl aniline (1.56g) and the resulting reaction mixture was heated at 125°C for 6 hours. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was purified by column chromatography using 20% ethyl acetate in hexane as eluent to furnish the title compound (815 mg).
Step b: Synthesis of (4R,5R)-5-(2,6-diethyl-phenyIcarbamoyI)-[l,3]-dioxolane-4- carboxylic acid.
To a solution of the compound obtained from step a above (815 mg) in tetrahydrofura methanol : water (3:1:1), was added lithium hydroxide monohydrate ( 106 mg). The reaction mixture was stirred for 3 hours and concentrated under reduced pressure. The residue thus obtained was taken in water (20 ml) and extracted with ethyl acetate. The aqueous layer was acidified and extracted with ethyl acetate (25 ml). The organic layer was concentrated under reduced pressure to furnish the title compound (715 mg).
Step c: Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6- diethyI-phenylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]-amino}-propionic acid ethyl ester.
To a solution of the compound obtained from step b above (250 mg) in dichloromethane at 0°C, was added trifluoro acetic acid and the reaction mixture was stirred for 2 hours at room temperature. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was taken in dimethylformamide and cooled to 0°C. To it was added (S)-2-amino-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid ethyl ester (Bioorg. & Med Chem. Letters 12(2002) 1591-1594) N-methylmorpholine (258 mg), hydroxybenzorriazole (115 mg). The reaction mixture was stirred at 0°C for 30 minutes followed by the addition of l-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (162 mg) and stirred the reaction mixture it room temperature for overnight. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated. The residue thus obtained was purified by column chromatography using 50% ethyl acetate in hexane as eluent to furnish the title compound (210 mg).
Step d: Synthesis of (S)-3-[4-(2,6-DichIoro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6- diethyl-phenylcarbamoyl)-[l,3]dioxoIane-4-carbonyl]-amino}-propionic acid (Compound No. 90)
To a solution of the compound obtained from step c above (429 mg) in tetrahydrofuran:water:methanol (3:1:1, 5ml), was added lithium hydroxide monohydrate (28 mg) and stirred the reaction mixture for 2 hours. The reaction mixture thus obtained was taken in water. The resulting solution was acidified with aqueous sodium bisulphate and extracted with ethyl acetate. The organic layer was concentrated to furnish the title compound (180 mg).
The analogues of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-diethyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90) described below, can be prepared by reaction of appropriate acid with an amine following the same protocol.
(S)-3[4-(2,6-Dichloro-benzyloxy)-phenyl]-2- {[(4R,5R)-5-(2,6-dichloro-phenyl carbonyl)- [l,3]dioxolane-4- carbonyl] -amino} -propionic acid (Compound No. 72)
Η NMR (DMSO-d6, 300 MHz): δ 10.14 (IH, s, NH), 8.37 (1Η, d, NH), 7.30-7.60 (6Η, m), 7.19 (2H, d, J=9Hz) & 6.96 (2H, d, J=9Hz) [aromatic], 5.24 (IH, s) & 5.18 (3H, s) [OCH2Ar and OCH2O], 4.69 (1Η, d, J=3Ηz) & 4.64 (IH, d, J=3Hz) [OCH x 2], 4.47 (1Η, m, NCH) and 3.07 (2Η, m, CH2Ar). LCMS (m/e): 629.5 (M+l, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-difluoro-phenyl carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92)
Η NMR (DMSO-d6, 300MΗz):δ 9.81 (IH, s), 8.19 (2H, s), 7.74 (IH, m), 7.40-7.49 (3H, m), 7.14-7.17 (3H, m) and 6.90-7.02 (3H, m) [12H, aromatic+2NH], 5.12-5.20 (4H, m, OCH2O and A1CH2O), 4.63-4.69 (2Η, m, 2xOCHCO), 4.48-4.50 (1Η, m, NΗCHCO), 2.99-3.07 (2Η, m, ArCH2CH).
LCMS (m/e): 595.11 (M+l, 100%), 597.13 (M+3, 70%). (S)-2- {[(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 93)
Η NMR (DMSO-d6, 300MHz):δ 10.43 (IH, s), 9.92 (IH, s), 8.76-8.78 (2H, m), 8.34-8.37 (IH, m), 7.83-7.84 (2H, m), 7.65-7.71 (3H, m), 7.30-7.36 (IH, m), 7.22-7.24 (2H, m) and 7.08 (IH, m) [11H Aromatic+3NH], 5.21 (IH, s) and 5.12 (IH, s) [OCH2], 4.68 (1Η, d, J=6Ηz) and 4.62 (IH, d, J=6H), [2xOCHCO], 4.47-4.50 (1Η, m, NΗCHCO), 3.01-3.10 (2Η, m, ArCH2CH). LCMS (m/e): 541.2 (M+l, 100%), 542.2 (M+3, 30%).
(S)-2-{[(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 94)
Η NMR (DMSO-d6, 300MHz):δ 10.43 (IH, s), 9.60 (IH, s), 8.77 (2H, d, J=6Hz), 8.34- 8.36 (IH, d), 7.83-7.84 (2H, m), 7.66-7.68 (2H, m) and 7.08-7.25 (5H, m) [1 IH aromatic+2NH], 5.23 (IH, s) and 5.17 (IH, s) [OCH2O], 4.65 (1Η, d, 3Ηz) and 4.60 (IH, d, 3Hz) [2χOCHCO], 4.49-4.51 (1Η, m, NΗCHCO), 3.01-3.10 (2Η, m, ArCH2CH), 2.43- 2.50 (4H, m, CH2CH3), 1.05-1.10 (6H, m, 2xCH3). LCMS (m/e): 561.3 (M+l, 100%).
SCHEME II (PATH A) PROCEDURE
Example 5: (SV3- (4-(2.6-Dichloro-benzyloxy)-phenyl-2- (f(4R.5R)-5-(4-methyl- piperazine-l-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino|-propionic acid salt with trifluoroacetic acid (Compound No. 44)
Stepl : Synthesis of (4R,5R)-{lS-tert-butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)- phenyl]-ethyl-carbamoyl}-[l,3]dioxolane-4-carboxylic acid ethyl ester
O-(2,6-dichloro-benzyl)-L-tyrosine-t-butyl ester (430 mg, 1.08 mmol) was added to the compound of Formula III (20.6 mg, 1.08 mmol) in dry dimethylformamide (5 ml) under stirring. The reaction mixture was cooled to 0°C and then N-methylmorpholine (109 mg, 1.08 mmol) and hydroxybenzotriazole (146 mg, 1.08 mmol) were added and the mixture was stirred for 20 minutes. To the mixture was then added l-(3-dimethylaminopropyl)-3- ethyl carbodiimide hydrochloride (EDC.HCl) (206 mg, 1.08 mmol) under stirring. Gradually the reaction mixture was allowed to warm to room temperature and stirred overnight. Water was added and the reaction mixture was extracted with ethyl acetate (3 X 15 ml). The combined organic extracts were washed with water and brine and dried over anhydrous sodium sulphate solution. Evaporation of the solvent under reduced pressure followed by purification of the residue over a silica gel column using 20% ethyl acetate-hexane solvent mixture as an eluent furnished the title compound. Yield = (350 mg, 57%).
Η NMR(CDC13, 300MHz):δ 7.37 (2H, d, J=7.8Hz), 7.24 (IH, m), 7.10 (2H, d, J=7.8Hz) & 6.97 (2H, m) [aromatic], 5.25 (2H, s, COCH2Ar), 5.23 (1Η, s) & 5.19 (1Η, s) [OCH2O], 4.81 (1Η, d, J=2.4Ηz) & 4.66 (IH, d, J=2.4Hz) [OCHx2], 4.73 (1Η, m, NCH), 4.28 (2Η, q, J=6.9Hz, OCH2), 3.09 (2Η, m, CH2Ar), 1.43 (9Η, s, CH3x3) and 1.32 (3Η, t, J=6.3Hz, CH3).
Step 2: Synthesis of S-(4R,5R)-5-{lS-tert-butoxy-carbamoyl-2-[4-(2,6-di-chloro- benzyIoxy)-phenyl]-ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid
Lithium hydroxide monohydrate (26 mg, 0.62 mmol) was added to the ethyl ester obtained from Step 1 above (350 mg, 0.62 mmol) in tetrahydrofuran: water: methanol (3:1:1 ml), was added and the reaction mixture was stirred at room temperature for 2 hours. The solvents were evaporated; the residue was taken into water and extracted the organic layer with ethyl acetate. The aqueous layer was then acidified with saturated aqueous sodium bisulphate solution and then extracted with ethyl acetate (3x20 ml). The combined organic extract was washed with brine and dried over sodium sulphate and concentrated to obtain the title compound as a white solid (330 mg).
1H NMR (DMSO-d6, 300 MΗz):δ 8.33 (IH, d, NH), 7.56 (2H, J=7.5Hz), 7.47 (IH, m), 7.17 (2H, d, J=8.1Hz) & 6.97 (2H, d, J=8.4Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.14 (1Η, s), & 5.08 (1Η, s) [OCH2O], 4.56 (1Η, d, J=3.6Ηz) & 4.53 (IH, d, J=3.6Hz) [OCHχ2], 4.37 (1Η, m, NCH), 2.98 (2Η, m, CH2Ar) (d, J=3.6Ηz) [OCHχ2], 4.37 (1Η, m, NCH), 2.98 (2Η, m, CH2Ar) and 1.36 (9Η, s, CH3χ3).
LCMS (m/e): 540.5 (M+l, 50%) and 484.5 ((M-+Bu)+2, 100%) Step 3: Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4- methyl-piperazine-l-carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid tert-butyl ester N-methylpiperazine (57 mg, 0.57 mmol), N-methylmorpholine (58 mg, 0.58 mmol) and hydroxybenzotriazole (78 mg, 0.58 mmol) was added to the acid obtained from Step 2 above (310 mg, 0.57 mmol) in dry dimethyl formamide (5 ml) at 0°C. The reaction mixture was stirred for 20 minutes and then l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC.HCl) (109 mg, 0.58 mmol) was added, and gradually warmed to room temperature and the reaction mixture stirred overnight. The reaction mixture was quenched with water and the aqueous layer was extracted with ethyl acetate (3x15 ml). The solvent was evaporated off and the crude organic compound thus obtained was purified through column chromatography using 2.5% methanol: dichloromethane solvent mixture as an eluent, which furnished the title compound as light yellow solid. Yield = (229 mg, 65%).
1H NMR (DMSO-d6, 300 MHz):δ 8.26 IH, d, NH), 7.56 (2Η, d, J=7.5Hz), 7.46 (IH, m), 7.16 (2H, d, J=8.1Hz) & 6.97 (2H, d, J=8.1Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.08 (2Η, s, OCH2O), 4.86 (1Η, d, J=3.3Ηz), 4.71 (IH, d, J=3.3Hz) [OCHχ2], 4.38 (1Η, m, NCH), 3.46 (4Η, m, NCH2x2), 2.97 (2Η, m, CH2Ar), 2.27 (4Η, m, NCH2χ2), 2.17 (3Η, s, N-CH3) and 1.37 (9Η, s, CH3x3).
Step 4: Synthesis of (S)-3-{4-(2,6-Dichloro-benzyloxy)-phenyl-2-{[(4R,5R)-5-(4- methyl-piperazine-l-carbamoyl)-[l,3]dioxolane-4-cabonyl]-amino}-propionic acid trifluoroacetic acid salt
Trifluoroacetic acid (2.5 ml) was added to the tert-butyl ester (220 mg, 0.35 mmol) in dichloromethane (2.5 ml) and the reaction mixture was stirred at room temperature for 3 hours. The volatiles were removed under reduced pressure and flushed with nitrogen to obtain the title compound as a yellow hygroscopic solid. Yield = (230 mg, 97%). Η NMR (DMSO-d6, 300 MHz): δ 10.1 (IH, bs, CO2H), 8.22 (1Η, d, NH), 7.56 (1Η, d, J=87.5Ηz), 7.55 (IH, s), 7.45 (IH, m), 7.18 (2H, d, J=8.4Hz) & 6.97 (2H, d, H=8.4Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.14 (1Η, s) & 5.11 (1Η, s) [OCH2O], 5.06 (1Η, d, J=3Ηz) & 4.77 (IH, d, J=2.4Hz) [OCHx2], 4.49 (1Η, m, NCHCO), 4.44 (2Η, m), 3.43 (3H, bs) & 3.07 (5H, m) [NCH2x4 (ring) and CH2Ar] and 2.81 (3Η, s, ArCH3). LCMS (m/e): 566.1 (M+l, freebase, 90%) and 568.1 (M+3), 100%). Analogs of (S)-3- {4-(2,6-dichloro-benzyloxy)-ρhenyl-2- {[(4R,5R)-5-(4-methyl- piperazine- 1 -carbamoyl)-[ 1 ,3]dioxolane-4-cabonyl]-amino} -propionic acid trifluoroacetic acid salt (Compound No. 44) which are described below were prepared by reaction of the appropriate amine with the acid obtained by Example 3, Step 2 following the same protocol.
(S)-2-[{(4R,5R)-5-tert-Butyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48)
'HNMR(DMSO-d6, 300 MHz): δ 8.22 (IH, d, NH), 7.40-7.60 (4Η, m), 7.17 (2H, d, J=8.1 Hz) & 6.96 (2H, d, J= 8.4 Hz) [aromatic], 5.18 (2H, s, OCH2Ar), 5.1 (1Η, s) & 5.04 (1Η, s) [OCH2O], 4.44 (1Η, m, NCH), 4.44 (1Η, d, J=4.2 Ηz) & 4.32 (1Η, d, J=3.9Ηz), 3.03 (2H, m, CH2Ar) and 1.27 (9Η, s, CH3 x 3). LCMS (m/e): 539.4 (M+l, 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-[{(4R,5R)-5-(3-methyl-butylcarbamoyl)- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 49)
1ΗNMR(DMSO-d6, 300 MHz): δ 8.26 (IH, d, NH), 8.17 (1Η, t, NH), 7.56 (2Η, d, J= 7.5 Hz), 7.46 (IH, m), 7.17 (2H, d, J=8.1 Hz) & 6.96(2H, d, J= 8.4 Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.09 (1Η, s) & 5.06 (1Η, s) [OCH2O], 4.47 (1Η, d, J=3.6 Ηz) & 4.37 (1Η, d, J=3.9 Ηz) [OCHx2], 4.43 (1Η, m, NCH), 2.95-3.20 (4Η, m, NCH2 and CH2Ar), 1.55 (1Η, m, CΗCH , 1.32 (2Η, m, CH2CH) and 0.85 (6H, d, J=6.6 Hz, CH3 x 2). LCMS (m/e): 553.5 (M+l, 100 %).
(S)-3-[4-(2,6,Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(R)-l-phenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 50)
'ΗNMR(DMSO-d6, 300 MHz); δ 8.61 (IH, d, NH), 8.22 (1Η, d, NH), 7.40-7.58 (3Η, m), 7.30 (4H, m), 7.10-7.25 (3H, m) & 6.93 (2H, m) [aromatic], 5.17(2H, s, OCH2Ar), 5.14 (1Η, s) & 5.09 (1Η, s) [OCH2O], 4.96 (1Η, m, NCH), 4.40-4.50 (3Η, m, OCHx2 and NCH), 2.90-3.10 (2Η, m, CH2Ar) and 1.39 (3Η, d, J=6.9 Hz, CH3). LCMS (m/e): 587.4 (M+l, 100%). (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(S)-l-phenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 51)
1HNMR(DMSO-d6, 300 MHz): δ 8.65 (IH, d, NH), d, NΗ), 8.27 (1Η, d, NH), 7.56 2Η, d,
J= 7.8 Hz), 7.46 (IH, t, J=7.2 Hz), 7.31 (3H, d, J=3Hz), 7.22 (2H, m) & 6.96 (2H, d, J=
7.8 Hz) [aromatic], 5.18 (2H, s, OCH2Ar), 5.11 (1Η, s) & 5.08 (1Η, s) [OCH2O], 4.96 (1Η, m, NCH), 4.47 (3Η, bs, OCHx2 and NCH), 3.00 (2Η, m), CH2Ar) and 1.39 (3Η, d, J= 6.6
Hz).
LCMS (m/e): 587.4 (M+l, 100%).
(S)-l-{(4R,5R)-5-{(S)-l-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl- carbamoyl}-[l,3]dipxolane-4-carbonyl}-pyrolidine-2-carboxylic acid benzyl ester(Compound No. 52)
1HNMR(DMSO-d6, 300 MHz) δ: 8.20 (IH, d, NH), 5.18 (2Η, s, OCH2Ar), 5.11 (3Η, s) & 5.03 (IH, s) [OCH2Ph and OCH2O], 4.76 (1Η, d, J-3.6 Ηz) & 4.66 (1Η, d, J=3.6 Ηz) [OCHx 2], 4.46 (1Η, m) & 4.38 (1Η, m) [NCHx 2], 3.07 (2Η, m, CH2Ar) and 2.20 (1Η, m) & 1.89 (3Η, m) [CH2 X 2 (ring)]. LCMS (m/e): 671.3 (M+l, 100%).
(S)-2-[(4R,5R)-{5-Benzyloxy-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl] -propionic acid (Compound No. 54)
1HNMR(DMSO-Cl6, 300 MHz) : δ 11.61 (IH, s, NH), 8.29 (1Η, d, NH) 7.30-7.60 (8Η, m), 7.16 (2H, m) & 6.96 (2H, d, J=6Hz) [aromatic], 5.18 (2H, s OCH2Ar), 5.08 (1Η, s) & 5.05 (1Η, s) [OCH2O], 4.81 (2Η, s, OCH2Ph), 4.53 (1Η, d, J=3Ηz) & 4.37 (IH, d, J=3Hz) [OCHx 2 ], 4.44 (1Η, m, NCH) and 3.05 (2Η, m, CH2Ar). LCMS (m/e): 589.4 (m+l, 100%).
(S)-2-[((4R,5R)-{5-allyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56)
'ΗNMR(DMSO-d6, 300 MHz): δ 8.38 (IH, m, NH), 8.27 (IH, d, NH) 7.45-7.60 (3Η, m), 7.17 (2H, d, J=8.1 Hz) and 6.96 (2H, d, J=8.4Hz) [aromatic], 5.73 (IH, m, olefmic H), 5.18 (2H, s, OCH2Ar), 5.11 (2Η, d, J=6 Hz, olefinicCH2) , 5.06 (s) & 5.03 (s) [OCH2O], 4.50 (1Η, d, J=3.9 Ηz) & 4.43 (2Η, m) [OCHX 2 and NCH] 3.57 (2Η, bs, NCH2 and 3.05 (2Η, m, CH2Ar). LCMS (m/e): 523.6 (M+l, 100%).
l-{(4R,5R)-5-[(S)-l-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid (Compound No.57)
1HNMR(DMSO-d6, 300 MHz): δ 8.18 (IH, d, NH), 7.40-7.60 (3Η, m), 7.32 (IH, d, NH), 7.16 (2Η, d, J=8.1Hz) & 6.96 (2H, d, J=8.1Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.13 (IH, s) & 5.06 (IH, s) [OCH2O], 4.74 (1Η, d, J=3.3 Ηz) & 4.64 (1Η, d, J=3.3 Ηz) [OCHx 2], 4.47 (1Η, m, NCH), 4.20 (1Η, m, NCH), 3.07 (2Η, m, CH2Ar), 2.08 (1Η, m) & 1.86
Figure imgf000072_0001
LCMS (m/e); 581.6 (M+l, 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(tetrahydro-furan-2-yl-methyl- carbamoyl]-[l ,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 58)
'ΗNMR^DCIS, 300 MHz): δ 7.34 (2H, d, J=9Hz), 7.10-7.27 (5H, m) & 6.94 (2H, d, J=9Hz) [aromatic], 5.22 (2H, s, OCH2Ar), 5.09 (1Η, d, J=6Ηz) & 5.07 (IH, d, J= 6Hz) [OCH∑O], 4.86 (1Η, m) & 4.62 (1Η, m) [OCHX 2), 4.48 (1Η, m, NCH), 4.02 (1Η, m, OCH), 3.70-3.90 (2Η, m, OCH2), 3.48 (1Η, m) & 3.05-3.25 (3Η, m) [NCH2 and CH2Ar] and 1.85-2.00 (3Η, m) & 1.52 (IH, m) [CH2 x 2 (ring)]. LCMS (m/e): 567.5 (M+l, 85 %) and 569.5 (M+3, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[2-(lΗ-indol-3-yl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 59)
'HNMR(DMSO-d6, 300 MHz): δ 6.9-7.55 (12H, aromatic), 5.17 (2H, s, OCH2Ar), 5.11
(1Η, s) & 5.05 (1Η, s) [OCH2O], 4.13-4.50 (3Η, m, OCHx 2 and NCH), 3.37 (1Η, m) &
2.70-3.20 (3Η, m) [CH2Ar and CH∑Ηet].
LCMs (m/e): 682.7 (M+l, 80 %).
(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(2-thiophen-2-yl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 60)
'ΗNMR(DMSO-d6, 300 MHz): δ 8.27 (2H, m, NHx2), 7.55 (2Η, d, J=6Hz), 7.46 (lH,m) 7.31 (lH,d, J= 6Hz), 7.18 (2H,d, J= 6Hz), 6.96 (3H,d, J=6Hz) & 6.87 (IH, s) [aromatic], 5.19 (2H, s, OCH2Ar), 5.07 (2Η, s, OCH2O), 4.49 (1Η, m, NCH), 4.49 (1Η, d, J=3Ηz) & 4.41 (IH, d, J=3Hz) [OCHx2], 3.36 (2Η, t, NCH2), 3.08 (m) & 2.98 (t) [4Η, CH2Ar and CH2ΗefJ. LCMS( m/e): 593.6 (M+l), 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[(pyridin-4-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.61)
1HNMR(DMSO-d6, 300 MHz): δ 9.00 (IH, t, NH), 8.78 (2Η, d, J=4.5 Hz), 8.30 (IH, d, NH), 7.78 (2Η, d, J=5.1 Hz), 7.55 (2H, d, J=7.2 Hz), 7.46 (IH, m), 7.17 (2H, d, J=7.8 Hz) & 6.95 (2H, d, J=8.1 Hz) [aromatic], 5.18 (3H, s) & 5.11 (IH, s) [OCH2Ar and OCH2O], 4.30-4.60 (5Η, m, OCHx 2, NCH and NCH2) and 2.98 (2Η, m, CH2Ar).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-(methyl-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.65)
'ΗNMR(DMSO-d6, 300 MHz): δ 8.23 (IH, d, NH), 7.30-7.60 (6Η, m), 7.10-7.22 (4H, m) & 6.94 (2H, d, J=8Hz) [aromatic], 5.16 (2H, s, OCH2Ar), 5.06 (1Η, s) & 4.90 (1Η, s) [OCH2O], 4.64 (1Η, d, J=4.2Ηz) & 4.29 (IH, d, J=3.9Hz), [OCHX 2], 4.28 (1Η, m, NCH), 3.19 (3Η, s, N-CH3) and 2.94 (2Η, m, CH2Ar). LCMS (m/e): 573.5 (M+l, 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[ {4R,5R)-5-[methyl-(l -methyl-piperidine-4- yl)-carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 66)
'ΗNMR(DMSO-d6, 300 MHz): δ 9.50 (IH, bs, CO2H), 8.21 (IH, m, NH), 7.56 (2Η, d, J=9Hz), 7.46 (IH, m), 7.17 (2H, d, J=6Hz) & 6.96 (2H, d, J= 9Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 4.25-5.15 (5Η,m, OCH2O, OCH x 2 and NCH), 2.70-3.20 (6Η,m, NCH2 x2 and CH2Ar), 2.51 (DMSO + N-CH3 X2), 1.70-2.05 (4Η, m, CH2x2 (ring)). LCMS (m/e): 594.6 (M+l, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-{[(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 67)
1ΗNMR(DMSO-d6, 300 MHz): δ 9.89 (IH, s, NH), 8.34 (1Η, d, NH), 7.76 (1Η, t), 7.55 (2Η, d, J=9Hz), 7.46 (IH, m), 7.15-7.30 (5H, m), & 6.96 (2H, d, J=9Hz) [aromatic], 5.22 (IH, s) & 5.13 (IH, s) [OCH2O], 5.18 (2Η, s, OCH2Ar), 4.71 (1Η, d, J=6Ηz) & 4.65 (lH,d, J=3Hz) [OCHx2], 4.49 (1Η, m, NCH) and 3.07 (2Η, m, CH2 Ar). LCMS (m/e): 577.6 (M+l, 100%). (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-phenyl- carbamoyl)-[l,3]dioxolane-4-carbony]-amino}-propionic acid (Compound No. 68)
1HNMR(DMSO-d6, 300 MHz): δ 9.17 (IH, s, NH), 8.37 (1Η, d, J= 8.1 Ηz), 8.06 (1Η, d, NH 7.55 (2Η, d, J=7.5 Hz), 7.45 (IH, m), 7.19 (2H, d, J=8.1Hz), 7.09 (2H, m) & 6.92- 6.98 (3H, m) [aromatic], 5.25 (IH, s) & 5.11 (IH, s) [OCH2O], 5.18 (2Η, s, OCH2Ar), 4.71 (1Η, d, J=3.6Ηz) & 4.66 (IH, m, J=3.9Hz)[OCHx2], 4.48 (1Η, m, NCH), 3.85 (3Η, s, OCH?) and 3.00 (2Η, m, CH2Ar). LCMS (m/e): 593.6 (M+l, 100%)
(S)-2-{[(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69)
1ΗNMR(DMSO-d6, 300 MHz) δ 10.30 (IH, s, NH), 8.36 (IH, d, NH), 7.72 (1Η, d,
J=9Ηz), 7.56 (2H, d, J=6Hz) 7.47 (IH, m), 7.39 (2H, d, J=9Hz), 7.18 (2H, d, J=6Hz) & 6.96 (2H, m) [aromatic], 5.18 (IH, s) & 5.13 (IH, s) [OCH2O], 5.16 (2Η, s, OCH2Ar), 4.66 (1Η, d, J=3Ηz) & 4.61 (IH, d, J=3Hz) [OCHx 2], 4.48 (1Η, m, NCH) and 3.06 (2Η, m, CH2Ar) LCMS (m e): 595.5 (M+3, 100%)
(S)-2-{[(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70)
1ΗNMR(DMSO-d6, 300 MHz): δ 10.33 (IH, s, NH), 8.37 (1Η, d, NH), 7.87 (1Η, s), 7.30- 7.60 (5Η, m), 7.20 (3H, d, J=9Hz) 8c 6.96 (2H, t, J=9Hz) [aromatic], 5.20 (IH, s) & 5.14 (lH,s) [OCH2O], 5.17 (2Η, s, OCH 2], 4.67 (1Η, d, J=3Ηz) 8c 4.61 (IH, d, J=3Hz) [OCHx2], 4.48 (1Η, m, NCH) and 3.06 (2Η, m, CH2Ar) LCMs (m/e): 593.5 (M+l, 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-O-tolyl-carbamoyl- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound no.73)
,ΗNMR(DMSO-d6, 300 MHz): δ 9.59 (IH, s, NH), 8.35 (1Η, d, NH), 7.30-7.60 (4Η, m), 7.20 (5H, m) & 6.95 (2H, d, J= 8.4 Hz) [aromatic], 5.23 (IH, s) & 5.14 (IH, s) [OCH2O], 5.18 (2Η, ABq J= 4.5 Hz, OCH2Ar), 4.64 (2Η, d, J= 5.1 Hz, OCHx2), 4.48 (1Η, m, NCH), 3.06 (2Η, m, CH2Ar) and 2.17 (3Η, s, ArCH3) LCMS (m/e): 573.5 (M+l, 100 %).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-dimethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74)
1HNMR(DMSO-d6, 300MHz):δ 8.20 ((IH, d, NH), 7.56 (2H, d, J=7.5Hz), 7.46 (IH, m),
7.16 (2H, d, J=8.4 Hz) & 6.97 (2H, d, J=8.4 Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5..08 (2Η, s, OCH2O), 4.66(1Η, d, J=3.6 Hz) & 4.54 (IH, d, J=3.6 (Hz) [OCHx2], 4.45 (1Η, m, NCH), 3.06 (1Η, m) 2.92 (1Η, m) [CH2Ar], 2.92 (3Η, s) and 2.84 (3H, s) [NCH3 X 2]. LCMS (m/e): 511.3 (m+l, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{(4R,5R)-5-methyl-carbamoyl- [l,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75)
'ΗNMR(DMSO-d6, 300 MHz): δ 8.26 (IH, d, NH), 8.12 (1Η, m, NH) 7.55 (2Η, d, J=7.5 Hz) 7.46 (IH, m), 7.17 (2H, d, J=8.4Hz) 8c 6.96 (2H, d, J= 8.4 Hz) [aromatic], 5.18 (2H, s, OCH2Ar], 5.09 & 5.07 (1Η, s) & 5.04 & 4.93 (1Η, s) [OCH2O}, 4.30-4.55 (3Η, m, OCHX2 and NCH), 2.90-3.10 (2Η, m, CH∑Ar) and 2.63 (s) & 2.61 (s) [3Η, CH3] LCMS(m/e) : 497.5 (M+l, 100 %).
(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methoxy-carbamoyl- [l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 76)
'ΗNMR(DMSO-d6, 300 MHz): δ 8.28 (lH,d, NH), 7.55 (lΗ,d,J=7.5 Hz), 7.45 (lH,m), 7.17 (2H,d, J= 8.1 Hz) & 6.96 (2H,d,J=8.1Hz)[aromatic], 5.19 (2H,s, OCH2Ar), 5.11
(lΗ,s) & 5.06 (lH,s) [OCH2O], 4.54 (lΗ,d,J=3.9Ηz) & 4.35 (lH,d, J= 3.9 Hz) [OCHX2], 4.45 (lΗ,m, NCH), 3.61 (3Η,s, OCH3) and 3.05 (2Η,m, CH2Ar). LCMS (m/e): 513.5 (M+l, 100%).
(4R,5R)-5-{(S)-l-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl]- ethylcarbonyl]-[l,3]dioxolane-4-carboxylic acid (Compound No.77)
'ΗNMR (DMSO-d6, 300 MHz): δ 8.33 (IH, d, NH), 7.56 (2Η, d, J=7.5 Hz), 7.47 (IH, m),
7.17 (2H,d, J=8.1Hz) & 6.97 (2H, d, J=8.4 Hz) [aromatic], 5.19 (2H, s, OCH2Ar), 5.14 (1Η, s) & 5.08 (1Η, s) [OCH2O], 4.56 (1Η, d, J=3.6 Ηz) & 4.53 (1Η, d, J= 3.6Ηz) [OCHx 2], 4.37 (1Η, m, NCH), 2.98 (2Η, m, CH2Ar) and 1.36 (9Η, s, CH3 x 3) LCMS (m/e): 540.5 (M+l, 50 %) and 484.5 (M-t-bu)+2, 100 %).
(S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[2-(4-hydroxy-ρhenyl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 78)
'HNMR (DMSO-d6, 300 MHz): δ 8.26 (IH, d, NH), 8.20 (1Η, bs, NH), 7.54 (2Η, m), 7.48
(IH, m), 7.17 (2H, d, J=6.9Hz), 6.97 (4H, bs) & 6.66 (2H, d, J= 6.3 Hz), 5.18 (2H, s,
OCH2Ar), 5.05 (2H, s, OCH2O), 4.30-4.48 (3Η, m, OCHx 2 and NCH), 3.24 (2Η, m,
NCH2), 3.04 (2Η, m) CH2Ar) and 2.63 (2Η, m, CH2Ar). LCMS (m/e): 603.5 (M+l, 100%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyrrolidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79)
Η NMR (DMSO, 300 MHz, D2O Exchange): δ 7.51 (2H, d, 8.4Hz), 7.42 (2H, m), 7.12 (2H, d, 8.4Hz), 6.92 (2H, d, 8.4Hz), 5.15 (2H, s), 5.05 (2H, s), 4.60-4.10 (5H, m), 3.42- 2.92 (4H, m), 1.74 (4H, bm). LCMS (m/e): 537.16 (M+l)+ [100%], 539.17 (M+3)+ [68%]
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-((R)-3-hydroxy-pyrrolidine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 80)
Η NMR (DMSO, 300 MHz): δ 8.19 (IH, bs), 7.55 (2H, d, 9Hz), 7.46 (IH, d, 9Hz), 7.16 (2H, d, 6Hz), 6.95 (2H, d, 8.1Hz), 5.18 (2H, s), 5.05 (2H, m), 4.68-4.23 (6H, m), 3.54 (2H, m), 3.00 (2H, m), 1.86 (2H, m).
LCMS (m/e): 553.17 (100%) [M+l]+
1 -((4R,5R)-5-((S)- 1 -tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]- ethylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81)
Η NMR (DMSO-d6): 7.56-7.47 (3H, m), 7.175 (2H, d, J= 9Hz), 6.975 (2H, d, J = 9Hz), 5.20 (2H, s), 5.06-5.15 (2H, m), 4.67-4.74 (2H, m), 4.41-4.43 (IH, m), 4.25-4.26 (IH, m), 3.57-3.59 (2H, m), 4.25-4.26 (IH, m), 1.82-2.22 (4H, m), 1.34-1.38 (9H, m). LCMS (m/e): 637.4 (M+), 639.3 (M+2) +.
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(l-hydroxymethyl-proρyl carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 82) 1H NMR (DMSO, 300 MHz):δ 8.25 (IH, bs, NH), 7.74 (IH, bs, NH), 7.55 (2H, d, 7.8Hz), 7.46 (IH, m), 7.17 (2H, d, 8.1Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.09 (2H, d, J=6Hz), 4.43-4.52 (3H, m), 3.66-3.28 (3H, m), 2.96-3.09 (2H, m), 1.58-1.23 (2H, m), 0.79 (3H, t, 7.2Hz). LCMS (m/e): 555.18 [(M+l), 100%].
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-ethylcarbamoyl-[l,3]dioxolane - 4-carbonyl)-amino] -propionic acid (Compound No. 83) 1H NMR (DMSO, 300 MHz):δ 8.25-8.16 (2H, m), 7.56-7.46 (3H, m), 7.16 (2H, d, 8.1Hz),
6.96 (2H, d, 8.1Hz), 5.18 (2H, s), 5.07 (2H, m), 4.51-4.44 (2H, m), 4.37 (IH, m), 3.17-
2.97 (4H, m), 1.02 (3H, t, 7.2Hz).
LCMS (m/e): 511.09 (M+, 100%), 513 (M+2, 60%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-prop-2-ynylcarbamoyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 84)
Η NMR (DMSO, 300 MHz):δ 8.65 (IH, m), 8.26 (IH, d, 6.9Hz), 7.57-7.45 (3H, m), 7.15 (2H, m), 6.96 (2H, d, 8.4Hz), 5.19 (2H, s), 5.09 (2H, m), 4.53-4.36 (3H, m), 3.88 (3H, d, 3.0Hz), 3.17-2.97 (3H, m).
LCMS (m/e): 521.17 (M+, 100%), 523 (M+2, 60%)
Trifluoroacetate salt of (S)-3-[4-(2,6-Dichloro-benzoloxy)-phenyl]-2- {[(4R,5R)-5-(2- morpholin-4-yl-ethylcarbamoyl)-[ 1 ,3]-dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 85)
Η NMR (DMSO-d6, 300 MHz):δ 9.5 (IH, bs), 8.4 (IH, t, 8.4Hz), 8.28 (IH, d, 8.2Hz), 7.5 (2H, m), 7.4 (IH, m), 7.18 (2H, d, J=8.4Hz), 7.96 (2H, d, J=8.4Hz), 5.74 (2H, s), 5.1 (2H, d, J=11.4Hz), 4.52 (2H, m), 4.4 (IH, bs), 3.66-3.05 (12H, m). LCMS (m/e): 596.25 (M+l)+ [100%], 598.22 [M+2]+ [70%].
(S)-3-[4-(2,6-Dichloro-benzoloxy)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 86)
Η NMR (DMSO, 300 MHz):δ 8.26 (IH, bs, NH), 7.55 (2H, d, 6Hz), 7.46 (IH, m), 7.16 (2H, m), 6.96 (2H, d, 6Hz), 5.19 (2H, s), 5.07 (2H, m), 4.49-4.34 (4H, m), 3.17-2.73 (6H, m), 1.57-1.2 (6H, m). LCMS (m/e): 566.19 (M+l) [100%]. (S)-3-[4-(2,6-Dichloro-benzoloxy)-ρhenyl]-2-{[(4R,5R)-5-(piperidin-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 87)
1H NMR (DMSO, 300 MHz):δ 8.20 (IH, bs, NH), 7.55 (2H, d, 7.2Hz), 7.46 (IH, m), 7.16 (2H, d, 8.4Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.06 (2H, s), 4.81 (IH, d, 3.9Hz), 4.66 (IH, d, 3.6Hz), 4.45 (IH, m), 3.16-2.95 (6H,m), 1.39-1.55 (6H, bm). LCMS (m/e): 551.17 (M+l)+ [100%], 553.15 (M+3)+ [66%]
(S)-2- {[(4R,5R)-5-(Bicyclo[2.2.1 ]hept-2-ylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89)
Η NMR (DMSO-de, 300 MHz):δ 8.14 (IH, m), 7.54-7.60 (3H, m), 7.45-7.48 (IH, m), 7.01-7.04 (2H, m) and 6.85-6.87 (2H, m) [aromatic and 2NH], 5.16 (2Η, s, ArCH20), 5.04-5.06 (2H, bs, OCH2O), 4.42-4.44 (2H, , OCH COχ2), 3.91 (2Η, bs, NHCHCO and NΗCHring), 3.0 (2Η, bs, ArCH2), 2.30 (1Η, bs), 2.14 (1Η, bs), 1.84 (1Η, bs) and 1.02- 1.50 (7Η, m) [Bicyclic ring). LCMS (m/e): 577.2 (M+l, 100%)
(S)-3-[4-(2,6-Dichloro-benzoloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropyl- phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 91)
Η NMR (DMSO, 300 MHz):δ 9.66 (IH, bs, NHO2COOH), 8.34 (IH, bs, NH), 7.54 (2H, d, 7.5Hz), 7.45 (IH, m), 7.33-7.16 (6H, m), 6.95 (2H, d, 8.4Hz), 5.21-5.14 (4H, m), 4.62 (2H, dd, 4Hz), 4.47 (IH, m), 2.98-3.16 (2H, m), 2.20 (IH, m), 1.11 (6H, d, 6.8Hz). LCMS (m/e): 601.12 (M+l)+ [100%], 603.11 (M+3)+ [70%]
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-((R)-2-hydroxy-l-phenyl- ethylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 97)
Η NMR (DMSO, 300 MHz):δ 8.45 (IH, d, J=9Hz), 8.24 (IH, d, J=9Hz), 7.55-7.57 (2H, m), 7.44-7.49 (IH, m), 7.15-7.32 (7H, m) and 6.93-6.96 (2H, m) [aromatic+2NH], 5.11- 5.19 (4H, m, ArCH2O and OCH2O), 4.84-4.87 (IH, m, NHCHCO), 4.44-4.48 (3H, m, 2OCHCO), 3.59-3.62 (3H, m, NHCH(PR)CH2OH), 2.98-3.08 (2H, m, ArCH2CH). LCMS (m/e): 603.15 (M+l, 100%), 605.11 (M+3, 70%)
(S)-2-{[(4R,5R)-5-(5-tert-Butyl-2-ρ-tolyl-2H-ρyrazol-3-ylcarbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 99) 1H NMR (DMSO-d6, 300 MHz):δ 10.02 (IH, s), 8.3 (IH, d, J=9Hz), 7.56-7.16 (9H, m), 6.96 (2H, d, 9Hz), 6.32 (IH, s, NH), 5.18 (2H, s), 5.10 (2H, d, 6Hz), 4.57-4.44 (3H, m), 2.97-3.06 (2H, m), 2.32 (3H, s), 1.27 (9H, s). LCMS (m/e): 695.29 (M+l)+ [85%], 697.27 (M+2)+ [60%]
(S)-2- {[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100)
Η NMR (DMSO-d6, 300 MHz):δ 9.64 (IH, s), 8.33 (IH, d, J=9Hz), 7.54-7.56 (2H, m), 7.43-7.48 (IH, m), 7.17-7.28 (6H, m) and 6.94-6.97 (2H, m) [1 IH, aromatic + 2NH], 5.15- 5.22 (4Η, m, OCH2O and ArCH2O), 4.61-4.66 (2Η, m, 2xOCHCO), 4.47-4.49 (1Η, m, NΗCHCO), 2.94-3.11 (2Η, m, ArCH2CH), 2.81-2.86 (IH, m, ArCHCH2), 1.47-1.49 (2H, m, ArCHCH2), 1.12 (3Η, d, J=7Hz CHCH3) and 0.74 (3Η, t, J=7Hz, CH2CH3). LCMS (m/e): 615.28 (M+l, 100%), 617.3 (M+2, 70%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-trifluoromethyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 102)
Η NMR (DMSO-d6, 300 MΗz):δ 9.75 (IH, s), 8.34-8.36 (IH, m), 7.43-7.77 (7H, m),
7.185 (2H, d, J=9Hz) and 6.96 (2H, d, J=9Hz) [1 IH aromatic + 2NH], 5.15-5.20 (4H, m,
OCH2O) and ArCH2O), 4.685 (1Η, d, J=3Ηz), 4.635 (IH, d, J=3Hz) [2xOCHCO], 4.44-
4.48 (1Η, m, NΗCHCO), 2.94-3.10 (2Η, m, ArCH2CH) LCMS (m e): 627.2 (M+l, 100%), 629.24 (M+3, 70%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropoxy-phenyl carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 103)
1H NMR (DMSO-d6, 300 MHz):δ 9.14 (IH, s), 8.385 (IH, d, 9Hz), 8.11 (2H, d, 6Hz), 7.43-7.56 (3H, m), 7.18-7.21 (2H, m), 7.08-7.09 (2H, m) and 6.93-6.98 (3H, m) [aromatic+2NH], 5.12 (IH, s) and 5.24 (IH, s) [OCH2O], 5.18 (2Η, s, ArCH2O), 4.59-4.69 (3Η, m, 2χOCHCO and NΗCHCO), 4.45-4.50 (1Η, m, ArOCH), 2.95-3.11 (2Η, m, ArCH2) and 1.28 (6Η, d, 6Hz, CH(CH3)2). LCMS (m/e): 617.3 (M+l, 100%), 619.2 (M+3, 70%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-piperidine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 104) 1H NMR (DMSO-d6, 300 MHz):δ 8.14-8.17 (IH, m), 7.54-7.57 (2H, m), 7.43-7.48 (IH, m), 7.16 (2H, d, 9Hz) and 6.96 (2H, d, J-9Hz), 5.18 (2H, s, ArCH2O), 5.065 (2Η, bs, OCH2O), 4.82-4.85 (1Η, m) and 4.68-4.70 (1Η, m), [OCΗCOx2], 4.44-4.45 (IH, m NHCHCO), 2.97-3.15 (6Η, m, 2χNCH2 and ArCH2CΗ), 3.75 (IH, m, OCH), 1.70 (4Η, m,
Figure imgf000080_0001
LCMS (m/e): 567.27 (M+l, 100%), 569.26 (M+3, 70%)
(S)-2-[((4R,5R)-5-Cyclopentylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 105)
1H NMR (DMSO-d6, 300 MΗz):δ 8.22 (IH, d, 8.16Hz), 8.073 (IH, m), 7.57-7.45 (3H, m), 7.16 (2H, d, 8.34Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.08 (2H, d, 11.4Hz), 4.47-4.46 (2H, m), 4.35 (IH, bs), 4.1 (IH, m), 3.04-2.97 (2H, m), 1.77-1.86 (2H, m), 1.62 (2H, m), 1.48-1.35 (4H, m). LCMS (m/e): 551.25 (M+, 100%), 553.27 (M+2, 60%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-hexylcarbamoyl-[l,3] dioxolane-4-carbonyl)-amino] -propionic acid (Compound No. 106)
1H NMR (DMSO, 300 MHz):δ 7.56 (2H, m), 7.54-7.57 (IH, m), 7.44-7.49 (2H, d, 6Hz),
6.96 (2H, d, 9Hz), 5.19 (2H, s), 5.07 (2H, d, 9Hz), 4.47-4.48 (2H, m), 4.38 (IH, s), 2.97- 3.08 (4H, m), 1.41 (3H, bs), 1.23 (9H, bs), 0.84 (3H, bs).
LCMS (m/e): 567.3 (M+, 100%), 569.32 (M+2, 70%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyridin-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 108)
1H NMR (DMSO, 300 MHz):δ 8.33-8.36 (2H, m), 7.84-8.08 (3H, m), 7.57-7.46 (3H, m), 7.20-6.94 (4H, m), 5.22-5.11 (4H, m), 4.73-4.45 (3H, m), 3.07-3.01 (2H, m). LCMS (m/e): 560.23 (M+, 50%), 562.21 (M+2).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 112)
Η NMR (DMSO, 300 MHz):δ 9.34 (IH, s), 8.24 (IH, d, 8Hz), 7.56-7.43 (3H, m), 7.15- 7.20 (2H, m), 6.96 (2H, d, 8Hz), 5.18 (2H, s), 5.07 (2H, d, 11Hz), 4.49-4.24 (7H, m), 3.05-
2.97 (2H, m), 2.73 (2H, bs).
LCMS (m/e): 568.25 (M+, 25%), 570.27 (M+2, 20%) (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-cyclohexyl carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 114)
Η NMR (DMSO, 300 MHz):δ 8.22 (IH, d, 8Hz), 7.96 (IH, d, 8Hz), 7.57-7.43 (3H, m),
7.17 (2H, d, 8.8Hz), 6.96 (2H, d, 8.8Hz), 5.18 (2H, s), 5.06 (2H, d, 10Hz), 4.46-4.40 (2H, m), 4.35 (IH, d, 4.8Hz), 3.39 (2H, bs), 3.07-2.92 (2H, m), 1.81-1.67 (4H, m), 1.33-1.15
(4H, m).
LCMS (m/e): 581.32 (M+l, 80%)
(4R,5R)-[l,3]Dioxolane-4,5-dicarboxylic acid 4-({(S)-l-[4-(2,6-dichloro-benzyloxy)- benzyl]-2-methyl-allyl} -amide) 5-heptylamide (Compound No. 116)
Η NMR (DMSO, 300 MHz):δ 8.14-8.25 (2H, m, NH), 7.43-7.56 (3H, m), 7.17 (2H, d, 8.4Hz), 6.96 (2H, d, 8.4), 5.18 (2H, s), 5.07 (2H, d, 8.8Hz), 4.47 (2H, bs),4.36-4.37 (IH, m) 3.16-2.89 (4H, m), 1.23 (10H, bs), 0.84 (3H, bs). LCMS (m/e): 581.27 (M+l)+ [85%], 583.25 [M+3]+ [62%], 603.25 (M+Na)+ [88%]
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 117)
Η NMR (DMSO, 300 MHz):δ 9.63 (IH, bs), 7.78 (IH, bs), 7.55 (2H, d, 7.5Hz), 7.46 (IH, d, 8.1Hz), 7.37 (IH, bs), 7.2 (4H, m), 7.05 (2H, bs), 6.87 (2H, d, 8.1Hz), 5.12-5.18 (4H,m), 4.68 (IH, bs), 4.59 (IH, bs), 4.0 (IH, bs), 3.03-2.56 (4H, m), 1.11 (3H, t, 7.5Hz). LCMS (m/e): 587.27 (M+l)+ [58%], 589.30 (M+3)+ [40%], 609.27 (M+Na)+ [30%].
(S)-2-[((4R,5R)-5-(2-Benzyl-5-tertbutyl-2H-pyrazol-3-ylcarbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119)
Η NMR (DMSO-d6, 300 MHz):δ 10.12 (IH, s), 8.32 (IH, d, 9Hz), 7.55 (2H, d, 6Hz), 7.47 (IH, m), 7.28-7.16 (5H, m), 7.09 (2H, d, 6Hz), 6.96 (2H, d, 9Hz), 6.15 (IH, s, NH), 5.18 (4H, bs), 5.07 (2H, m), 4.63-4.46 (3H, m), 2.70-3.06 (2H, m), 1.21 (9H, s). LCMS (m/e): 695.29 (M+l)+ [80%], 697.27 (M+2)+ [60%].
(S)-2-[((4R,5R)-5-Cycloheptylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120) 1H NMR (DMSO, 300 MHz):δ 8.22 (IH, bs, NH), 8.02 (IH, bs, NH), 7.56-7.43 (3H, m),
7.17 (2H, d, 8.3Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.08 (IH, s), 5.05 (IH, s), 4.28-
4.46(3H,m), 3.07-2.89 (3H, m), 1.72-1.23 (12H, m).
LCMS (m/e): 579.27 (M+l)+ [35%], 781.27 (M+3)+ [25%], 60% 25 [M+Na]+ [32%]
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulfanyl- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 121)
Η NMR (DMSO, 300 MHz):δ 8.31 (IH, d, 6Hz, NH), 7.55 (2H, d, 7.2Hz), 7.45 (IH, m), 7.17 (2H, d, 8.1Hz), 6.95 (2H, d, 8.2Hz), 5.16 (3H, bs), 5.11 (IH, s), 4.66-4.71 (2H, m), 4.43 (IH, bs), 3.23-2.99 (4H, m), 1.32 (3H, t, 7.2Hz). LCMS (m/e): 627.22 (M+l) [50%], 629.20 [40%], 649.20 [M+Na] [18%]
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethyl-thiazol-2- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 123)
1H NMR (DMSO, 300 MHz):δ 8.32 (IH, d, 7.5Hz), 7.55-7.42 (3H, m), 7.17 (2H, d, 7.5Hz), 6.95 (2H, d, 7.6Hz), 5.19-5.10 (4H, m), 4.66 (2H, m), 4.50-4.43 (IH, m), 3.06- 2.99 (2H, m), 2.24 (3H, s), 2.15 (3H, s). LCMS (m/e): 594.24 (M+, 80%), 596.3 (M+2, 60%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-oxo-piperidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 125)
1H NMR (DMSO, 300 MHz):δ 8.18 (IH, d, 6Hz), 7.56-7.43 (3H, m), 7.17 (2H, d, 9Hz), 6.97 (2H, d, 9Hz), 5.19-5.12 (4H, m), 5.00 (IH, d, 3Hz), 4.78 (IH, d, 3Hz), 4.4 (IH, m), 3.85-3.67 (4H, m), 3.07-2.99 (2H, m), 2.51-2.36 (4H, m). LCMS (m/e): 565.22 (M+), 567 (M+2).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(indan-5-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 127)
1H NMR (CDC13, 300 MHz):δ 8.29 (IH, bs, NH), 7.55-7.45 (5H, m), 7.13-7.19 (3H, m), 6.92 (2H, d, 6Hz), 5.13-5.20 (4H, m), 4.57-4.64 (3H, m), 3.23-2.76 (6H, m), 2.00 (2H, m). LCMS (m/e): 599.22 [M+l]+ [100%], 601.24 [M+3]+ [68%].
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-phenethylcarbamoyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 128) 1H NMR (DMSO, 300 MHz):δ 8.22 (2H, m), 7.56-7.45 (2H, m), 7.27-7.16 (8H, m), 6.95
(2H, d, 9Hz), 5.19 (2H, s), 5.11 (2H, s), 4.46-4.38 (3H, m), 3.08-2.96 (2H, m), 2.77-2.70
(2H, m).
LCMS (m/e): 587.21 (M+, 100%), 589.23 (M+2, 70%).
(S)-2-(((4R,5R)-5-[(Benzo[l,3]dioxol-5-ylmethyl)-carbamoyl]-[l,3]dioxolane-4- carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129)
1H NMR (DMSO-d6, 300 MHz):δ 8.72 (IH, bs), 8.32 (IH, bs), 7.62-7.48 (3H, m), 7.22
(2H, d, 8.7Hz), 7.00 (2H, d, 8.4Hz), 6.88 (2H, d, 8.1Hz), 6.77 (IH, d, 8.4Hz), 6.01 (2H, s),
5.22 (2H, s), 5.14 (2H, d, 16.5Hz), 4.57-4.45 (3H, m), 4.25 (2H, d, 6Hz), 3.00-3.12 (2H, m).
LCMS (m/e): 617.29 (M+l)+ [25%], 641.25 (M+Na)+ [15%].
(S)-2-(((4R,5R)-5-Butylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro- benzyloxy)-phenyl]-propionic acid (Compound No. 130)
1H NMR (DMSO-d6, 300 MHz):δ 8.22 (IH, bs), 8.14 (IH, bs), 7.57-7.43 (3H, m), 7.17 (2H, d, 8.4Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.07 (2H, d, 12Hz), 4.48-4.37 (3H, m), 3.11-2.95 (4H, m), 1.42-1.23 (4H, m), 0.85 (3H, t, 7.2Hz). LCMS (m/e): 539.30 (M+l)+ [100%], 541.26 (M+2)+ [70%], 561.30 (M+Na)+ [60%].
(S)-2-([(4R,5R)-5-(4-Acetyl-piperazine-l-carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}- 3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 131)
1H NMR (DMSO, 300 MHz):δ 8.18 (IH, d, 9Hz), 7.56-7.45 (3H, m), 7.17 (2H, d, 9Hz), 6.97 (2H, d, 9Hz), 5.19 (2H, s), 5.09 (2H, s), 4.91 (IH, bs), 4.72-4.75 (2H, m), 3.59-3.32 (8H, m), 3.00-3.07 (2H, m), 2.01 (3H, s). LCMS (m/e): 594.23 (M+, 70%), 596.25 (M+2, 50%), 597.26 (M+3)
(S)-2-([(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 132)
1H NMR (DMSO-d6, 300 MHz):δ 9.09 (IH, s), 8.37 (IH, d, J=6Hz), 8.15 (IH, d, J=9Hz), 7.44-7.55 (3H, m), 7.18-7.21 (2H, m), 6.91-7.07 (5H, m) [11 aromatic+2NH], 5.11 (1Η, s) and 5.22 (1Η, s) [OCΗ2O], 5.18 (2H, s, ArCH2O), 4.90-4.93 (1Η, m, OCΗCΗ2), 4.66 (2H, bs, OCHCO), 4.50-4.53 (1Η, m, NHCHCO), 3.00-3.08 (2Η, m, ArCH2), 1.60-1.91 (8Η,
Figure imgf000083_0001
LCMS (m/e): 643.4 (M+l, 100%), 645.3 (M+3, 70%)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-phenethylcarbamoyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 139)
1H NMR (DMSO, 300 MHz):δ 8.25 (IH, bs, NH), 8.14 (IH, bs, NH), 7.55 (2H, d, 7.5),
7.46 (IH, m), 7.17 (2H, d, 8.4Hz), 6.96 (2H, d, 8.4Hz), 5.18 (2H, s), 5.08 (IH, s), 5.05
(IH, s), 4.46 (2H, bs), 4.36-4.37 (IH, t, 3.9Hz), 3.17-2.96 (4H, m), 1.23 (12H, bs), 0.84
(3H, t, 6.6Hz). LCMS (m/e): 595.36 (M+l)+ [54%], 597.33 [38%] (M+3)+, 617.35 (M+Na)+ [30%].
(S)-3-[4-(2,6-Dichloro-benzylamino)-phenyl]-2- { [(4R,5R)-5-(4-methyl-piperazine- 1 - carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 152)
Η NMR (DMSO, 300 MHz):δ 10.66 (IH, bs), 8.31 (IH, m), 77.49-7.58 (4H, m), 7.20 (2H, d, 6Hz), 5.10 (2H, d, 9Hz), 4.75 (IH, m), 4.75 (2H, bs), 3 (4H, m), 2.96 (4H, m), 2.50-2.52(2H, m). LCMS (m/e): 579, 100%
(S)-2-[((4R,5R)-5-Cyclopropylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl] -propionic acid (Compound No. 153)
1H NMR (DMSO, 300 MHz):δ 10.65 (IH, bs), 8.31 (IH, bs), 8.20 (IH, bs), 7.58-7.46 (5H, m), 7.16 (2H, m), 5.05 (2H, d, 6Hz), 4.52 (IH, m), 4.36 (2H, m), 3.00-3.12 (2H, m), 2.68-2.71 (IH, m), 0.63 (2H, m), 0.50 (2H, m). LCMS (m/e): 536, 100%.
SCHEME II, PATH C PROCEDURE
Example 6: (4R,5R)-5-((S)-l-carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl carbamov -π,3]dioxolane-4-carboxylic acid Compound No. 35)
Step a: Synthesis of (4R,5R)-5-[(S)-l-benzyloxycarbonyl-2-(4-hydroxy-phenyl)- ethylcarbamoyl]-[l,3]dioxolane-4-carboxy!ic acid ethyl ester
To a solution of the compound of Formula III (1 g) in dimethylformamide (10 ml) at 0°C, was added L-tyrosine benzyl ester p-toluene sulphonic acid salt (2.3 g), hydroxybenzotriazole (0.78 g) and N-methylmorpholine (1.3 g). The reaction mixture was stirred for 30 minutes at the same temperature followed by the addition of l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.1 g). The reaction mixture was stirred at room temperature for overnight, diluted with ethyl acetate and water. The organic layer was separated and washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 40% ethyl acetate in hexane as eluent to furnish the title compound (1.5 g).
Step b: Synthesis of (4R,5R)-5-{(S)-l-benzyloxy carbonyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethylcarbamoyl-[l,3]dioxolane-4-carboxylic acid ethyl ester
To solution of the compound obtained from step a above (500 mg) in acetone (5 ml), was added potassium carbonate (310 mg) and stirred the reaction mixture at room temperature for 10 minutes. To it was added benzyl 2,6-dichlorobenzyl bromide (285 mg) and stirred the reaction mixture at 60-70°C for 8 hours. The reaction mixture was concentrated under reduced pressure. The residue thus obtained was washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 30% ethyl acetate in hexane as eluent to furnish the title compound (1.16 g).
Step c: Synthesis of (4R,5R)-5-{(S)-l-carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]- ethylcarbamoyl}-[l,3]dioxolane-4-carboxylic acid (Compound No. 35)
To a solution of the compound obtained from step b above (150 mg) in tetrahydrofuran: methanol: water (3:1 :1) ( 1 ml) was added lithium hydroxide monohydrate (26 mg). The reaction mixture was stirred for overnight and concentrated under reduced pressure. The residue thus obtained was taken in water and extracted with ethyl acetate. The aqueous layer was acidified using sodium bisulphate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound (100 mg).
Η NMR (DMSO, 300 MHz):δ 8.26 (IH, d, 6Hz), 7.57-7.46 (3H, m), 7.17 (2H, d, 9Hz),
6.96 (2H, d, 9Hz), 5.19 (IH, s), 5.11 (IH, s), 5.05 (IH, s), 4.54-4.43 (3H, m), 3.08-2.97
(2H, m).
LCMS (m/e): 484 (M+). SCHEME II, PATH B PROCEDURE
Example 7: (4R,5R)-5-{(S)-l-carboxy-2-f4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl carbamoyll-π,31dioxolane-4-carboxylic acid ethyl ester (Compound No. 46)
Step a: Synthesis of (4R,5R)-5-{(S)-l-tert-butoxycarbenyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethylcarbamoyl}-[l,3]dioxolane-4-carboxylic acid ethyl ester
To a solution of the compound of Formula III (1.32 g) in dimethylformamide (10 ml) at 0°C, was added N-methylmorpholine (703 mg), hydroxybenzotriazole (939 mg) and (S)-2- amino-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionic acid tert-butyl ester (2.75 g). The reaction mixture was stirred at same temperature for 30 minutes followed by the addition of l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.32 g). The reaction mixture was stirred at room temperature for overnight. The reaction mixture was diluted with ethylacetate and water. The organic layer was separated and washed with water and brine. The combined organic extract was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound (2.7 g).
Step b: Synthesis of (4R,5R)-5-{(S)-l-carboxy-2-[4-(2,6-dichloro-benzyloxy)- phenyl)ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46)
To the solution of the compound obtained from step a above (220 mg) in dichloromethane (2.5 ml), was added trifluoroacetic acid (2.5 ml). The reaction mixture was stirred for 2 hours and concentrated under reduced pressure. The residue thus obtained was taken in water and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound (165 mg).
Η NMR (DMSO, 300MHz):δ 8.30 (IH, m), 7.55-7.44 (3H, m), 7.15 (2H, d, 6Hz), 6.94 (2H, d, 6Hz), 5.17-5.04 (4H, m), 4.55-4.40 (3H, m), 4.14 (2H, q, 6.9Hz), 3.08-2.94 (2H, m), 1.19 (3H, t, 7.2Hz). LCMS (m/e): 512 (M++l).
Example 8: (S) -2-r((4R,5RV5-Carbamoyl-ri.31dioxolane-4-carbonylVamino1-3-r4-(2.6- dichloro-benzyloxyVphenyll-propionic acid (Compound No. 96)
To the (4R,5R)-5-{(S)-l-carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl)ethylcarbamoyl] - [l,3]dioxolane-4-carboxylic acid ethyl ester (250mg) (Compound No. 46) was added methanolic ammonia (20 ml) and stirred the reaction mixture for 4 days at room temperature. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was taken in ethyl acetate and washed with dilute aqueous hydrochloric acid and water and dried over anhydrous sodium sulphate. The solvent was evaporated under reduced pressure to furnish the title compound (230 mg).
1H NMR (DMSO-d6, 300 MHz):δ 8.25 (IH, d, J=8Hz), 7.54-7.59 (3H, m), 7.43-7.48 (2H, m), 7.16-7.18 (2H, m) and 6.95-6.97 (2H, m) [7 aromatic+3NH], 5.18 (2H, s, OCH2Ar), 5.05-5.09 (2Η, m, OCH2O), 4.35-4.49 (3Η, m, 2xOCHCO and NΗCHCO), 2.95-3.09 (2Η, m, ArCH2CH).
LCMS (m/e): 483.0 (M+l, 100%), 485 (M+3, 70%).
SCHEME III, PATH A PROCEDURE Example 9: (S)-3-r4-(2.6-Dichloro-benzyloxy -phenyll-2-r((4R.5SV5-hvdroxymethyl- [1.3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 95)
Step a: Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxy methyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert butyl ester
To a solution of compound No. 77 (250 mg) at -15°C in 1,2-dimethoxyethane (2 ml) was added N-methylmorpholine hydrochloride salt (51 mg) and isobutyl chloroformate (70 mg). N-methylmorpholine was removed by filtration, washed with 1,2-dimethoxyethane (10 ml) and the filtrate was cooled to -10°C. To the filtrate was added a solution of sodium borohydride in water (2 ml) followed by the addition of water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure and the residue thus obtained was purified by column chromatography using 50% ethyl acetate in hexane to furnish the title compound (180 mg).
Step b: Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- hydroxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid
To a solution of the compound obtained from step a above (150 mg) in dichloromethane (2 ml), was added trifluoroacetic acid (2 ml) and stirred the reaction mixture at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was taken in water and basified using aqueous lithium hydroxide and washed with ethyl acetate. The aqueous layer was acidified and extracted with ethyl acetate. The organic layer was concentrated and the residue thus obtained was purified by column chromatography using 40% ethyl acetate in hexane as eluent to furnish the title compound (130 mg).
1H NMR (DMSO-d6) 300 MHz):δ 8.06-8.09 (IH, m), 7.43-7.57 (2H, m), 7.14-7.17 (3H, m) and 6.95-6.98 (2H, m) [7H aromatic+lNH], 5.18 (2H, bs, ASCH2O), 5.06 (IH, s) and 4.89 (IH, s) [OCH2O], 4.46 (1Η, m, NΗCΗCO), 4.04-4.09 (1Η, m, OCHCO), 3.79 (1Η, bs, OCHCΗ2), 3.58-3.62 (2H, m, CHCH2OH), 2.92-3.11 (2H, m, ArCH2CH). LCMS (m/e): 470.07 (M+l, 100%), 472.05 (M+3, 70%).
SCHEME III, PATH B PROCEDURE
Example 10: (SV3- 4-(2.6-Dichloro-benzyloxy)-phenyl1-2-r((4R.5SV5-methoxymethyl- [l, ]dioxolane-4-carbonviymethyl-amino]-propionic acid (Compound No. 126)
Step a: Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxy methyI-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert butyl ester and (S)-3- [4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[l,3]dioxoIane-4- carbonyl)-methyI-amino]-propionic acid tert-butyl ester
To a solution of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxymethyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert butyl ester (200 mg) in tetrahydrofuran (5 ml) at 0°C was added sodium hydride (14 mg) and stirred the reaction mixture for 30 minutes at same temperature. To it was added methyl iodide (108 mg) and stirred the resulting reaction mixture for 1 hour at 0°C and subsequently at room temperature for overnight. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified through column chromatography using 25% ethyl acetate in hexane as eluent to furnish (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- methoxymethyl-[l,3]dioxolane-4-carbonyl)-methyl-amino]-propionic acid tert-butyl ester (98 mg) and 30% ethyl acetate in hexane as eluent to furnish (S)-3-[4-(2,6-dichloro- benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[l,3]dioxolane-4-carbonyl)-amino]- propionic acid tert butyl ester (33 mg).
Step b: Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- methoxymethyl-[l,3]dioxolane-4-carbonyl)-methyI-amino]-propionic acid (Compound No. 126) To a solution of the compound obtained from step a above (33 mg) in dichloromethane (1 ml), was added trifluoro acetic acid (1 ml) and the reaction mixture was stirred for 2 hours.
The reaction mixture was concentrated under reduced pressure to furnish the title compound (82 mg).
1H NMR (DMSO-d6, 300 MHz):δ 7.42-7.56 (3H, m), 7.12-7.21 (2H, m), 7.12-7.21 (2H, m), 6.93-6.98 (2H, m) [Aromatic] 5.18-5.19 (2H, bs, ArCH2O), 4.87-5.01 (2Η, m,
OCH2O), 4.51-4.55 (1Η, m, OCHCO), 4.25-4.4 (1Η, m, OCHCΗ2), 3.82-3.83 (IH, m,
OCCHNH), 3.17-3.33 (6H, OCH2CH, NCH3 and OCH3), 2.76-2.99 (5Η, m, NCH3 and ArCH2).
LCMS (m/e): 498.3 (M+l, 100%), 500.31 (M+3, 70%).
Example 11 : (S)-3-r4-(2.6-Dichloro-benzyloxyVphenyll-2-r((4R.5S)-5-methoxymethyl- [ 3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 141)
Step a: (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl- [1, 3] dioxolane-4-carbonyl)-amino] -propionic acid (Compound No. 141) To a solution of the compound 3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- methoxymethyl-[l,3]dioxolane-4-carbonyl)-methyl-amino]-propionic acid tert-butyl ester (obtained from step a, Example 10) (98 mg) in dichloromethane (1 ml), was added trifluoroacetic acid (1 ml) and stirred the reaction mixture for 1 hour. The reaction mixture was concentrated to under reduced pressure to furnish the title compound (24 mg).
1H NMR (CDCI3, 300 MΗz):δ 7.36-6.96 [8H, m, Aromatic+NH), 5.24 (2H, bs, OCH2-Ar), 5.13 (1Η, s) & 5.10 (1Η, s) [OCH2O], 4.86 (1Η, m, OCHCO), 4.22 (2Η, m) (NHCHC(=O) & OCHCΗ2), 3.73-3.57 (2H, m, OCH2), 3.41 (3Η, s, OCH3), 3.19-3.10 (2Η, m, AR-CH2). LCMS (m/e): 484.29 (M+l, 44%), 486.27 (M+3, 28%), 506.27 (M+Na, 10%).
The analogues (s) of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- methoxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 141) described below, can be prepared by using appropriate alkyl halide in place of methyl iodide, respectively, as applicable in each case
(S)-2-[((4R,5S)-5-Benzyloxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101) Η NMR (DMSO-d6, 300 MHz):δ 8.11-8.16 (IH, m), 7.43-7.56 (3H, m), 7.31-7.32 (5H, m), 7.14-7.16 (2H,m) and 6.93-6.96 (2H, m) [12H aromatic+lNH], 5.16 (2Η, s, ArCH2O), 5.075-5.094 (1Η, s) and 4.91 (1Η, s) [OCH2O], 4.46-4.52 (3Η, m, OCHCO and ArCH2OCΗ2), 4.08-4.11 (IH, m, NHCHO), 3.94 (1Η, bs, OCHCΗ2), 3.33-3.55 (2H, m, CHCH2O), 2.95-3.10 (2Η, m, ArCH2CH). LCMS (m/e): 560.23 (M+l, 70%), 582.19 (M+Na, 75%).
SCHEME III, PATH C PROCEDURE
Example 12: Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezyloxy)-phenyl]-2- r((4R,5S)-5-pyrrolidin- 1 -ylmethyl-[ 1 ,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146)
Step a: Synthesis of (S)-3-[4-(2,6-dichloro-benzyIoxy)-phenyl]-2-[((4R,5S)-5-methane sulphonyloxymethyI-[l,3]-dioxolane-4-carbonyl amino]-propionic acid tert-butyl ester
To a solution of the compound (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- hydroxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-propionic acid tert-butyl ester (step a, Example 9) (200 mg) in dichloromethane (3 ml) at 0°C, was added methanesulphonyl chloride (43.6 mg, 0.06 ml) and triethylamine (0.051 ml). The resulting reaction mixture was stirred for 30 minutes at same temperature and subsequently at room temperature for 4 hours. The reaction mixture was diluted with dichloromethane and washed with water and brine. The organic layer was dried over anhydrous sodium sulphate and concentrated to furnish the title compound (310 mg).
Step b: Synthesis of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5- pyrrolidin-l-yloxymethyl)-[l,3]-dioxolane-4-carbonyl]-amino}-propionic acid tert- butyl ester.
To a solution of the compound obtained from step a above (200 mg) in tetrahydrofuran (5 ml), was added diisopropylethyl amine (98 mg) and pyrrolidine (27 mg). The resulting reaction mixture was refluxed for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated to furnish the crude compound which was purified by column chromatography using 5% ethyl acetate in dichloromethane as eluent to furnish the title compound (102 mg).
Step c: Synthesis of triflate salt of l-((4S,5R)-{(S)-l-Carboxy-2-[4-(2,6-dichloro- benzyloxy)-phenyI]-ethylcarbomoyl}-[l,3]dioxolane-4-ylmethyl)-pyrrolidinum To a solution of the compound obtained from step b above (102 mg) in dichloromethane
(5 ml), was added triethylamine (2.5 ml) and the reaction mixture was stirred for 2 hours.
The reaction mixture was concentrated to under reduced pressure to furnish the title compound (68 mg).
1H NMR (DMSO-d6, 300 MHz):δ 8.24-8.29 (IH, m, NH), 7.43-7.56 (3H, m), 7.18 (2H, d,
6Hz), 6.975 (2H, d, 9Hz) [aromatic], 5.19 (2H, s, ArCH2O), 5.19 (1Η, s) and 5.00 (1Η, s)
[OCH2O], 4.48-4.50 (1, m, NΗCHCO), 4.25-4.28 (2Η, m, NCH2CH), 3.57 (OCHCO),
3.42-3.45 (2Η, m, NCH2), 2.99-3.19 (4Η, m, NCH2 and ArCH2), 1.89-2.05 (4Η, m, CH2- CH2).
LCMS (m/e): 523.36 (M+l, 100%), 525.34 (M+3, 70%).
SCHEME IV PROCEDURE
Example 13: (SV3-r4-(2.6-Dichloro-benzyloxy -phenyll-2-r((S)-2,2-dimethyl-π.31 dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 122)
Step a: Synthesis of lithium salt (S)-2,2-dmethyl-[l,3]dioxoIane-4-carboxylic acid To a solution of (S)-2,2-dimethyl-[l,3]dioxolane-4-carboxylic acid methyl ester
(commercially available) (1 g) in tetrahydrofurammethanol: water (3:1:1), was added lithium hydroxide monohydrate (262 mg) and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to furnish the title compound (890 mg).
Step b: Synthesis of (S)-3-[4-(2,6-Dichloro-benzyIoxy)-phenyl]-2-[((S)-2,2-dimethyl- [l,3]dioxo!ane-4-carbonyI)-amino]-propionic acid ethyl ester
To a solution of the compound obtained from step a above (890 g) in dimethylformamide (15 ml) at 0°C, was added N-methylmorpholine (1.42 g), and (S)-2-amino-3-[4-(2,6- dichlorobezyloxy)-phenyl]-propionic acid ethyl ester (1,47 g), hydroxybenzotriazole (lg) and (1.47g) of trifluoroacetic acid. The reaction mixture was stirred for 30 minutes at the same temperature. To it was added l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.42 g). The reaction mixture was stirred at room temperature for overnight. The reaction mixture was diluted with water, extracted with ethylacetate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 40% ethyl acetate in hexane as eluent to furnish the title compound (2-2 g). Step c: Synthesis of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid ethyl ester (Compound No. 122) To a solution of the compound (150 mg) obtained form step b above in tetrahydrofuran: methanol: water (3:1:1, 2ml) was added lithium hydroxide monohydrate (13 mg) and stirred the reaction mixture for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue thus obtained was taken into water and extracted with ethyl acetate. The aqueous layer was acidified with sodium bisulphate and extracted with ethyl acetate. The combined organic extract was washed with water and brine. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound (93 mg).
LCMS (m/e): 496.26 (M+l, 20%), 518.25 (M+l, 100%).
1H NMR (DMSO-d6, 300 MHz):δ 7.45-7.62 (4H, m), 7.13 (2H, d, 9Hz), 6.95 (2H, d, J=9Hz) [7 aromatic+lNH], 5.18 (2H, s, ArCH2O), 5.065 (2Η, bs, OCH2O), 4.82-4.85 (1Η, m) and 4.68-4.70 (1Η, m) [OCΗCOχ2], 4.44-4.45 (IH, m, NHCHCO), 2.97-3.15 (6Η, m, 2xNCH2 and ArCH2CΗ), 3.75 (IH, m, OCH), 1.70 (4Η, m, 2CH2 ring). LCMS (m/e): 567.27 (M+l, 100%), 569.26 (M+3, 70%).
The analogues of (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 122), described below, can be prepared by condensing an appropriate acid with an amine, as applicable in each case.
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((R)-2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-amino] -propionic acid (Compound No. 124)
1H NMR (DMSO, 300 MΗz):δ 7.63-7.45 (3H, m), 7.12 (2H, d, 8Hz), 6.97 (2H, d, 8Hz), 5.18 (2H, s), 4.49-4.39 (2H, m), 4.11 (IH, t, 10Hz), 3.80-3,84 (IH, m), 3.08-2.99 (2H, m), 1.33 (3H, s), 1.30 (3H,s). LCMS (m/e): 468.19 (M+, 25%), 470.22 (M+2, 17%).
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-2,2,5-trimethyl-[l,3]dioxolane-4- carbonyl)-amino] -propionic acid (Compound No. 149) 1H NMR (DMSO-d6, 300 MHz):δ 7.66 (IH, d, 8Hz), 7.42-7.55 (3H, m), 7.14 (2H, d, 9Hz), 6.94 (2H, d, 9Hz) [aromatic], 5.18 (2H, s, ArCH2O), 4.52-4.55 (1Η, m, OCHCO), 3.78-3.81 (1Η, m, 9Ηz, NHCHCO), 3.64-3.67 (1Η, m, OCHCΗ3), 2.99-3.12 (2H, m, ArCH2), 1.34 (3Η, s, CH3), 1.22-1.24 (6Η, bs, CH3CH and CH3). LCMS (m/e): 482.34 (M+l, 100%), 484.33 (M+3, 70%), 504.33 (M+Na, 25%).
SCHEME V PROCEDURE
Example 14: (4R,5R)-[l,3]Dioxolane-4,5-dicarboxylic acid 4-(((S)-l-carbamoyl-2-[4- (2,6-dichloro-benzyloxy)-phenyl1-ethyl)-amino)-5-[(2-chloro-phenyl)-amide (Compound No. 118)
To a solution of the compound (4R,5R)-5-(2-chloro-phenylcarbamoyl)-[l,3]dioxolane-4- carboxylic acid (200 mg) in tetrahydrofuran (10 ml) cooled to -15°C, was added N-methyl morpholine (0.08 ml) and stirred the reaction mixture 10 minutes. To the resulting reaction mixture was added ethyl chloroformate (0.06 ml) and stirred for 20 minutes. To it was added (S)-2-amino-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionamide (199 mg) and p-toluene sulphonic acid (13 mg) at -15 to 20°C and stirred the reaction mixture for overnight after warming it slowly to room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic extracts were washed with brine and dried over anhydrous sodium sulphate. The organic layer was concentrated under reduced pressure and the residue thus obtained was purified by column chromatography using 7.5% methanol in dichloromethane as eluent to furnish the title compound (196 mg). 1H NMR (DMSO, 300 MHz):δ 9.64 (IH, bs), 8.07 (IH, bs), 7.78 (IH, m), 7.79-7.16 (8H, m), 6.95 (2H, d, 8.7Hz), 5.23-5.06 (4H, m), 4.66-4.46 (3H, m), 3.09-2.92 (2H, m). LCMS (m/e): 592.15 (M+l)+ [100%], 594.0 (M+3) [98%], 614.17 [M+Na]+ [72%].
Primary Screening- Cell Adhesion Assay
VCAM-1 (lOOng/well) was coated in Maxisorp microtitre modules at 4°C overnight. Non-specific blocking was carried out with 3% BSA for two hours and the wells washed with TBS (50mM) Tris, 0.15M NaCI pH 7.4, O.lmM CaCl , O.lmM MgCl2). U937 cells were suspended in fresh medium and incubated at 37°C for two hours before the assay. Cells were then washed in TBS solution and 180 μl of cell suspension (lxl 06 cells/ml in TBS buffer) was added per well in VCAM-1 coated wells. 20 μl of sample solution in 50%) DMSO and 50% TBS was then added and the cells were incubated at 37°C for one hour three to five dilutions of each sample were tested in duplicate in a primary screen, samples are tested at 1, 10 and 100 μm. If activity were present, the compounds were tested at lower (<lμm) concentrates. After incubation, the non-adherent cells were removed by washing with TBS and the numbers of adhered cells were quantified by LDH activity estimation. The percent adhesion was calculated as compared to control.
Compounds of this invention tested for activity have shown activities following this assay in the range of from about 100 nM to about 100 μM, for example, from about 100 nM to 10 μM, or from about 100 nM to about 3 μM, or from about 100 nM to about 1 μM.
The compounds disclosed herein for utility for the treatment of asthma and the symptoms of asthma, as well as for the treatment of multiple sclerosis, rheumatoid arthritis, allergic rhinitis, inflammatory bowel disease, and other cell adhesion - associated diseases and conditions and relief from the symptoms thereof.

Claims

We claim:
1. A compound having the structure of Formula I
Figure imgf000095_0001
Formula I
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides
wherein
m is an integer from 0-2;
Ri can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclylalkyl;
R2 can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;
Ri and R2 may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F,C1, Br, I), aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl;
R3 can be NH2) NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or ORm (wherein Rm can be hydrogen, alkyl, aralkyl, aryl, or metal ions ( Na+, K+, Li+, Ca+ or Mg+));
R» can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, -(CH2)ι-4-O-R' (wherein R' can be selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclylalkyl, or heteroarylalkyl), -C(=O)-R (wherein R3 is the same as defined above) -C(=O)Rz (wherein Rz is -NR7Rs wherein R7 and R8 can be independently selected from hydrogen (provided that both R7 and R8 are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO2R9 (wherein R9 can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R7 and Rg may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F,C1, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or (CH2)ι-4NRxRy [wherein Rx and Ry can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YRU (wherein Y is C(=O), C(=S) or SO2 and Ru is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), -C(=T)NRU (wherein T is oxygen, sulphur, -CH(NO2), -N(NO2) or -N(CN) and Ru is the same as defined above) or - C(=O)ORu (wherein Ru is the same as defined above)];
R5 and Re may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R5 and Re may together join to form a cycloalkyl ring.
2. A compound according to claim 1, wherein Ri is hydrogen or alkyl.
3. A compound according to claim 1, wherein Ri is hydrogen.
4. A compound of claim 1, wherein is Rj alkyl.
5. A compound according to claim 1, wherein R\ is methyl.
6. A compound according to claim 1, wherein R2 is hydrogen, aralkyl, heteroarylalkyl or aryl.
7. A compound according to claim 1, wherein R2 is hydrogen.
8. A compound according to claim 1, wherein R2 is optionally substituted aralkyl.
9. A compound according to claim 8, wherein the optional substituents on aralkyl are halo, hydroxy, alkynyloxy, aryl, -NHC(=O)R9, -OC(=O)R9 or -OCH2R9.
10. A compound according to claim 10, wherein the optional substituent on aralkyl is
-NHC(=O)R9 wherein R is optionally substituted group selected from heteroaryl, heterocyclyl or aryl.
11. A compound according to claim 10, wherein R9 is pyridyl, morpholinyl, methylpiperazinyl, bromopyridyl, phenyl, piperidinyl, difluorophenyl, dichlorophenyl, dichloropyridyl or methoxyphenyl.
12. A compound according to claim 9, wherein the optional substituent on aralkyl is
-OC(=O)R9 wherein R9 is optionally substituted group selected from heterocyclyl.
13. A compound according to claim 12, wherein R is morpholinyl, methylpiperazinyl.
14. A compound according to claim 9, wherein the optional substituent on aralkyl is
-OCH2R wherein R9 is optionally substituted group is selected from aryl, heterocyclyl and alkynyl.
15. A compound according to claim 14, wherein R9 is difluorophenyl, chlorophenyl, dichlorophenyl, piperidinyl, morpholinyl, methylpiperazinyl or propargyl.
16. A compound according to claim 1, wherein R2 is heteroarylalkyl.
17. A compound according to claim 16, wherein R2 is indolylmethyl.
18. A compound according to claim 1 , wherein R2 is aryl.
19. A compound according to claim 18, wherein R2 is phenyl or benzodioxolyl.
20. A compound according to claim 1, wherein Ri and R2 may also together join to form cyclic ring (3-8 membered), optionally benzofused containing 0-4 heteroatoms O, S or N.
21. A compound according to claim 20, wherein R] and R2 together joins to form tetrahydroisoquinoline ring.
22. A compound according to claim 1, wherein R3 is -ORm or -NH2.
23. A compound according to claim 22, wherein R3 is -ORm.
24. A compound according to claim 23, wherein Rm is hydrogen, aralkyl or alkyl,
25. A compound according to claim 24, wherein Rm is hydrogen.
26. A compound according to claim 23, wherein Rm is alkyl or aralkyl.
27. A compound according to claim 26, wherein Rm is methyl, ethyl, butyl or tert- butyl.
28. A compound according to claim 22, wherein R3 is -NH2.
29. A compound according to claim 1, wherein i is -C(=O)Rz, optionally substituted alkyl or -C(=O)R3.
30. A compound according to claim 29, wherein Rt is -C(=O)Rz.
31. A compound according to claim 30, wherein Rz is -NR7Rs.
32. A compound according to claim 31 , wherein R7 is hydrogen, optionally substituted alkyl or heteroarylalkyl.
33. A compound according to claim 32, wherein R7 is hydrogen.
34. A compound according to claim 32, wherein R7 is optionally substituted alkyl.
35. A compound of claim 34, wherein R7 is hydroxymethyl or methyl.
36. A compound of claim 32, wherein R7 is heteroarylalkyl.
37. A compound of claim 36, wherein R7 is thiophenylmethyl.
38. A compound according to claim 31, wherein R8 is hydrogen or optionally substituted groups selected from aryl, aralkyl, heteroarylalkyl, cycloalkyl, alkyl, heterocyclylalkyl, heterocyclyl, heteroaryl, alkenyl, alkynyl and alkoxy.
39. A compound of claim 38, wherein R8 is hydrogen.
40. A compound of claim 38, wherein R8 is optionally substituted aryl or aralkyl.
41. A compound of claim 40, wherein R8 is chlorophenyl, dichlorophenyl, methoxyphenyl biphenyl, methylphenyl, fluorophenyl, diethylphenyl, isopropylphenyl, difluorophenyl, trifluoromethylphenyl, ethylphenyl, cyclopentyloxyphenyl, methoxybenzyl, dihydroindolyl, indolyl or benzodioxolyl.
42. A compound of claim 38, wherein R8 is heteroarylalkyl or heteroaryl.
43. A compound of claim 42, wherein R8 is thiophenylmethyl, thiazolyl, benzothiazolyl, pyridyl, thiadiazolylmethyl, indolylethyl, thiophenylethyl, pyndylmethyl, indolylethyl, methylthiadiazolyl, benzyl-tert-butyl-pyrazolyl, tolyl-tert-butyl-pyrazolyl, ethylsulphenylthiadiazolyl, dimethylthiazolyl or thiazolyl.
44. A compound of claim 38, wherein R8 is optionally substituted heterocyclyl.
45. A compound of claim 44, wherein R8 is methylpiperazinyl, methylpiperidinyl, piperidinyl or morpholinyl.
46. A compound of claim 38, wherein R8 is optionally substituted cycloalkyl.
47. A compound of claim 46, wherein R8 is cyclopropyl, cyclohexyl, adamantyl, cyclopentyl, hydroxycyclohexyl or cycloheptyl.
48. A compound of claim 38, wherein R8 is optionally substituted alkyl, alkenyl or alkynyl.
49. A compound of claim 48, wherein R8 is isopropyl, isobutyl, isopentyl, propenyl, propynyl, hydroxymethyl, hexyl or butyl.
50. A compound of claim 38, wherein R8 is optionally substituted alkoxy.
51. A compound of claim 50, wherein R8 is benzyloxy or methoxy.
52. A compound of claim 31, wherein R7 and R8 together joins to form an optionally substituted heterocyclic ring system.
53. A compound of claim 52, wherein R7 and R8 together joins to form methylpiperazinyl, benzyloxycarbonyl pyrrolidinyl, carboxypyrrolidinyl, dihydroindolyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, oxo-piperidinyl or piperazinyl.
54. A compound of claim 29, wherein R4 is optionally substituted alkyl selected from methyl.
55. A compound of claim 29, wherein Rt is -(CH2)ι-4ORl.
56. A compound of claim 55, wherein j is hydroxymethyl, methoxymethyl or benzyloxymethyl.
57. A compound of claim 29, wherein Rt is -(CH2)ι-4NRxRy.
58. A compound of claim 57, wherein ; is methylenepyrrolidmyl.
59. A compound of claim 1 , wherein R4 is -C(=O)R .
60. A compound claim 59, wherein R is -ORm.
61. A compound of claim 60, wherein Rm is hydrogen or alkyl.
62. A compound of claim 61 , wherein Rm is hydrogen.
63. A compound of claim 61 , wherein Rm is alkyl.
64. A compound of claim 63, wherein Rm is ethyl.
65. A compound of claim 1, wherein R5 is hydrogen, alkyl or aryl.
66. A compound of claim 65, wherein R5 is hydrogen.
67. A compound of claim 65, wherein R5 is alkyl.
68. A compound of claim 67, wherein R5 is methyl.
69. A compound of claim 65, wherein R5 is aryl.
70. A compound of claim 69, wherein R5 is phenyl.
71. A compound of claim 1 , wherein Rό is hydrogen.
72. A compound of claim 1 , wherein Re is alkyl.
73. A compound of claim 72, wherein R^ is methyl.
74. A compound of claim 1, wherein Rβ is aryl.
75. A compound of claim 74, wherein Rό is phenyl.
76. A compound of claim 1, wherein m is 0 or 1.
77. A compound selected from
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxy-phenyl)-propionic acid (Compound No. 1),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 2),
(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-chloro-phenyl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 3),
(S)-3-(4-Hydroxy-phenyl)-2- { [(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[ 1 ,3]dioxolane- 4-carbonyl]-amino} -propionic acid (Compound No. 4),
(S)-2-{[(4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- {4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 5), (S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl-carbamoyl)- [l,3]-dioxolane-4-carbonyl]-amino} -propionic acid (Compound no. 6),
(S)-3-(4-Benzoylamino-phenyl)-2-{[(4R,5R)-5-(2-methoxy-benzylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 7), (S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-benzyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No.10), Lithium salt of (S)-2-{[(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4- carbonyl]-amino}-3-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No.11),
Lithium salt of (S)-2- {[(4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(3-piperidin-l-yl-propoxy)-phenyl]-propionate (Compound No. 12),
Lithium salt of (S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxalane-4-carbonyl]- amino}-3-[4-(2-piperidin-l-yl-ethoxy)-phenyl]-propionate (Compound No. 13), (S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14),
Morpholine-4-carboxylic acid 4-((S)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15), 4-Methyl-piperazine-l-carboxylic acid 4-((S)-2-{[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenylester (Compound No. 16),
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- {4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 17),
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l ,3]dioxolane-4-carbonyl]-amino}-3- {4- [(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 18),
(S)-2-{[(4R,5R)-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(piperidine-4-carbonyl)-amino]-phenyl}-propionic-acid, salt with trifluoroacetic acid (Compound No.19),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridine-3-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 20),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridine-2-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 21),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [6-bromo-pyridine-2-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 22), (S)-3-(4-Benzoylamino-phenyl)-2- {[(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[l ,3]dioxolane- 4-carbonyl]-amino} -propionic acid (Compound No. 23),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxyl-phenyl)-propionic acid (Compound No. 24),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 25),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2-chloro-benzyloxy)-phenyl]-propionic-acid (Compound No. 26),
(S)-2- {[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3-(4- prop-2-ynyloxy-phenyl)-propionic-acid (Compound No. 27), (S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(4R,5R)-5-(2-methoxy- benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 28),
(S)-2-{[(4R,5R)-5-(Biphenyl-2-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4-(2- methoxy-benzyl-amino)-phenyl]-propionic acid (Compound No 29),
(S)-2-{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-difluoro-benzyloxy]-phenyl]-propionic-acid (Compound No. 30), (S)-3-(4-(2,6-Dichlorobenzyloxy)-ρhenyl]-2-[{(4R,5R)-5-[thiophen-2-yl-methyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 31),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-phenyl-carbamoyl- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (compound no 32), (S)-2-{[(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- [(pyridin-4-carbonyl)-amino] -phenyl} -propionic acid (Compound No 33),
(S)-2-{[(4S,5S)-5-(Chlorophenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichlorobenzloxy-phenyl]-propionic acid (Compound No.34),
(4R,5R)-5-{(S)-l-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl}- [l,3]dioxolane-4-carboxylic acid (Compound No. 35),
Lithium salt of (S)-2-[ {(4R,5R)-5-Cyclopropyl-carbamoyl-[ 1 ,3]dioxolane-4-carbonyl} - amino]-3-[4-(2,6-dichlorobenzyloxy)-phenyl]-propionate (Compound No. 36),
(S)-2-[{(4R,5R)-5-Cyclohexane-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No 37) , (S)-3-[4-(2,6-Dichlorobenzyloxy)-ρhenyl]-2- {([4R,5R)-5-(thiazol-2-yl-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 38) ,
(S)-2-{[(4R,5R)-5-(Cyclopropyl-carbamoyl)-[l,3]dioxolane-4-carbonyl)-amino]-3-{4- [(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No 39) ,
(S)-2-[{(4R,5R)-5-Cyclohexyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-{4- [(pyridine-4-carbonyl)-amino] -phenyl} -propionic acid (Compound No. 40),
(S)-2-{[4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbamoyl]-amino}- 3-{4-[(pyridine-4-carbonyl-amino]-phenyl}-propionic acid (Compound No. 41) ,
(4R,5R)-5-[(S)-l-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[l,3]dioxolane-4- carboxylic acid ethyl ester (Compound No. 42) , (S)-3-(4-benzoylaminophenyl)-2-[ {(4R,5R)-5-(isopropyl-carbamoyι)-[ 1 ,3]dioxolane-4- carbonyl}-amino]-propionic acid (Compound No. 43),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl-2- {[(4R,5R)-5-(4-methyl-piperazine- 1 - carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid salt with trifluoroacetic acid (Compound No 44), (S)-2-{[(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}- 3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 45),
(4R,5R)-5-{(S)-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethylcarbamoyl]- [l,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-isopropylcarbamoyl- [l,3]dioxolane-4-carbonyl} -amino]- propionic acid (Compound No.47), (S)-2-[{(4R,5R)-5-tert-Butyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 48),
(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-[{(4R,5R)-5-(3-methyl-butylcarbamoyl)- [l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 49), (S)-3-[4-(2,6,Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(R)-l-phenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 50),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(S)-l-ρhenyl-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 51),
(S)-l-{(4R,5R)-5-{(S)-l-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl- carbamoyl}-[l,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid benzyl ester(Compound No. 52),
(S)-2- {[(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.53),
(S)-2-[(4R,5R)-{5-Benzyloxy-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54),
(S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholine-4-carbamoyl)- [l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No.55),
(S)-2-[((4R,5R)-{5-allyl-carbamoyl-[l,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56), l-{(4R,5R)-5-[(S)-l-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl}-pyrolidine-2-carboxylic acid (Compound No.57),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(tetrahydro-furan-2-yl- methyl)-carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 58), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[2-(lH-indol-3-yl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 59),
(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-[(2-thiophen-2-yl-ethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 60),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[(pyridin-4-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.61),
(S)-3-[4-(2,6,-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,3-dihydro-indole-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 62),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-methyl-[l,3,4]thiadiazol-2- yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No.63), (S)-2{[(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- hydroxyphenyl)-propionic acid (Compound No. 64), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-(methyl-phenyl-carbamoyl)- l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No.65), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{4R,5R)-5-[methyl-(l-methyl-piperidine-4- yl)-carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound No. 66), S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl]-2-{[(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)- l,3]dioxolane-4-carbonyl]-amino-propionic acid (Compound No. 67), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-methoxy-phenyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 68), S)-2-{[(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69), S)-2-{[(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- 2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,5-dichloro-phenyl- carbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No.71), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2- {[4R,5R)-5-(2,6-dichlorophenylcarbamoyl)- l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 72), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-O-tolyl-carbamoyl- l,3]dioxolane-4-carbonyl}-amino]-propionic acid (Compound no.73), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-dimethyl-carbamoyl]- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl)-2-[{(4R,5R)-5-methyl-carbamoyl- l,3]dioxolane-4-carbonyl]-amino]- propionic acid (Compound No.75), S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-methoxy-carbamoyl- l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 76), (4R,5R)-5-{(S)-l-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl]- ethylcarbamoyl]-[l,3]dioxolane-4-carboxylic acid (Compound No.77), S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]-2-[{(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino]-propionic-acid (Compound No. 78), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(pyrrolidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79), S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(R)-3-hydroxy-pyrrolidine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 80), -((4R,5R)-5-{(S)-l-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]- ethylcarbamoyl} -[ 1 ,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(l-hydroxymethyl- propylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 82),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-[((4R,5R)-5-ethylcarbamoyl-[l,3]dioxolane- 4-carbonyl)-amino] -propionic acid (Compound No. 83),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-prop-2-ynylcarbamoyl- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 84),
Trifluoroacetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2- {[(4R,5R)-5-(2- morpholin-4-yl-ethylcarbamoyl)-[ 1 ,3]-dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 85),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 86),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-{[(4R,5R)-5-(piperidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 87), (S)-2- {[4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88),
(S)-2-{[(4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90)
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 91),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2,6-difluoro- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92),
(S)-2- {[(4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl)-amino} -3- (4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 93),
(S)-2- { [(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -3- (4-[(pyridine-4-carbonyl)-amino]-phenyl} -propionic acid (Compound No. 94),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-hydroxymethyl-[l,3]dioxolane- 4-carbonyl)-amino]-propionic acid (Compound No. 95),
(S)-2-[((4R,5R)-5-Carbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro- benzyloxy)-phenyl]-propionic acid (Compound No. 96), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-((R)-2-hydrox-l-phenyl- ethylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 97), (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[l,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 98,)
(S)-2- {[(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 99),
(S)-2-{[(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- [4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 100),
(S)-2-[((4R,5R)-5-Benzyloxymethyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 101), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-trifluoromethyl- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 102),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-isopropoxy- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 103),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-ρiperidine-l- carbonyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid Compound No. 104),
(S)-2-{[(4R,5R)-5-Cyclopentylcarbamoyl-[l,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 105), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-hexylcarbamoyl- [l,3]dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 106), (S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{[(4R,5R)-5-(3,4-dimethyl-isoxazol-5- ylcarbamoyl)-[l,3]-dioxolane-4-carbonyl]amino-propionic acid (Compound No. 107),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-ρhenyl]-2-{[(4R,5R)-5-(pyridin-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 108),
{2-[(4R,5R)-5-(2-Chloro-ρhenylcarbamoyl)-[ 1 ,3]dioxolone-4-carbonyl]- 1 ,2,3,4- tetrahydro-isoqunoline}-3-carboxylic acid (Compound No. 109),
2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(lH- indol-3-yl)-propionic acid (Compound No. 110), (S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino)-3-[4- (2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 111),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 112),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[l,3]dioxolane-4-carbonyl]- amino} -3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy- cyclohexylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 114),
(S)-2- {[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[ 1 ,3]dioxolane-4- carbonyl]amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 115),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-heptylcarbamoyl- [1, 3 ]dioxolane-4-carbonyl] -amino} -propionic acid (Compound No. 116),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 117),
(4R,5R)-[l,3]Dioxolane-4,5-dicarboxylic acid-4-({(S)-l-carbamoyl-2-[4-(2,6-dichloro- benzyloxy)-phenyl]-ethyl}-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118),
(S)-2-{[(4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[l,3]dioxolane-4- carbonyl]-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119),
(S)-2-[((4R,5R)-5-cycloheptylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzyloxy)-phenyl] -propionic acid (Compound No. 120),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulphanyl- [ 1 ,3,4]thiadiazol-2-ylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 121),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((S)-2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-amino]-propionic acid (Compound No. 122),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethylthiazol-2- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 123), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((R)-2,2-dimethyl-[l,3]dioxolane-4- carbonyl)-amino]-propionic acid (Compound No. 124),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-oxo-piperidine-l-carbonyl)- [l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 125),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-methoxymethyl-[l,3]dioxolane- 4-carbonyι)-methyl-amino] -propionic acid (Compound No. 126),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(indan-5-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 127),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{((4R,5R)-5-phenethylcarbamoyl- [l,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 128), (S)-2-({(4R,5R)-5-[(Benzo[l,3]dioxol-5-ylmethyl)-carbamoyl]-[l,3]dioxolane-4- carbonyl}-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129), (S)-2-{[(4R,5R)-5-Butylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6-dichloro- benzyloxy)-phenyl]-propionic acid (Compound No. 130),
(S)-2-{[(4R,5R)-5-(4-Acetyl-piperazine-l-carbonyl)-[l,3]dioxolane-4-carbonyl]-amino}- 3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 131), (S)-2- {[(4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[ 1 ,3]dioxolane-4-carbonyl]- amino}-3-[4-(2,6-dichloro-benzylxoy)-phenyl]-propionic acid (Compound No. 132),
(S)-2- {[(4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[ 1 ,3]dioxolane-4- carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133), 3-Benzo[l,3]dioxol-5-yl-3-{[(4R,5R)-5-(2-chloro-phenylcarbamoyl)-[l,3]dioxolane-4- carbonyl] -amino} -propionic acid (Compound No. 134),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(2- methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid (Compound No. 136),
(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3- (2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137),
(S)-3-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}- propionic acid (Compound No. 138), (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-octylcarbamoyl-[ 1 ,3]dioxolane- 4-carbonyl)-amino] -propionic acid (Compound No. 139),
3-[((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-(3,4-dimethoxy- benzyl)-amino] -propionic acid (Compound No. 140),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-5-methoxymethyl-[l,3]dioxolane- 4-carbonyl)-amino]-propionic acid (Compound No. 141),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5R)-5-(3,5-dichloro-pyridin-4- ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 142),
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-[((4R,5R)-5-(2-fluoro- phenylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 143),
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[2-(lH-indol-3-yl)- ethylcarbamoyl]-[l,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 144),
(S)-2-[((4R,5R)-5-Cyclohexylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl] -propionic acid (Compound No. 145), Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezyloxy)-phenyl]-2-[((4R,5S)-5-pyrrolidin- l-ylmethyl-[l,3]Dioxolane-4-carbonyl)-amino]-propionic acid (Compound No. 146),
(S)-2-[((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-3-[4- (2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147), (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-({(4R,5R)-5-[(thiophen-2-ylmethyl)- carbamoyl]-[l,3]dioxolane-4-carbonyl}-amino)-propionic acid (Compound No. 148),
(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[((4R,5S)-2,2,5-trimethyl-[l,3]dioxolane-4- carbonyl)-amino]-propionic acid (Compound No. 149),
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(thiazol-2-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 150),
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(2-methoxy- benzylcarbamoyl)-[l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 151),
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(4-methyl-piperazine-l- carbonyl)-[l,3]dioxolane-4-carbonyl]-amino} -propionic acid (Compound No. 152),
(S)-2-{[(4R,5R)-5-Cyclopropylcarbamoyl-[l,3]dioxolane-4-carbonyl)-amino]-3-[4-(2,6- dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 153), and
(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{[(4R,5R)-5-(piperidin-l-ylcarbamoyl)- [l,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 154).
78. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 together with pharmaceutically acceptable carrier, excipients or diluents.
79. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable excipient.
80. A method of preventing, inhibiting or suppressing inflammatory condition in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1.
81. A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 79.
82. A method of preventing, inhibiting or suppressing inflammatory disease in an animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 78.
83. A method of preparing a compound of Formula XVI
Figure imgf000111_0001
Formula XVI
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;
Figure imgf000111_0002
condensing the compound of Formula III with a compound of Formula IN to yield a compound of Formula V;
Figure imgf000111_0003
hydrolyzing the compound of Formula V to yield a compound of Formula VI;
Figure imgf000112_0001
Formula VI
condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);
Figure imgf000112_0002
Formula VII Formula VIII
reducing the compound of Formula VIII to yield a compound of Formula XIII
Figure imgf000112_0003
Figure imgf000112_0004
Formula XIII
reacting the compound of Formula XIII with a compound of Formula XIV to yield a compound of Formula XV; and
Figure imgf000112_0005
Formula XIV Formula XV
hydrolyzing the compound of Formula XIV to yield a compound of Formula XVI.
I l l
Figure imgf000113_0001
Formula XVI
84. A method of preparing a compound of Formula XI
Figure imgf000113_0002
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;
Figure imgf000113_0003
condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;
Fo
Figure imgf000113_0004
hydrolyzing the compound of Formula V to yield a compound of Formula VI;
Figure imgf000114_0001
Formula VI
condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);
Figure imgf000114_0002
Formula VII Formula VIII
condensing the compound of Formula VIII with a compound of Formula IX to yield a compound of Formula X (when R2 is ?-CH2-C6H -OH);
Figure imgf000114_0004
Formula IX
Figure imgf000114_0003
hydrolyzing the compound of Formula X to yield a compound of Formula XI.
Figure imgf000114_0005
85. A method of preparing a compound of Formula XII
Figure imgf000115_0001
Formula XII
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;
Figure imgf000115_0002
condensing the compound of Formula III with a compound of Formula IN to yield a compound of Formula V;
Fo
Figure imgf000115_0003
hydrolyzing the compound of Formula V to yield a compound of Formula VI;
Figure imgf000115_0004
Formula VI
condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);
Figure imgf000116_0001
Formula VIII
the compound of Formula VIII is hydrolyzed to yield a compound of Formula XII.
y rCOOH
Formula XII
86. A method for preparing a compound of Formula XXI
Figure imgf000116_0002
Formula XXI
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;
Figure imgf000116_0003
hydrolyzing the compound of Formula XVIII to yield a compound of Formula XIX;
Figure imgf000117_0001
condensing the compound of Formula XIX with a compound of Formula IV to furnish a compound of Formula XX; and
Figure imgf000117_0002
hydrolyzing the compound of Formula XX to yield a compound of Formula XXI.
Figure imgf000117_0003
Formula XXI
87. A method for preparing a compound of Formula XXI
Figure imgf000117_0004
Formula XXI
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;
Figure imgf000118_0003
Figure imgf000118_0001
Formula XVII
Figure imgf000118_0002
hydrolyzing the compound of Formula XVIII to yield a compound of Formula XXII; and
Figure imgf000118_0004
condensing the compound of Formula XXIII with a compound of Formula IN to yield a compound of Formula XXI.
Figure imgf000118_0005
Formula XXI
88. A method for preparing a compound of Formula XX1N
Figure imgf000118_0006
Formula XXIV
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;
Figure imgf000119_0001
reacting the compound of Formula XVIII with a compound of Formula IX (when R2 is p- hydroxy benzyl) to yield a compound of Formula XXIII; and
Figure imgf000119_0002
hydrolyzing the compound of Formula XXIII to yield a compound of Formula XXIV.
Figure imgf000119_0003
Formula XXIV
89. A method for preparation of compound of Formula XXVII
Figure imgf000119_0004
Formula XXVII
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV
Figure imgf000120_0001
Formula XXV
to yield a compound of Formula XXVI (wherein Pj is ethyl, t-butyl, or benzyl); and
Figure imgf000120_0002
Formula XXVI
hydrolyzing the compound of Formula XXVI to furnish a compound of Formula XXVII.
Figure imgf000120_0003
Formula XXVII
90. A method for preparation of compound of Formula XXIII
Figure imgf000120_0004
Formula XXXIII
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV
Figure imgf000121_0001
Formula XXV
to yield a compound of Formula XXVI (wherein Pi is ethyl, t-butyl, or benzyl); and
reacting the compound of Formula XXVI with a compound of Formula Rm-hal to yield a compound of Formula XXVIII; and
Figure imgf000121_0002
Formula XXVIII
hydrolyzing the compound of Formula XXVIII to yield a compound of Formula XXXIII.
Figure imgf000121_0003
Formula XXXIII
91. A method for preparation of compound of Formula XXXIV
Figure imgf000121_0004
Formula XXXIV its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV
Figure imgf000122_0001
Formula XXV
to yield a compound of Formula XXVI (wherein Pj is ethyl, t-butyl, or benzyl); and
reacting the compound of Formula XXVI with a compound of Formula Rm-hal to yield a compound of Formula XXD ; and
Figure imgf000122_0002
Formula XXIX
hydrolyzing the compound of Formula XXIX to yield a compound of Formula XXXIN.
Figure imgf000122_0003
Formula XXXIV
92. A method for preparation of compound of Formula XXXII
Figure imgf000123_0001
Formula XXXII
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises reducing the compound of Formula XXV
Figure imgf000123_0002
Formula XXV
to yield a compound of Formula XXVI (wherein Pi is ethyl, t-butyl, or benzyl); and
reacting the compound of Formula XXVI with a compound of Formula L-hal to yield a compound of Formula XXX;
Figure imgf000123_0003
Formula XXX
condensing the compound of Formula XXX with a compound of Formula IN (wherein OL is a leaving group selected from, mesyl or tosyl) to yield a compound of Formula XXXI; and
Figure imgf000124_0001
Formula IV Formula XXXI
hydrolyzing the compound of Formula XXXI to yield a compound of Formula XXXII.
Figure imgf000124_0002
Formula XXXII
93. A method for the preparation of the compound of Formula XXXVIII
Figure imgf000124_0003
Formula XXXVIII
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymoφhs or N-oxides wherein the method comprises hydrolyzing a compound of Formula XXXV to yield a compound of Formula XXXVI;
Figure imgf000124_0004
Formula XXXV
Figure imgf000125_0001
Formula XXXVI
reacting the compound of Formula XXXVI with a compound of Formula VII to yield a compound of Formula XXXVII; and
Figure imgf000125_0002
Formula VII Formula XXXVII
hydrolyzing the compound of Formula XXXIII to yield a compound of Formula XXXVIII.
94. A method for the preparation of the compound of Formula XL
Figure imgf000125_0003
Formula XL
its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises condensing a compound of Formula VI with a compound of Formula XXXIX
Figure imgf000126_0001
Formula XXXIX
to yield a compound of Formula XL.
95. A compound of claim 1, wherein Ri is hydrogen; R2 is ^ w ; R3 is -OH;
Figure imgf000126_0002
R5 is hydrogen; Rό is hydrogen; and m is O.
96. The compound of claim 95, wherein Rz is -NH-(CH2)0-3-aryl, -NH-(CH2)0-2- substituted aryl, -NH-(CH2)0-3-cycloalkyl, -NH-(CH2)0-3-heteroaryl, -NH-(CH2)0-3- heterocyclyl, -NH-(CH2)0-3-substituted cycloalkyl, -NH-(CH2)0-3-substituted heteroaryl, - NH-(CH2)0- -substituted heterocyclyl, N-containing heterocyclyl, substituted N-containing heterocyclyl, NH-alkyl, NH-substituted alkyl and NH2.
97. The compound of claim 95, wherein W is H, OH, NHCO-(CH2)0-3-aryl, NHCO- (CH2)0-3-substituted aryl, NHCO-(CH2)0-3-heteroaryl, NHCO-(CH2)0-3-substituted aryl, OCO-(CH2)0-3-aryl, OCO-(CH2)0.3-substituted aryl, OCO-(CH2)0-3-heterosryl, OCO- (CH2)0-3-substituted aryl, O-(CH2)0-3-heterocyclyl, -O-(CH2)0-3-substituted heterocyclyl, NHCO-(CH2)0-3-heterocyclyl, NHCO-(CH2)0.3-substituted heterocyclyl, O-(CH2)0-3- alkynyl, O-(CH2)o-3-alkenyl, or halogen.
98. A compound of claim 1, wherein Ri is hydrogen; R2 is ^< ^; R3 is -ORm; R5 is hydrogen; Rό is hydrogen; and m is O.
99. The compound of claim 98, wherein Rt is carboxyl, CM alkyl ester, hydroxyl methyl, CH2OCH -C6H5, or CH2OCH3.
100. The compound of claim 98, where Rm is hydrogen or Cι-C5 alkyl.
101. The compound of claim 98, herein W is H, OH, NHCO-(CH2)0-3-aryl, NHCO- (CH2)0-3-substituted aryl, NHCO-(CH2)0-3-heteroaryl, NHCO-(CH2)0-3-substituted aryl, OCO-(CH2)0-3-aryl, OCO-(CH2)o-3-substituted aryl, OCO-(CH2)0-3-heterosryl, OCO- (CH2)o-3-substituted aryl, O-(CH2)0-3-heterocyclyl, -O-(CH2)0-3-substituted heterocyclyl, NHCO-(CH2)o-3-heterocyclyl, NHCO-(CH2)o-3-substituted heterocyclyl, O-(CH2)0-3- alkynyl, O-(CH2)o-3-alkenyl, or halogen.
102. A compound of claim 1, wherein Ri is hydrogen or Cι-5 alkyl; R2 is OH, or NH2; R is hydrogen; Rό is hydrogen; and m is 0.
103. The compound of claim 102, wherein R is CONH-aryl, CONH-substituted aryl, or (CH2)1-3-O-CH3.
PCT/IB2004/003047 2003-09-17 2004-09-17 Dioxolane derivatives as cell adhesion inhibitors WO2005026163A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04769418A EP1668007A1 (en) 2003-09-17 2004-09-17 Dioxolane derivatives as cell adhesion inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50364303P 2003-09-17 2003-09-17
US60/503,643 2003-09-17

Publications (1)

Publication Number Publication Date
WO2005026163A1 true WO2005026163A1 (en) 2005-03-24

Family

ID=34312446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003047 WO2005026163A1 (en) 2003-09-17 2004-09-17 Dioxolane derivatives as cell adhesion inhibitors

Country Status (2)

Country Link
EP (1) EP1668007A1 (en)
WO (1) WO2005026163A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338435A1 (en) * 1988-04-21 1989-10-25 Hoechst Aktiengesellschaft 3,4-Dihydroxypyrrolidin-2-one derivatives, process for their preparation, agents containing them and their use as well as the intermediates resulting from the preparation
EP0460239A1 (en) * 1989-12-27 1991-12-11 Japan Tobacco Inc. 1,3,2-dioxathiolane oxide derivative
EP0536713A1 (en) * 1991-10-07 1993-04-14 E.R. SQUIBB &amp; SONS, INC. Oxazole and imidazole derivatives as prostaglandin analogs
JPH06199831A (en) * 1992-12-28 1994-07-19 Japan Tobacco Inc New 1,3,2-dioxathiolane oxide derivative having platelet coagulation suppressing activity and its intermediate compound
JPH07228549A (en) * 1994-02-17 1995-08-29 Japan Tobacco Inc Ne 4-aryl-2,3-dihydroxylactic acid derivative and its production
WO2001012183A1 (en) * 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338435A1 (en) * 1988-04-21 1989-10-25 Hoechst Aktiengesellschaft 3,4-Dihydroxypyrrolidin-2-one derivatives, process for their preparation, agents containing them and their use as well as the intermediates resulting from the preparation
EP0460239A1 (en) * 1989-12-27 1991-12-11 Japan Tobacco Inc. 1,3,2-dioxathiolane oxide derivative
EP0536713A1 (en) * 1991-10-07 1993-04-14 E.R. SQUIBB &amp; SONS, INC. Oxazole and imidazole derivatives as prostaglandin analogs
JPH06199831A (en) * 1992-12-28 1994-07-19 Japan Tobacco Inc New 1,3,2-dioxathiolane oxide derivative having platelet coagulation suppressing activity and its intermediate compound
JPH07228549A (en) * 1994-02-17 1995-08-29 Japan Tobacco Inc Ne 4-aryl-2,3-dihydroxylactic acid derivative and its production
WO2001012183A1 (en) * 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANGRICK, MICHAEL ET AL: "Binding of sugars and related polyfunctional compounds with amino acids. 4. N-Acylation of amino acids with glyceric acid Binding of sugars and related polyfunctional compounds with amino acids. 4. N-Acylation of amino acids with glyceric acid", MONATSHEFTE FUER CHEMIE , 116(3), 377-84 CODEN: MOCMB7; ISSN: 0026-9247, 1985, XP009043312 *
KOSEKI, KOSHI ET AL: "Synthesis of bestatin, a potent inhibitor of leukotriene A4 hydrolase, by an N3 nucleophile reaction to a non-protected diol Synthesis of bestatin, a potent inhibitor of leukotriene A4 hydrolase, by an N3 nucleophile reaction to a non-protected diol", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY , 60(3), 534-6 CODEN: BBBIEJ; ISSN: 0916-8451, 1996, XP009043318 *
LLEWELLYN D B ET AL: "DESIGN, SYNTHESIS, AND CHARACTERIZATION OF A NEW CLASS OF AMINO ACID-BASED CHIRAL BORATE COUNTERANIONS", ORGANOMETALLICS, ACS, COLUMBUS, OH, US, vol. 23, no. 12, 7 June 2004 (2004-06-07), pages 2838 - 2840, XP001200001, ISSN: 0276-7333 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 558 (C - 1264) 25 October 1994 (1994-10-25) *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 11 26 December 1995 (1995-12-26) *
PHILLIPS A J ET AL: "SYNTHESIS OF FUNCTIONALIZED OXAZOLINES AND OXAZOLES WITH DAST AND DEOXO-FLUOR", ORGANIC LETTERS, ACS, WASHINGTON, DC, US, vol. 2, no. 8, 2000, pages 1165 - 1168, XP002951623, ISSN: 1523-7060 *
PIRO J ET AL: "3-Amino-2-piperidones as Constrained Pseudopeptides: Preparation of a New Ser-Leu Surrogate", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 40, no. 26, 25 June 1999 (1999-06-25), pages 4865 - 4868, XP004168667, ISSN: 0040-4039 *
TALMA A G ET AL: "REDUCTIONS OF ACTIVATED CARBONYL COMPOUNDS WITH CHIRAL BRIDGED 1,4-DIHYDROPYRIDINES. AN INVESTIGATION OF SCOPE AND STRUCTURAL EFFECTS", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 107, no. 13, 1985, pages 3981 - 3997, XP001182536, ISSN: 0002-7863 *
TILLEY J W ET AL: "VLA-4 Antagonists", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 26, no. 10, 2001, pages 985 - 998, XP002975527, ISSN: 0377-8282 *

Also Published As

Publication number Publication date
EP1668007A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
Gordon et al. O-Sulfated. beta.-lactam hydroxamic acids (monosulfactams). Novel monocyclic. beta.-lactam antibiotics of synthetic origin
US6271238B1 (en) Acetamide derivatives and protease inhibitors
KR100637110B1 (en) Cell adhesion inhibitors
US6069250A (en) Method and compositions for the synthesis of dioxolane nucleosides with β-configuration
EP0751145B1 (en) HIV-protease inhibitors
AU9458098A (en) Aminobutanoic acid derivatives
US9469609B2 (en) Synthesis of pyrrolidine compounds
WO2006090234A1 (en) Heterocyclic derivatives as cell adhesion inhibitors
US5210266A (en) N-substituted mercaptopropanamide derivatives
RU2316546C2 (en) Novel compounds as cathepsin inhibitors, pharmaceutical composition based on thereof, their using and method for their preparing
US5179125A (en) N-substituted mercaptopropanamide derivatives
US6222043B1 (en) Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
JPH05320119A (en) Trifluoromethane sulfonyloxycarboxylic acid derivative and preparation thereof
WO2005026163A1 (en) Dioxolane derivatives as cell adhesion inhibitors
KR20010023830A (en) Pyrrolopyrrolone Derivatives as Inhibitors of Neutrophil Elastase
US6787559B2 (en) Sulfonamide compounds
US20030087831A1 (en) 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
KR870000528B1 (en) Process for preparing 3-azidocephalosporins
IE870861L (en) Azepine and thiazepine derivatives
EP1692104A1 (en) Methods of preparing compounds useful as protease inhibitors
KR930005174B1 (en) Process for preparing antibiotic derivatives
JPH07113020B2 (en) Process for producing perhydro-1,4-thiazepine derivative
JP2005029470A (en) New norstatine derivative
US20020151718A1 (en) Synthesis of pyrrole amides
JP3391038B2 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1690/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004769418

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004769418

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004769418

Country of ref document: EP